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A B S T R A C T
Background
The ’off-label’ effect of alprazolam on depression has not been systematically evaluated.
Objectives
To determine the antidepressant effect, including tolerability and acceptability, of alprazolam as monotherapy for major depression,
when compared to placebo and conventional antidepressants in outpatients and patients in primary care.
Search methods
We searched the Cochrane Central Register of Controlled Trials and the Cochrane Depression, Anxiety and Neurosis Group Register,
which includes relevant randomised controlled trials from the following bibliographic databases: The Cochrane Library (all years to
February 2012); EMBASE (1970 to February 2012); MEDLINE (1950 to February 2012) and PsycINFO (1960 to February 2012).
Two review authors identified relevant trials by assessing the abstracts of all possible studies. We applied no language restrictions.
Selection criteria
We selected randomised controlled trials (RCTs) of alprazolam versus placebo or conventional antidepressants for depression in adults,
excluding studies with inpatients only.
Data collection and analysis
Two review authors performed the data extraction and ’Risk of bias’ assessment independently with disagreements resolved through
discussion with a third review author. Primary outcomes included the mean difference (MD) in reduction of depression on a continuous
measure of depression symptoms, and the risk ratio (RR) of the clinical response based on a dichotomous measure, with 95% confidence
intervals (CI).
Main results
We identified 21 alprazolam studies (22 reports) with a total of 2693 participants. Seven studies used a placebo (n = 771) and 20 used
cyclic antidepressants (n = 1765). The typical duration of the studies was four to six weeks. We considered six studies to have a high
risk of bias.
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When alprazolam was compared with placebo for reduction in symptoms all estimates indicated a positive effect for alprazolam. Pooled
estimates of efficacy data showed a moderately large continuous mean difference (MD) at the end of trial (-5.34, 95% CI -7.48 to -
3.20; I2 = 68%). The risk difference (RD) for the dichotomous measure of clinical response (50% improvement) was 0.32 in favour
of alprazolam (95% CI 0.22 to 0.42; I2 = 0%), with a number needed to treat to benefit (NNTB) of 3 (95% CI 2 to 5). The RD of
all-cause withdrawals did not differ between alprazolam and placebo.
When depression severity was measured as a continuum the effect of alprazolam did not differ statistically or clinically from the effects of
any of the conventional antidepressants combined (MD 0.25, 95% CI -0.93 to 1.43; I2 = 55%). However, for dichotomised depression
severity, alprazolam had less effect than antidepressants (RR 0.86, 95% CI 0.75 to 0.99; I2 = 37%; RD -0.11, 95% CI -0.24 to 0.01;
I2 = 58%; NNTB 9, 95% CI 4 to 100). The RD of all-cause withdrawals was -0.04 (95% CI -0.07 to 0.00; I2 = 35%), in favour of
alprazolam.
Authors’ conclusions
Alprazolam appears to reduce depressive symptomsmore effectively than placebo and as effectively as tricyclic antidepressants. However,
the studies included in the reviewwere heterogeneous, of poor quality and only addressed short-term effects, thus limiting our confidence
in the findings. Whilst the rate of all-cause withdrawals did not appear to differ between alprazolam and placebo, and withdrawals
were less frequent in the alprazolam group than in any of the conventional antidepressants combined group, these findings should be
interpreted with caution, given the dependency properties of benzodiazepines.
P L A I N L A N G U A G E S U M M A R Y
Alprazolam for depression
Additional options to help those with depression control their mood, besides psychotherapy and antidepressants, can be important,
especially when there is also anxiety involved. One of the drug options is alprazolam, a benzodiazepine. We evaluated the effect of
alprazolam for depression. The best evidence currently available suggests that alprazolam may be moderately more effective than a
placebo, and as effective as conventional antidepressants, in the treatment of major depression. We cannot conclude whether this is
due to its specific antidepressant effect or to a non-specific effect on sleep and anxiety. There were relatively few short-term side effects.
However, the multiple shortcomings of the currently available evidence, including probable sponsorship bias, publication bias, the age
of the studies and the heterogeneity of the results, limit confidence in these findings.
B A C K G R O U N D
Description of the condition
Depression is a broad andheterogeneous diagnostic grouping, cen-
tral to which is depressed mood or loss of interest or pleasure in
most activities. Depressive symptoms are frequently accompanied
by symptoms of anxiety, but may also occur on their own. Sleeping
problems, lack of energy, eating problems, abnormal feelings of
guilt, concentration problems, psychomotor agitation or retarda-
tion, and suicidal ideation are other depressive symptoms. Symp-
toms should be present for at least two weeks or more and every
symptom should be present for most of every day (APA 2000).
It is doubtful whether the severity of the depressive illness can re-
alistically be captured in a single symptom count. Clinicians will
consider family and previous history, as well as the degree of asso-
ciated disability, in making this assessment.
Description of the intervention
In most countries, the vast majority of patients with major de-
pression are treated in primary care or as outpatients. Specific an-
tidepressant drugs, such as the tricyclics (TCAs) and the selective
serotonin reuptake inhibitors (SSRIs), are generally recommended
as the primary classes of drugs for these patients, if and when drug
treatment is indicated. However, treatment with antidepressants
may be difficult in primary care for several reasons: a) antidepres-
sants have a low acceptance and compliance rate and more than
50% of patients who start antidepressant treatment may cease
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taking their medication (Hansen 2004; Lawrenson 2000); b) de-
pressive symptoms frequently co-occur with symptoms of stress
and anxiety; c) antidepressants have a long latency time of several
weeks; and d) depression in primary care or outpatient settings fre-
quently starts with mild symptoms, which are not severe enough
to warrant long-term conventional antidepressant treatment.
Primary care physicians sometimes prescribe brief courses of ben-
zodiazepines to patients with mild to moderate major depression,
who represent the majority of their depression caseload (Rijswijk
2007).However,most depression treatment guidelines do not sup-
port this indication (Furukawa 2001; NICE 2009; Van Marwijk
2003). Evidence of a specific antidepressant effect of benzodi-
azepines as a single treatment is inconclusive, although benzo-
diazepines can have additional effects when combined with an-
tidepressants (Furukawa 2001; NICE 2009). Caution with long-
term psychotropic drugs, as well as with high-potency tranquil-
lisers, such as alprazolam, may however be a good clinical policy
(Committee 1980). Benzodiazepines may lose their efficacy with
long-term administration (Committee 1980).
How the intervention might work
Alprazolam, a triazolo 1,4-benzodiazepine, is one of the high-po-
tency benzodiazepines. Early claims were that it combined an anx-
iolytic effect with a specific and fast-onset antidepressant effect
(Sethy 1982). Alprazolam differs from the classic benzodiazepines
by the incorporation of a triazolo ring in the basic molecular struc-
ture. The addition of this ring is believed to have provided al-
prazolam with antidepressant properties. Benzodiazepines bind to
a specific area of the GABA-A benzodiazepine receptor and may
modulate transmission of the inhibitory neurotransmitter GABA
as agonists, by their allosteric actions facilitating the opening of
the receptor’s chloride channel.
No independent systematic evaluation of its antidepressant effect
has ever been undertaken. In daily practice, a number of patients
still use alprazolam. Although as a class benzodiazepines act rapidly
and are well tolerated for anxiety, their use presents clinical issues
such as dependence, rebound anxiety, memory impairment and
discontinuation syndrome (Schweizer 1998). Accident-proneness,
including traffic accidents and falls, are other particularly impor-
tant considerations (Barbone 1998). These side effects occur early
in the course of treatment (Neutel 1996).
Why it is important to do this review
As doubts about the magnitude of the specific antidepressant ef-
fect of antidepressants remain, it may be worthwhile to evaluate
alternatives (Moncrieff 2004).One non-systematic review in 1995
showed that benzodiazepines were less effective than conventional
antidepressants in treating major depression (Birkenhager 1995).
Alprazolam is internationally registered for the treatment of anx-
iety, panic disorder and anxiety associated with depression (Jonas
1993). However, there is still debate about its efficacy for the treat-
ment of depression alone (Petty 1995). Therefore, a systematic
review to evaluate whether alprazolam is a suitable alternative for
outpatients with major depression, requiring drug treatment but
not wishing to take conventional antidepressants, may generate
clinically useful information.
O B J E C T I V E S
To determine the effectiveness, including tolerability and accept-
ability, of alprazolamasmonotherapy formajor depression in com-
parison with placebo and conventional antidepressants in outpa-
tients and patients in primary care.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We selected double-blind randomised controlled trials (RCTs).
Double-blind indicates that both provider and participant are un-
aware of the exact nature of the intervention or control. We did
not apply any language restriction andwe included both published
and unpublished trials.
Types of participants
Participant characteristics and setting
Trial participants were adults (18 years of age and over), both male
and female.
Diagnosis
The primary diagnosis for trial participants was major depression
according to the Research Diagnostic Criteria (RDC) (Feighner
1972); Diagnostic and Statistical Manual (DSM III (APA 1980)
or DSM IV (APA 1994)); a depressive episode according to the
International Classification of Diseases (ICD) (WHO 2003); or
if the clinician considered the patient to be depressed and eligible
for antidepressant treatment.
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Setting
Studies were included if they were conducted in an outpatient or
primary care setting. However, studies conducted in mixed inpa-
tient and outpatient settings were included in the review.
Exclusion criteria
We excluded patients with a primary diagnosis of another major
psychiatric condition, such as anxiety disorder, or important med-
ical problems.
We excluded studies limited to inpatient populations, as the sever-
ity of their depressive symptoms is likely to be considerably higher
(Hubain 1990; Lenox 1984). Hubain 1990
Types of interventions
Intervention
At least one of the treatment arms had to include alprazolam as a
monotherapy (variable dosages and exposure times). There were
no restrictions on dose or duration of treatment. We excluded
studies that combined alprazolam with other interventions, such
as alprazolam plus forms of psychotherapy.
Control conditions
Alprazolam had to be compared with placebo, conventional an-
tidepressants or both.
Types of outcome measures
Primary outcomes
1) Our primary continuous outcome was the last mean assess-
ment score on a depression severity measure (end of trial): Hamil-
ton Depression Rating Scale (HDRS), or the equivalent Mont-
gomery-Asberg Depression Rating Scale (MADRS) in an inten-
tion-to-treat analysis (Hamilton 1960; Montgomery 1979). The
primary dichotomous outcome was ’improvement of depression’
which was dichotomised as 50% reduction on the initial mean
depression severity score (end of trial HDRS or MADRS). We
used the HDRS-based response as the primary outcome measure
when multiple measures were reported.
Secondary outcomes
2) Our primary measure of harm was the number of reported
drug adverse events and data on tolerability, which were abstracted
by collecting ’all-cause’ withdrawals from each treatment group,
including the reason attributed for withdrawal from therapy (lack
of efficacy and adverse effects).
3) We assessed withdrawals, rebound symptoms and tolerance,
which may not have been manifested as a loss of efficacy due to
concomitant dose increase.
Search methods for identification of studies
Electronic searches
We identified relevant trials from systematic searches in the
following electronic databases: CCDANCTR-Studies and CC-
DANCTR-References (Specialised Registers of the Cochrane De-
pression, Anxiety and Neurosis Group. For a description see
Appendix 1).
We also carried out complementary searches in: PubMed, EM-
BASE (Elsevier, EMBASE and MEDLINE combined) and
PsycINFO.
We conducted searches using a controlled vocabulary of terms
related to ALPRAZOLAM, DEPRESSIVE DISORDERS and
DEPRESSION (using the APA Thesaurus of Psychological In-
dex Terms in PsycINFO, Medical Subject Headings (MeSH) in
PubMed, and EMTREE in EMBASE.com). Search strategies are
listed below:
CCDANCTR-Studies
Diagnosis = Depress* or Dysthymi* or “Adjustment Disorder*”
or “Mood Disorder*” or “Affective Disorder” or “Affective Symp-
toms”
AND
Intervention = Alprazolam
CCDANCTR-References
Keyword = Depress* or Dysthymi* or “Adjustment Disorder*”
or “Mood Disorder*” or “Affective Disorder” or “Affective Symp-
toms”
AND
Free-text = Alprazolam
PubMed (MEDLINE)
(“Depressive Disorder”[mh] OR Depression[mh]) AND “Alpra-
zolam”[mh] AND humans[mh] NOT case reports[pt]
EMBASE.com
’major depression’/exp AND ’alprazolam’/de AND [humans]/lim
NOT ’case report’/exp
OR
’major depression’/exp AND ’alprazolam’/dd_ae,dd_ct
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PsycINFO
DE=(“depression emotion” OR “major depression”) AND DE=
“alprazolam”
Searching other resources
Reference lists
We checked the reference lists of selected reviews and published
studies. We also searched for additional trials in the reference lists
of studies initially identified and by scrutinising other relevant
review articles.
Personal communication
We consulted authors of studies included and experts in the field
to find out if they know of any relevant published or unpub-
lished RCTs, which had not been identified through the electronic
searches. We mailed and emailed four traceable authors, however
they were unable to provide any information.
Pharmaceutical companies
We also contacted the company that had developed alprazolam.
Unpublished studies
We searched theWorld Health Organization (WHO) trials portal
(http://apps.who.int/trialsearch/), Clinical Studies Results (http:/
/www.clinicalstudyresults.org/) and Current Controlled Trials (
http://www.controlled-trials.com/) for ongoing trials on depres-
sion.
We searched the four open databases suggested in the Cochrane
Handbook for Systematic Reviews of Interventions as suitable for
locating grey literature for alprazolam and Xanax. We searched
Open Sigle (opensigle.inist.fr), the National Technical Informa-
tion Service (NTIS), which provides access to the results of both
US and non-US government-sponsored research (www.ntis.gov),
PsycExtra (www.apa.ort/psycextra) and Healthcare Management
Information Consortium (HMIC). The large literature databases
we used cover conference reports and abstracts published in jour-
nals.
Data collection and analysis
Selection of studies
Two review authors independently assessed the abstracts from all
the studies potentially eligible for inclusion against relevant study
inclusion criteria (FW, HvM). We made decisions about selection
of studies through discussion and consensus. Any disagreement
was resolved through consultationwith an independent third party
(GA).
Data extraction and management
Both review authors extracted data independently on the inclusion
and exclusion criteria for each study, the dose and regimen of
alprazolam and the medication or placebo compared, the number
of patients randomised, dropouts, length of follow-up, age, in
or outpatient status, relevant clinical outcomes reported (such as
HDRS score) and also noted side effects. Any disagreement about
the data extraction process was resolved through discussion and
consensus, or through consultationwithGA.Weused the results of
the data extraction mainly to consider the generalisability of study
findings (external validity) and to evaluate clinical heterogeneity
across trials. We set no minimum quality score for inclusion.
Comparisons
1. Alprazolam versus placebo
2. Alprazolam versus tricyclic antidepressants
3. Alprazolam versus heterocyclic antidepressants
4. Alprazolam versus SSRIs
Assessment of risk of bias in included studies
We assessed risk of bias for each included study using theCochrane
Collaboration ’Risk of bias’ assessment tool (Higgins 2009). We
considered the following six domains:
1. Sequence generation: was the allocation sequence
adequately generated?
2. Allocation concealment: was allocation adequately
concealed?
3. Blinding of participants, personnel and outcome assessors
for each main outcome or class of outcomes: was knowledge of
the allocated treatment adequately prevented during the study?
4. Incomplete outcome data for each main outcome or class of
outcomes: were incomplete outcome data adequately addressed?
5. Selective outcome reporting: are reports of the study free of
suggestion of selective outcome reporting?
6. Other sources of bias: was the study apparently free of other
problems that could put it at a high risk of bias? Additional items
included here are therapist qualifications, treatment fidelity and
researcher allegiance/conflict of interest.
We provided a description of what was reported to have happened
in each study, and made a judgement on the risk of bias for each
domain within and across studies, based on the following three
categories: low risk of bias, unclear risk of bias and high risk of
bias.
Two independent review authors assessed the risk of bias in the se-
lected studies. Any disagreement was discussed with a third review
author. Where necessary, we contacted the authors of the studies
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for further information. All ’Risk of bias’ data are presented graph-
ically and described in the text.
Two review authors (FW, (AB) and HvM) independently assessed
the methodological quality or internal validity of each trial using
the Cochrane Handbook for Systematic Reviews of Interventions cri-
teria (Higgins 2009).
Measures of treatment effect
Standardised mean differences (SMD) are reported for continu-
ous outcomes, together with 95% confidence intervals (CI). The
SMD is the difference between the group means divided by the
combined standard deviation. We used these to calculate a stan-
dard measure of effect for each trial. We calculated the mean dif-
ference (MD) where the same outcome scale was used.We defined
change in mood at the end of treatment as the outcome of inter-
est. We selected observer-rated measures in preference to patient-
rated ones as we expected these to be employed most consistently
at the time that most alprazolam studies were undertaken. Many
different outcome measures are used in depression studies. It is
assumed that these all measure an underlying construct which we
calledmood.We reported both risk ratios (RR) and risk differences
(RD) for dichotomous data, as RRs are more precise and RDs
allow calculation of numbers needed to treat to benefit (NNTb)
and numbers needed to treat to harm (NNTh), with 95% CI for
those studies which were statistically significant.
Unit of analysis issues
We expected few problems in this area, as most studies used par-
ticipants as the unit of analysis. Some studies had multiple treat-
ment groups.We used the relevant data separately in each compar-
ison (alprazolam versus placebo, alprazolam versus other antide-
pressant). Where more than one active treatment group with the
same drug was eligible for inclusion in a comparison, we pooled
the groups for comparison against the control group, to avoid in-
cluding the same group of participants twice in the same meta-
analysis.
Dealing with missing data
We either analysed missing continuous data on an endpoint basis,
including only participants with a final assessment, or analysed
them using last observation carried forward to the final assessment
(LOCF) if LOCF data had been reported by the trial authors.
For dichotomous outcomes, we assigned the worst possible out-
come to dropouts (intention-to-treat). As many of the studies on
the antidepressant effects of alprazolam were published some years
ago, it was difficult to recover missing data. To estimate standard
deviations (SDs), we used the method described by Furukawa et
al (Furukawa 2006). Where data were available in graphic format
only, we made an approximation of the mean to assess the out-
comes.
Assessment of heterogeneity
We explored inconsistency across studies visually. We also used a
Chi2 test, the Q-statistic, with a P value set at 0.1. Furthermore,
we used the I2 statistic, a measure of effect size estimates that is
due to heterogeneity rather than sampling error (Higgins 2009),
with 30% to 50% representing moderate heterogeneity, 50% to
80% substantial, and 80% to 100% considerable heterogeneity.
Assessment of reporting biases
We addressed publication bias and other reporting biases bymeans
of visual inspection for signs of asymmetry, and generated the
funnel plots using Review Manager 5.1 software (RevMan 2011).
Data synthesis
We pooled discrete outcomes (recovered/not recovered) and,
where possible, continuous outcomes, using both fixed and ran-
dom-effects approaches. Fixed-effect models assume that the un-
derlying true treatment effect in each trial is the same and that the
observed differences are due to chance. Random-effects models
assume the true treatment effects in different trials are randomly
placed around some central value and incorporates the within and
between-study variation into the calculation, generating a wider
confidence interval if heterogeneity is present, and allowing for an
appropriate degree of statistical caution (DerSimonian 1986). The
fixed-effect approach used was the Mantel-Haenszel-Peto method
which allows the calculationof an estimate knownas the ’typical’ or
pooled odds ratio with a 95% confidence interval (DerSimonian
1986). We chose random-effects models when there was more
than 50% heterogeneity.
Subgroup analysis and investigation of heterogeneity
We planned to perform two subgroup analyses for:
1. speed of recovery; and
2. alprazolam dosage.
Given that these trial characteristics may have influenced the ob-
served treatment effect, they were planned to identify potential
sources of heterogeneity. The use of multiple statistical analyses
leads to an increase in the probability of type I errors.
Sensitivity analysis
We planned to perform two sensitivity analyses to determine
whether certain methodological decisions made during the review
process were robust. We planned to test these decisions by remov-
ing studies from the main analysis to investigate the effect of their
inclusion. The following two analyses were planned:
1. to test the inclusion of studies with divergent diagnostic
criteria for depression; and
2. to test the reliance on self reported measures of depression
only.
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We also conducted a post hoc sensitivity analysis:
1. to investigate the effects of bias on the results of the meta-
analysis by excluding studies classified as having a high risk of
bias.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
See: Characteristics of included studies.
Results of the search
Electronic searches
The search of the CCDAN registers yielded 391 references of po-
tentially eligible studies. We excluded papers that were not rele-
vant (mainly because they did not fulfil the inclusion criteria or
were non-randomised studies). We included 21 randomised con-
trolled alprazolam trials. Seven studies used a placebo comparison
(n = 771) and 18 used tricyclic or heterocyclic antidepressants (n
= 1697). The studies typically lasted four to six weeks.
Reference lists
We found three reviews of alprazolam by checking the reference
lists of selected reviews and published studies (Birkenhager 1995;
Jonas 1993; Srisurapanont 1997). The findings of these other re-
views are summarised below in the Agreements and disagreements
with other studies or reviews section. No additional studies were
found through checking reference lists.
Personal communication
Few authors of included studies were available for advice on rele-
vant published or unpublished RCTs not identified through elec-
tronic searches. We contacted one author (Carl Rickels). No new
studies were identified.
Pharmaceutical companies
Wecontacted the company that developed alprazolam: theUpjohn
Company. In 1995, Upjohn merged with Pharmacia AB to form
Pharmacia & Upjohn. Today, through a series of mergers, the
remainder of Upjohn is owned by Pfizer. The Dutch branch of
Pharmacia/Pfizer was unable to provide information as alprazolam
is no longer a priority or a marketable drug for them. Alprazolam
is generically available.
Unpublished studies
We found no unpublished studies in the World Health Organi-
zation (WHO) trials portal (http://apps.who.int/trialsearch/), in
Clinical Studies Results (http://www.clinicalstudyresults.org/) or
in Current Controlled Trials (http://www.controlled-trials.com/).
The latter database is where we expected pharmaceutical compa-
nies to post their results (although alprazolam is mainly prescribed
for anxiety and panic disorders).
We searched the three open databases advised in the Cochrane
Handbook for Systematic Reviews of Interventions as suitable for lo-
cating grey literature for alprazolam and Xanax, but we found
no relevant information for our research question. The fourth
database mentioned, the Healthcare Management Information
Consortium (HMIC), is only accessible through a license at
OVID.Our two universities do not have such a license. The search
results were: Open Sigle (opensigle.inist.fr) (two hits, none rele-
vant); the National Technical Information Service (NTIS) which
provides access to the results of both US and non-US government-
sponsored research (www.ntis.gov) (five hits, none relevant); and
PsycExtra (www.apa.org/psycextra) (one hit, but again not rele-
vant).
Included studies
Design
Length of the studies
Five studies were four-week trials (Banerji 1989; Bassi 1990;
Cropper 1987; di Perri 1990; Imlah 1985). One study was a five-
week trial (Mendels 1986). Fifteen studies were six-week trials
(Ansseau 1984; Borison 1989; Draper 1983; Fabre 1980; Feighner
1983a; Goldberg 1986; Laakman 1995; Lapierre 1994; Murthy
1991; Overall 1987; Remick 1988; Rickels 1985; Rickels 1987;
Rush 1985; Singh 1988).
Sample size
The mean number of participants who entered the studies was
129.2 (SD 111.5), with a minimum sample size of 43 (Lapierre
1994) and a maximum of 504 (Rickels 1985).
Setting
In 19 studies, the participants were outpatients (Ansseau 1984;
Banerji 1989; Bassi 1990; Borison 1989; Cropper 1987; Draper
1983; Fabre 1980; Feighner 1983a; Goldberg 1986; Laakman
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1995; Lapierre 1994;Mendels 1986;Murthy 1991; Overall 1987;
Remick 1985; Remick 1988; Rickels 1985; Rickels 1987; Singh
1988). Two studies included both in- and outpatients, and one
study failed to provide information about the setting (di Perri
1990; Imlah 1985; Rush 1985).
Participants
Age
Studies were limited to adults and excluded elderly patients (one
used 55 years of age as the upper age limit, four used 60, five
used 65, eight used 69/70 and one used 75). Two studies did not
provide any details on age (Murthy 1991; Remick 1988).
Diagnosis
Most patients were diagnosed with depressive disorder according
to explicit diagnostic criteria (16 studies), with added severity cri-
teria. In 14 studies, a Raskin Depression Scale (RDS) score of at
least six (Banerji 1989), eight (Ansseau 1984; Draper 1983; di
Perri 1990; Fabre 1980; Feighner 1983a; Laakman 1995; Lapierre
1994; Murthy 1991; Rickels 1985; Rickels 1987; Singh 1988) or
nine was added (Bassi 1990; Raskin 1970). In 16 studies, a Hamil-
ton Depression Rating Scale (HDRS) score of at least 17 (Draper
1983), 18 (Bassi 1990; Borison 1989; di Perri 1990; Fabre 1980;
Feighner 1983a; Goldberg 1986; Laakman 1995; Lapierre 1994;
Murthy 1991; Rickels 1985; Rickels 1987; Rush 1985; Singh
1988), 20 (Mendels 1986) or 21 (Remick 1985; Remick 1988)
was required. The Covi Anxiety Score (CAS) had to be less than
or equal to the RDS score in many studies (Ansseau 1984; Banerji
1989; di Perri 1990; Draper 1983; Feighner 1983a; Goldberg
1986; Lapierre 1994;Mendels 1986;Murthy 1991; Rickels 1985;
Rickels 1987; Singh 1988), while anxiety was not addressed in
seven studies (Bassi 1990; Borison 1989; Covi 1976; Laakman
1995; Overall 1987; Remick 1988; Rush 1985).
Diagnostic criteria were:
1. DSM-III or its predecessors (Bassi 1990; di Perri 1990;
Goldberg 1986; Murthy 1991; Rickels 1987); the Feighner
Diagnostic Criteria (di Perri 1990; Draper 1983; Feighner
1983a; Goldberg 1986; Mendels 1986; Murthy 1991; Overall
1987; Rickels 1985; Rickels 1987); or the Research Diagnostic
Criteria (RDC) (Remick 1985; Remick 1988; Rush 1985);
2. ICD-9 (di Perri 1990; Laakman 1995; Singh 1988); or
3. unspecified criteria (Ansseau 1984; Banerji 1989; Cropper
1987; Imlah 1985; Lapierre 1994).
Two studies included patients with anxiety: mixed symptoms of
anxiety and depression, and neurotic depression with or without
anxiety (Cropper 1987; Imlah 1985).
Interventions
Eight studies included a placebo arm (Borison 1989; Fabre 1980;
Feighner 1983a; Imlah 1985; Laakman 1995; Mendels 1986;
Rickels 1985; Rickels 1987). Three studies presented a com-
parison between four arms (alprazolam-amitriptyline-lorazepam-
placebo, alprazolam-amitriptyline-doxepin-placebo and alprazo-
lam-imipramine-diazepam-placebo, respectively (Laakman 1995;
Rickels 1985; Rickels 1987). One study presented a comparison
between three arms (alprazolam-imipramine-placebo) (Mendels
1986). In seven studies, alprazolam was compared with amitripty-
line (Banerji 1989; Imlah 1985; Laakman 1995; Lapierre 1994;
di Perri 1990; Rickels 1985; Rush 1985; Singh 1988). In six stud-
ies it was compared with imipramine (Feighner 1983a; Goldberg
1986;Mendels 1986; Murthy 1991; Overall 1987; Rickels 1987).
In five separate studies it was compared with other heterocyclic
antidepressants (’other TCAs’): mianserin (Bassi 1990), dothiepin
(Cropper 1987), desipramine (Remick 1985; Remick 1988) or
doxepin (Rickels 1985).
Dosage of study drugs
The maximum alprazolam dose allowed was within the recom-
mended therapeutic range for anxiety (1.5 to 8 mg; Bandelow
2008) in all studies. The mean alprazolam dose (2.9 mg; SD 0.7)
was also within the recommended therapeutic range in all studies,
although it was not reported in one study (Imlah 1985). Doses
therefore did not seem tobe extraordinarily high.Drugs in the con-
trol groups were within the recommended therapeutic range, al-
though there was considerable variation in themean dose between
control groups. One further option is to classify mean dosages for
the purposes of subgroup analyses in the first revision.
Outcomes
For the continuous outcomes, the HDRS was used in all but two
studies (Cropper 1987; Imlah 1985). Dichotomous outcomes, a
50% reduction of the initial depression score, were reported in six
studies (di Perri 1990; Laakman 1995; Lapierre 1994; Mendels
1986; Rickels 1987; Rush 1985). All studies reported all-cause
withdrawals, but withdrawals due to adverse effects and inef-
fectiveness were not specified in five studies (Feighner 1983a;
Lapierre 1994; Murthy 1991; Rickels 1987; Rush 1985) and
10 studies respectively (Cropper 1987; di Perri 1990; Feighner
1983a; Goldberg 1986; Imlah 1985; Lapierre 1994; Mendels
1986; Murthy 1991; Rickels 1987; Rush 1985).
Sponsorship
Seven studies were clearly supported by the manufacturer of al-
prazolam (Cropper 1987; Goldberg 1986; Imlah 1985; Remick
1988; Rickels 1985; Rickels 1987; Rush 1985) and although the
other studies did not offer any disclosures in the text, they were
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remarkably similar in methodology, suggesting sponsorship by the
manufacturer of alprazolam in all studies.
Risk of bias in included studies
See Figure 1 and Figure 2 for a graphical summary of the method-
ological quality for the 22 included studies. Most of the studies
were older, and many of the recent developments to enhance the
quality of reporting of clinical trials such as the requirement of a
CONSORT statement did not apply at that time. On the basis
of the assessments, we considered six studies to have a high risk of
bias (Ansseau 1984; Banerji 1989; Borison 1989; Draper 1983;
Fabre 1980; Overall 1987). One study we presumed to be a du-
plicate of another study by the same authors and so we considered
it a secondary reference to that study (Remick 1985).
Figure 1.
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Allocation
All studies were reported to be randomised trials, however only
one study reported sufficient details on allocation, and used a
computer-generated randomisation list (Singh 1988).
Blinding
All studies were reported to be double-blind trials, however none
of the studies reported sufficient details on blinding. The best
study described that weekly assessments were completed by the
research psychiatrist (Remick 1988), but did not further describe
the blinding procedures. Independent outcome assessment was a
rarity and was scored unclearly at best in most studies.
Incomplete outcome data
To have adequately addressed incomplete outcome data, studies
had to demonstrate that an intention-to-treat (ITT) analysis was
performed based on all persons randomised, or that attrition was
balanced in numbers with similar reasons for dropout across treat-
ment groups, or that outcome data were complete. Incomplete
outcome data were judged to have been adequately addressed in
eight studies.
Selective reporting
We only included trials in which the primary outcome was severity
of depressive symptoms. However, trial investigators may have
used still other depression rating scales, and only reported data
from the scale that showed a positive effect. Investigators may have
also selectively reported outcomes at the time point(s) at which the
largest effect was found. Selective reporting was difficult to assess
as few trials had pre-published study protocols.
Other potential sources of bias
Over half of the included studies were explicitly supported by the
manufacturer of alprazolam. Another potential source of bias is
the placebo washout phase that all studies bar two used before
entry (Banerji 1989; Cropper 1987).
Effects of interventions
1. Alprazolam versus placebo
Primary outcome
1.1 Hamilton Depression Rating Scale (HDRS) end of trial
Alprazolam produced a moderately better effect than placebo,
based on data from seven studies and 771 persons. For contin-
uous depression severity, the mean difference (MD) was -5.34
(95% confidence interval (CI) -7.48 to -3.20; I2 = 68%), which
was higher than the UK National Institute for Clinical Excellence
(NICE) cut-off of three as being clinically meaningful. When ap-
plying a sensitivity analysis to exclude the two studies of low qual-
ity, with 131 participants, theMD changed slightly to -6.22 (95%
CI -7.42 to -5.02; I2 = 23%; fixed-effect model). For depression
severity, dichotomised as a 50% reduction in the initial mean de-
pression severity score, the risk ratio (RR) was 2.47 (95% CI 1.78
to 3.43; I2 = 0%; fixed-effect model), but only three studies with
312 participants, none of them high-risk, were available for this
comparison. The risk difference (RD) was 0.32 (95% CI 0.22 to
0.42; I2 = 0%; fixed-effect model) and the number needed to treat
to benefit (NNTB) was 3 (95% CI 2 to 5).
Secondary outcomes
1.2 Tolerability
Tolerability was expressed as all-cause withdrawals, based on data
from four studies and 640 participants. The RR of all-cause with-
drawals was 0.78 (95% CI 0.48 to 1.27; I2 = 76%; random-ef-
fects model) for alprazolam versus placebo, indicating that alpra-
zolam did not result in significantly more all-cause withdrawals
than placebo. Without two high-risk studies, this was 0.68 (95%
CI 0.37 to 1.26; I2 = 72%; random-effects model). The RD was
-0.09 (95% CI -0.26 to 0.08; I2 = 87%; random-effects model);
without the high-risk studies it was -0.11 (95% CI -0.30 to 0.09;
I2 = 87%; random-effects model). The number needed to treat to
harm (NNTH) was 11 (95% CI 4 to 13 ). Drowsiness, dry mouth
and dizziness were more common among alprazolam users than
placebo users.
1.2 Adverse effects
For alprazolam versus placebo, the RR of withdrawals due to ad-
verse effects was 1.14 (95% CI 0.05 to 26.35; I2 = 75%; random-
effects model), based on data from two studies with 402 partici-
pants. The RD was -0.01 (95% CI -0.10 to 0.09; I2 = 85%; ran-
dom-effects model). The NNTH was 25 (95% CI -8 to 58).
1.3 Lack of efficacy
For alprazolam versus placebo, the RR of withdrawals due to inef-
fectiveness was 0.40 (95% CI 0.26 to 0.64; I2 = 0%; fixed-effect
11Alprazolam for depression (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
model) favouring alprazolam over placebo, with a RD of -0.13
(95% CI -0.35 to 0.09; I2 = 92%; random-effects model) and a
NNTH of 8 (95% CI 3 to 11), in two studies with 402 partici-
pants.
Subgroup analysis
Speed of recovery
For alprazolam versus placebo, the following MD pattern for de-
pression severity emerged, favouring alprazolam over placebo at
all time points but three weeks: -2.88 (95% CI -4.95 to -0.81; I
2 = 79%) at one week; -3.34 (95% CI -6.07 to -0.61; I2 = 75%)
at two weeks; -0.42 (95% CI -3.69 to 2.85; I2 = 70%) at three
weeks; -4.78 (95%CI -8.17 to -1.39; I2 = 85%) at four weeks; and
-5.19 (95% CI -7.72 to -2.66; I2 = 76%) at six weeks. Without
the high-risk studies, these results were MD -3.20 (95% CI -5.66
to -0.74; I2 = 82%); -4.55 (95% CI -8.48 to -0.63; I2 = 78%); -
2.00 (95%CI -4.31 to 0.31; single study: no I2 estimate possible);
-6.58 (95% CI -9.96 to -3.20; I2 = 80%); and -6.07 (95% CI -
7.33 to -4.82; I2 = 46%). Allmodels but the last one were random-
effects.
2. Alprazolam versus tricyclic antidepressants
Primary outcome
2.1 Hamilton Depression Rating Scale (HDRS) end of trial
The effect of alprazolam did not differ from the effects of all tri-
cyclic antidepressants (TCAs) combined, based on 17 studies and
1636 participants. For continuous depression severity, the pooled
mean difference (MD) was 0.25 (95%CI -0.93 to 1.43; I2 = 55%;
random-effects model), which was similar to the estimate without
the five studies with a high risk of bias: MD 0.06 (95%CI -1.40 to
1.52 ; I2 = 63%; random-effects model). For 50% reduction in the
initial mean depression severity score, the RR was 0.86 (95% CI
0.75 to 0.99; I2 = 37%; fixed-effect model), which was available
for 543 participants in seven studies. Without the one high-risk
study, this was 0.87 (95% CI 0.74 to 1.02; I2 = 47%; fixed-effect
model). The RD was -0.11 (95% CI -0.24 to 0.01; I2 = 58%; ran-
dom-effects model); without the one high-risk study it remained
-0.11 (95% CI -0.26 to 0.04; I2 = 65%, random-effects model).
The NNTB on the basis of the RD was 9 (95% CI 4 to 100).
All TCA subgroups gave similar HDRS estimates (amitriptyline,
imipramine, doxepin) to alprazolam, except for one study with
desipramine, which did worse (-1.14, 95% CI -1.93 to -0.34).
Amitriptyline produced a better dichotomous HDRS outcome
than alprazolam with a RR of 0.77 (95% CI 0.66 to 0.89; I2 =
1%; fixed-effect model) and a RD of -0.19 (95% CI -0.30 to -
0.07; I2 = 27%; fixed-effect model).
Secondary outcomes
2.2 Tolerability
For alprazolam versus all TCAs, based on data from 18 studies
and 1873 participants, the RR for all-cause withdrawals was 0.84
(95% CI 0.72 to 1.00; I2 = 18%; fixed-effect model), indicating
that alprazolam was better tolerated than the group of TCAs as a
whole. Without the four high-risk studies with 378 participants,
the RR was 0.83 (95% CI 0.69 to 1.01; I2 = 9%; fixed-effect
model). The RD was -0.04 (95% -0.07 to 0.00; I2 = 35%; fixed-
effect model), while without the three high-risk studies it was still
-0.04 (95% CI -0.08 to 0.00; I2 = 20%; fixed-effect model). The
NNTHwas 25 (95%CI 14 to 100). The tolerability of alprazolam
did not differ from that of most TCAs, but imipramine had more
all-cause withdrawals (RR 0.71, 95% CI 0.56 to 0.90, I2 = 0%;
RD -0.10, 95% CI -0.17 to -0.03; I2 = 0%).
2.3 Adverse effects
For alprazolam versus all TCAs, the RR of withdrawals due to
adverse effects was 0.62 (95% CI 0.43 to 0.88; I2 = 24%; fixed-
effect model), in favour of alprazolam, based on 11 studies with
1139 participants. Without the high-risk studies, the RR was 0.57
(95% CI 0.37 to 0.90; I2 = 28%; fixed-effect model). However,
the RD was only -0.04 (95% CI -0.08 to 0.01; I2 =60%; random-
effects model) and without the high-risk studies -0.03 (95% CI -
0.08 to 0.03; I2 = 62%; random-effects model). The NNTH was
25 (95% CI 11 to 100). Alprazolam had fewer withdrawals due
to adverse effects than amitriptyline with a RR of 0.58 (95% CI
0.37 to 0.90, I2 = 55%) but with a RD of -0.03 (95% CI -0.10
to 0.04, I2 = 77%) and doxepin (RR 0.24, 95% CI 0.07 to 0.82;
RD -0.08, 95% CI -0.14 to -0.03).
2.4 Lack of efficacy
For alprazolam versus all TCAs, the RR of withdrawals due to lack
of efficacy was 1.66 (95% CI 0.99 to 2.79; I2 = 0%; fixed-effect
model), with a RD of 0.02 (95% CI -0.04 to 0.08; I2 = 67%;
random-effects model) and a NNTH of 50 (95% CI 25 to 13)
in four studies with 686 participants. It had more ineffectiveness
withdrawals than doxepin (RR 2.26, 95% CI 1.03 to 4.98; RD
0.08, 95% CI 0.01 to 0.16).
Subgroup analysis
Speed of recovery
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The MD for depression severity for alprazolam versus all TCAs
was -1.48 (95% CI -2.77 to -0.18; I2 = 73%) at one week; -1.57
(95% CI -3.39 to 0.25; I2 = 79%) at two weeks; 1.47 (95% CI
-1.99 to 4.94; I2 = 74%) at three weeks; 0.25 (95% CI -1.20 to
1.70; I2 = 64%) at four weeks; 0.83 (95% CI -5.13 to 6.80; I2 =
85%) at five weeks and 0.24 (95% CI -1.06 to 1.54; I2 = 54%) at
six weeks. At two weeks, the difference lost significance. Without
the high-risk studies, the difference lost significance at three weeks:
MD -2.04 (95% CI -3.30 to -0.77; I2 = 64%); -2.42 (95% CI -
4.39 to -0.46; I2 = 72%); 1.47 (95% CI -1.99 to 4.94 ; I2 = 74%);
-0.13 (95% CI -1.81 to 2.08; I2 = 70%); 0.83 (95% CI -5.13 to
6.08; I2 = 85%) and 0.33 (95% CI -1.32 to 1.99; I2 = 66%). All
models were random-effects.
3. Alprazolam versus heterocyclic antidepressants
Primary outcome
3.1 Hamilton Depression Rating Scale (HDRS) end of trial
The effect of alprazolam did not differ from the effects of mi-
anserin, based on one study and 61 participants: the MD was -
2.50 (95% CI -7.02 to 2.02).
Secondary outcomes
3.2 Tolerability
The RR of all-cause withdrawals for alprazolam versus mianserin,
based on data from one study and 61 participants, was 0.24 (95%
CI 0.03 to 2.04), indicating that alprazolam did not result in
significantly more all-cause withdrawals than mianserin. The RD
was -0.10 (95% CI -0.24 to 0.04).
3.3 Adverse effects
For alprazolam versus mianserin, the RR of withdrawals due to
adverse effects was 0.48 (95% CI 0.05 to 5.06), with a RD of -
0.03 (95% CI -0.14 to 0.07).
3.4 Lack of efficacy
For alprazolam versus mianserin, the RR of withdrawals due to
ineffectiveness was 0.19 (95% CI 0.01 to 3.88), with a RD of -
0.07 (95% CI -0.17 to 0.04).
4. Alprazolam versus SSRIs
We found no trials that assessed the effects of alprazolam versus
SSRIs.
Sensitivity analysis
Two of the three planned sensitivity analyses were not considered
useful post hoc as all but one study used formal diagnostic criteria
(see ’Types of participants’ ’Diagnosis’). We were also able to use
a physician-rated outcome for all studies and, therefore, no self
reports were required. We added two other sensitivity analyses:
1. To test the effect of including trials with imputed SD values
in three of the seven studies of alprazolam versus placebo, we
excluded these, but this did not change the MD much (MD -
5.35, 95% CI -9.29 to -1.40; I2 = 83%). Alprazolam did worse
than all TCAs combined after we excluded eight studies with
imputed SDs, as the MD point estimate became 1.44 (95% CI -
0.05 to 2.93; I2 = 50%; random-effects model).
2. To test for the effect of including sub-samples of inpatients,
we excluded a study on alprazolam versus all TCAs with 17
inpatients of 49 patients available at three weeks who perhaps
had a more severe depression (Rush 1985). This did not alter the
MD point estimate (-0.06, 95% CI -1.16 to 1.05; I2 = 47%;
fixed-effect model). The other study with some inpatients did
not report a usable primary outcome, therefore this study did not
affect any of the effect estimates. We could not include it in a
sensitivity analysis (Imlah 1985).
D I S C U S S I O N
Summary of main results
Alprazolam versus placebo
At the end of trial, alprazolam was more effective than placebo,
based on the mean difference (MD) of -5.34 (95% confidence
interval (CI) -7.48 to -3.20; I2 = 68%) of reduction in symptoms
on the Hamilton Depression Rating Scale (HDRS). The high
heterogeneity found for this important comparison indicates that
the positive effects of alprazolam in treating depression are to some
extent provisional and should be weighed against the potential
adverse effects of the medication. However, several studies were
of low quality and when applying a sensitivity analysis the results
changed to a slightly higherMD of -6.22 (95%CI -7.42 to -5.02),
but with less heterogeneity (I2 = 23%).
Based on the dichotomous 50% reduction in the initial mean
depression severity scores, alprazolam was also more effective than
placebo, with a risk ratio (RR) of 2.47 (95% CI 1.78 to 3.43; I2
= 0%) and risk difference (RD) of 0.32 (95% CI 0.22 to 0.42; I2
= 0%). There was less heterogeneity in this comparison.
Tolerability was expressed as all-cause withdrawals, with a RR of
0.78 (95% CI 0.48 to 1.27; I2 = 76%), indicating that alprazolam
didnot have significantly fewer all-causewithdrawals thanplacebo.
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Leaving the high-risk studies out did not reduce heterogeneity
substantially (I2 = 72%).
Alprazolam versus tricyclic antidepressants
Alprazolam was as effective as its tricyclic comparators. Based on
17 studies and 1636 participants, the pooled mean difference
(MD) for depression severity was 0.25 (95% CI -0.93 to 1.43; I
2 = 55%), which was similar to the estimate without studies with
a high risk of bias: MD 0.06 (95% CI -1.40 to 1.52; I2 = 63%).
However, based on the dichotomous 50% reduction on the initial
mean depression severity scores, and considerably fewer studies,
alprazolam was less effective than the tricyclics with a RR of 0.86
(95% CI 0.75 to 0.99; I2 = 37%). There was some evidence that
alprazolam produces a response faster than placebo and than tri-
cyclic antidepressants (TCAs). The RR of all-cause withdrawals
was 0.84 (95% CI 0.72 to 1.00; I2 = 18%) for alprazolam versus
the tricyclics, indicating that alprazolam had significantly fewer
all-cause withdrawals. Leaving the high-risk studies out further
reduced heterogeneity (I2 = 9%) in this comparison.
Alprazolam versus heterocyclic antidepressants
The effects of alprazolam did not differ from those of mianserin
in any comparison.
Overall completeness and applicability of
evidence
Most of the included studies are older trials; comparisons with
newer antidepressants would have been informative, but these
were not found. We doubt whether there will be many new stud-
ies on the subject but in a future update, we will assess anxiety
as a secondary outcome as alprazolam’s effect on depression may
be due to underlying anxiety. Undiagnosed anxiety disorders or
substantial sub-threshold anxiety symptoms may have placed the
benzodiazepine at an advantage. We will also add inpatient studies
and a severity subgroup analysis as it may exert its effect on de-
pression through non-specific sedative effects on improved sleep
and reduced agitation, particularly for mild to moderate depres-
sion. One of the key limitations of the review is that the crucial
issue of dependence on benzodiazepines (and the allied problems
of tolerance, dose escalation and difficult withdrawal) cannot be
captured by the present methodology. Indeed, it is even possi-
ble when using the conventional methodology, including all-cause
withdrawals as the main measure of tolerability, that a drug which
causes dependence and is difficult towithdraw frommay inevitably
be associated with fewer withdrawals than one that does not. After
long-term treatment with benzodiazepines (e.g. over two to eight
months), dependency may occur in a substantial number of pa-
tients (Bandelow 2008; Rickels 1990; Schweizer 1990), especially
in predisposed persons with, for instance, an alcohol problem.
Quality of the evidence
There is ample room for methodological improvement as Figure
1 and Figure 2 show: important quality criteria such as allocation
concealment and adequate randomisation procedures were largely
absent. Very few studies also used independent outcome assess-
ments: doctors typically assessed subjects themselves. Another po-
tentially worrying issue is publication bias as was demonstrated in
other antidepressant studies (Kirsch 2008). The role of the sponsor
in the presentation of results could have been large. Many studies,
for instance, used exactly the same set of instruments, and it is not
clear what results or studies have not been published. Psychotropic
drug studies frequently have methodological problems that tend
to weaken the contrast between the drug and placebo, and inflate
claimed effects (Van Marwijk 2006). To give two examples: many
studies used a placebowashout period. This design feature severely
limits the ability to generate accurate estimates of the placebo re-
sponse rate (Fournier 2010). Because early placebo responders are
removed from the trial before they can contribute data, the true
rate of placebo response may be underestimated in trials that use
this feature. Another example is the difficulty of blinding: subjects
quickly experience alprazolam’s sedative effects. Most of the stud-
ies were performed before the publication and implementation of
current quality criteria for conducting and reporting randomised
controlled clinical trials (CONSORT).
Potential biases in the review process
Although this review has several strengths, such as a pre-pub-
lished protocol, an experienced librarian who performed thorough
searches, two authors to select studies/data extract/assess risk of
bias and a third to resolve disputes, there were also post hoc de-
cisions. The management of antidepressant classes was one. We
would have also liked to analyse the effects of alprazolam dosage
and the loss of efficacy due to concomitant dose increase but this
was not possible due to insufficient data. The review authors have
the impression that all studies were in some way sponsored by the
pharmaceutical company that manufactured alprazolam. Publica-
tion bias cannot be excluded.
Agreements and disagreements with other
studies or reviews
There are no related non-Cochrane systematic reviews, however
we did identify three literature reviews (Birkenhager 1995; Jonas
1993; Srisurapanont 1997). In Birkenhager 1995 alprazolam was
found to be effective in mild to moderate depression, but inferior
to TCAs in patients with endogenous or melancholic depression.
It may not cause amelioration of core symptoms. In Jonas 1993 al-
prazolam demonstrated efficacy for depression, equal in efficacy to
comparison agents. Medical events were reported infrequently or
not at all for alprazolam and the comparator drugs; there were no
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marked differences between drug classes. In Srisurapanont 1997,
the antidepressant effect of alprazolam was comparable to that of
low-dose TCAs, but the lack of long-term treatment studies makes
the issue of alprazolam’s benefits and disadvantages still undeter-
mined. The results of these three reviews are therefore consistent
with our findings here.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The best evidence currently available suggests that alprazolammay
be moderately more effective than a placebo and as effective as
conventional antidepressants in the treatment of major depres-
sion. We cannot conclude whether this is due to its specifically an-
tidepressant effect or rather to its non-specific effect on sleep and
anxiety. There were relatively few short-term side effects. How-
ever, the multiple shortcomings of the evidence, including proba-
ble sponsorship bias, publication bias, age of the studies and het-
erogeneity of the results, lessen our confidence in the estimates
of its effectiveness based on the currently available evidence. The
negative effects of benzodiazepine treatment, such as dependence
and withdrawal reactions, cast further doubt on the risk-benefit
ratio of the use of alprazolam as an antidepressant. It is also likely
that some participants had undiagnosed anxiety disorders or sub-
stantial sub-threshold anxiety symptoms, which may have placed
the benzodiazepine at an advantage.
Implications for research
We found no studies that compared alprazolam to newer antide-
pressants, such as selective serotonin reuptake inhibitors (SSRIs),
which would have been informative. SSRIs are as effective as other
antidepressants but may have a more favourable risk-benefit ratio
(NICE 2009; Van Marwijk 2003), however, the included stud-
ies compared alprazolam to antidepressants which may no longer
be used as first-line treatment for depression. In view of the re-
markable similarity of the design of nearly all studies, we have the
distinct impression that the manufacturer of alprazolam funded
all of them. An independently funded study comparing the ef-
fects of alprazolam to placebo or to SSRIs would, therefore, be
desirable. Claims of the clinical utility of benzodiazepines would
best be tested using a cost-benefit analysis. All studies looked at
short-term effects, but many of the potential side effects of ben-
zodiazepines, except accident-proneness, are to be expected in the
longer term. Research into the effects of alprazolam in different
patient subgroups (the elderly and severely depressed) should be
conducted. Investigation of the contribution of possible method-
ological sources of heterogeneity observed in this study, such as
different medication doses, is also warranted. An interesting pos-
sibility for future studies would be to evaluate core items on the
Hamilton Depression Rating Scale (HDRS) (for example, exclud-
ing sleep) to consider non-specific effects.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Ansseau 1984
Methods Randomised controlled trial, 6 weeks
Participants 126 outpatients with primary affective non-psychotic depression of at least moderate
severity, required to have a Raskin Depression Scale (RDS) score of at least 8, at least 5
items on Feighner Depression Checklist (FDC), a Covi Anxiety Score (CAS) equal to
or less than RDS, a HDRS score of at least 18 on the 21-item HDRS, and an anxiolytic
antidepressant was warranted
145 participants were enrolled of whom 19 were not available; 126 outpatients were
therefore available
Aged 18 to 70 years
Interventions Alprazolam versus doxepin
Placebo washout for 4 to 7 days
Maximum dose for alprazolam 4.5 mg and for doxepin 225 mg
Mean final doses 2.7 mg for alprazolam and 137.5 mg for doxepin
Outcomes Primary outcome:
Mean HDRS after 6 weeks: alprazolam 11 (initial 24.9), doxepin 11 (initial 25.1)
Secondary outcomes:
All-cause withdrawals: 23% for alprazolam, 12% for doxepin
Side effects: drowsiness (alprazolam 22%, doxepin 28%), dry mouth (alprazolam 3%,
doxepin 36%), constipation (alprazolam 3%, doxepin 28%), lightheadedness (alprazo-
lam 15%, doxepin 18%)
32 alprazolam patients (of 59) reported 142 side effects (mean of 4.4 per reporting
patient), versus 45 (of 67) doxepin patients who reported 357 side effects (mean of 8.5
per patient)
Notes Results reported in table 1 (change scores) and figure 1 do not match
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Patients were randomly assigned to treatment.
” “... no statistical differences between the two
treatment groups except for sex.”
No further information provided
Allocation concealment (selection bias) Unclear risk No further information provided
Blinding (performance bias and detection
bias)
Patients
Unclear risk “Double-blind study” “Initial dose of 2 tablets.
..”
They probably used identical tablets, but this is
20Alprazolam for depression (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Ansseau 1984 (Continued)
not described in the study
Blinding (performance bias and detection
bias)
Physicians
Unclear risk They used a standard scheme for dose increase
Blinding (performance bias and detection
bias)
Investigators
Unclear risk Not described how they managed to keep the
medication separated for each patient so that
the investigators were blinded for the therapy as
well.No information is provided about whether
they used an investigator to do the assessments
Incomplete outcome data (attrition bias)
HDRS
High risk Initially, “13 patients in the alprazolam group
and 6 patients in the doxepin group were not
available”. Thus, 19/145 (13%) of the enrolled
patients enrolled were not available
They further describe that 7 patients in the al-
prazolam group and 4 patients in the doxepin
group were not available at final assessment; but
it is not clear why these are left out of the eval-
uation
”Concomitant medical events, which may or
may not have been adverse reactions to treat-
ment, prompted the investigators to discon-
tinue treatment for 11 patients.”
Incomplete outcome data (attrition bias)
Withdrawals/side effects
Low risk Unclear why numbers do not seem to match
Selective reporting (reporting bias) Unclear risk No information provided
Other bias Low risk Dosing:
Both drugs were given in the therapeutic range
Placebo washout High risk Yes
Banerji 1989
Methods Randomised controlled trial, 4 weeks
Participants 104 patients in general practice suffering from neurotic or reactive depression (for at
least 2 weeks) entered the study, 3 were lost to follow-up, 104 patients were included.
An RDS score of at least 6 with a CAS score of no more than the RDS was required to
be eligible for entry
Patients who were withdrawn from the study before week 2 were not included in the
analysis of data for therapeutic efficacy, but were evaluated for side effects. 21 patients
failed to complete 2 weeks treatment -> 80 participants (40 each group) were evaluated
for treatment
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Banerji 1989 (Continued)
Aged 18 to 70 years
Interventions Alprazolam versus amitriptyline
Maximum dose: alprazolam 3 mg and amitriptyline 150 mg
Average daily dose alprazolam 1.8 mg and for amitriptyline 63.8 mg
Outcomes Primary outcome:
Mean HDRS after 4 weeks: alprazolam 9.2 (initial 21.9) and amitriptyline 5.9 (initial
21.1)
50% reduction of baseline HDRS score: alprazolam 26/40 (72%), 32/40 amitriptyline
(84%)
Secondary outcome:
All-cause withdrawals: alprazolam 10/51 (20%), amitriptyline 13/53 (25%)
Withdrawals due to side effects: alprazolam 6/51 (12%), amitriptyline 11/53 (21)%
Physicians’ evaluation of no side effects: alprazolam 36%, amitriptyline 54%
Side effects: insomnia alprazolam 22%, amitriptyline 6%, headache alprazolam 20%,
amitriptyline 4%, dry mouth 30%, amitriptyline 65%
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomised design”. No information pro-
vided
Allocation concealment (selection bias) Unclear risk No information provided
Blinding (performance bias and detection
bias)
Patients
Low risk “The drugs were presented in identical capsules.
” The drugs looked the same, but there appears
to have been a difference in side effect profile
Blinding (performance bias and detection
bias)
Physicians
Unclear risk “The drugs were presented in identical capsules.
”No further informationprovided; unclear how
physicians administered the drugs, while the
tablets looked the same
Blinding (performance bias and detection
bias)
Investigators
Unclear risk “The drugswere presented in identical capsules”
Incomplete outcome data (attrition bias)
HDRS
High risk 20% of the included patients were withdrawn
from the study and were not evaluated for treat-
ment
Incomplete outcome data (attrition bias)
Withdrawals/side effects
Unclear risk “...21 patients failed to complete two weeks
treatment with the investigational drug (seven
protocol violations and 14 withdrawals)”
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Banerji 1989 (Continued)
From table: 7 protocol violations: 5 alprazolam
and 2 amitriptyline, 13 withdrawals due to side
effects: 4 alprazolam and 9 amitriptyline and 1
withdrawal due to feeling improved: alprazolam
Selective reporting (reporting bias) Unclear risk No information provided
Other bias Unclear risk Low therapeutic dosage of amitriptyline in com-
parison to that of alprazolam
Placebo washout Low risk No information provided
Bassi 1990
Methods Randomised controlled trial, 4 weeks
Participants 61 outpatients diagnosed with depressive neurosis according to DSM-III. Score of at
least 9 on RDS and at least 18 on HDRS
Aged 19 to 70 years
Interventions Alprazolam versus mianserin (30/31 patients)
Placebo washout 7 days
Maximum dose: alprazolam 5 mg and mianserin 90 mg
Mean maximum daily dose: alprazolam 2.4 mg and mianserin 47 mg
Outcomes Primary outcome:
Mean HDRS after 4 weeks: alprazolam 10, mianserin 12.5 (estimate from figure)
Secondary outcome:
All-cause withdrawals: alprazolam 1 (3%) and mianserin 4 (13%)
Withdrawals due to side effects: alprazolam 1 (3%), mianserin 2 (7)
Notes In the abstract, “depression neurosis (or dysthymic disorder)” is described as the diag-
nosis for inclusion, but the results are not specified for major depressive episode and/or
dysthymia. As all participants had at least a HDRS score of 18, we assume that some
patients had so called double depression
HDRS version not specified, HDRS-21 assumed
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomized allocation”. No other informa-
tion is provided
Allocation concealment (selection bias) Unclear risk No information is provided
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Bassi 1990 (Continued)
Blinding (performance bias and detection
bias)
Patients
Low risk “Double blind”. No other information is pro-
vided
Blinding (performance bias and detection
bias)
Physicians
Unclear risk No information is provided
Blinding (performance bias and detection
bias)
Investigators
Unclear risk No information is provided
Incomplete outcome data (attrition bias)
HDRS
Low risk No information is provided
Incomplete outcome data (attrition bias)
Withdrawals/side effects
Low risk No information is provided
Selective reporting (reporting bias) Unclear risk SD not reported
Other bias Unclear risk No information provided
Dosages are in adequate range
Placebo washout High risk 7 days
Borison 1989
Methods Randomised, double-blind study, 6 weeks
Participants 119 outpatients, who met DSM III criteria for major depressive disorder and scored at
least 18 on the HDRS
82 patients, data analysis on those who completed a minimum of 28 days of treatment
(25 patients on 3 mg and 25 patients on 6 mg of alprazolam and 32 patients on placebo)
Aged 18 to 65 years
Interventions Alprazolam versus placebo (25/25/32)
Placebo washout 7 days
Outcomes Primary outcome:
Mean HDRS after 6 weeks: alprazolam 7.2 (initial 23.86), placebo 6.71 (initial 22.16)
Secondary outcome:
All withdrawals: alprazolam 3 mg 38%, alprazolam 6 mg 36% and placebo 20%
Side effects:
Drowsiness alprazolam 3mg 73%, alprazolam 6mg 59%, placebo 35%; lightheadedness
alprazolam 3 mg 35%, alprazolam 6 mg 21%, placebo 15%; dry mouth: alprazolam
3 mg 28%, alprazolam 6 mg 23%, placebo 13%; confusion: alprazolam 3 mg 23%,
alprazolam 6 mg 18%, placebo 5%; nervousness alprazolam 3 mg 18%, alprazolam 6
mg 8%, placebo 5%
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Borison 1989 (Continued)
Notes We collapsed both alprazolam arms (3 mg and 6 mg) into 1 arm and pooled means and
SDs for the HDRS
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “...randomized double-blind phase of the
study.”
No further information provided
Allocation concealment (selection bias) Unclear risk No information provided
Blinding (performance bias and detection
bias)
Patients
Unclear risk “randomised double-blind phase of the
study.” Identical tablets
Medication: alprazolam was compared to
placebo; the experience of (side) effects
could influence the patient; thinking they
are using the ‘real’ medication
Blinding (performance bias and detection
bias)
Physicians
Unclear risk No information provided
Blinding (performance bias and detection
bias)
Investigators
Unclear risk Three investigators are used, but no other
information is provided
Incomplete outcome data (attrition bias)
HDRS
High risk “The early dropout rate in the active treat-
ment groups was primarily due to ad-
verse effects ofmedication,whereas placebo
dropouts were due to administrative rea-
sons.”
69% of the 119 patients who entered the
study could be analysed
Incomplete outcome data (attrition bias)
Withdrawals/side effects
Unclear risk There were different reasons for early
dropout between the patients using medi-
cation and those using placebo
Selective reporting (reporting bias) Unclear risk No information provided
Other bias Unclear risk 6 mg alprazolam is a very high, not recom-
mended dose
Placebo washout High risk 7 days
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Cropper 1987
Methods Randomised controlled trial, 4 weeks
Participants 100 patients in general practice with mixed symptoms of anxiety and depression. Min-
imum score of at least 9 in both components of the Hospital Anxiety and Depression
Scale (HADS)
Aged 18 to 69 years
Interventions Alprazolam versus dothiepin (50/50 patients)
Maximum dose: alprazolam 3 mg, dothiepin 150 mg
Mean maximum daily dose: alprazolam 2.33 mg, dothiepin 115 mg
Outcomes Primary outcomes: not described
Secondary outcomes:
All-cause withdrawals after 4 weeks: alprazolam 8 (4.0%), dothiepin 8 (4.0%)
Withdrawals due to side effects: alprazolam 2 (4.1%), dothiepin 5 (10.6%)
Number drug-related adverse effects: alprazolam 5 (10.2%), dothiepin 9 (19.2%)
Physician’s global assessment of severity of illness after 4 weeks: alprazolam 0.95 (initial
score of 2.47, SD 0.58), dothiepin 0.76 (initial score of 2.38, SD 0.66)
HADS, self report, depression scale score after 4 weeks: alprazolam: 6.6 (SD 3.76) and
dothiepin 5.9 (SD 3.11)
Notes Patients must have complied with the protocol for 2 weeks to be included in the analysis
of the treatment. Side effect data are available for those who attended the first week
follow-up assessment
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Patients were randomly and blindly allocated
to treatment groups...” No other information is
provided
Allocation concealment (selection bias) Unclear risk No information provided
Blinding (performance bias and detection
bias)
Patients
Low risk “The study medications were presented in iden-
tical capsules, each containing...”
Blinding (performance bias and detection
bias)
Physicians
Unclear risk “...and a new bottle was dispensed for the next
study period.”Noother information is provided
Blinding (performance bias and detection
bias)
Investigators
Unclear risk No information provided
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Cropper 1987 (Continued)
Incomplete outcome data (attrition bias)
HDRS
Unclear risk 16 patients were not included for analysis due to
protocol violations (alprazolam 6, dothiepin 3)
and adverse effects (alprazolam 2, dothiepin 5).
Different reasons for dropout were not equally
distributed between the treatment groups; there
was no intention-to-treat analysis
Incomplete outcome data (attrition bias)
Withdrawals/side effects
Low risk All data for patients who attended the week 1
follow-up assessment were analysed
Selective reporting (reporting bias) Unclear risk No information provided
Other bias High risk Patients included with mixed anxiety and de-
pression
Maximum dose of alprazolam is adequate ther-
apeutic maximum dose in contrast to the max-
imum dose of dothiepin, which is lower than
the recommended maximum therapeutic range
(100 to 200 mg)
Support from alprazolam manufacturer
Placebo washout Unclear risk No information provided
di Perri 1990
Methods Randomised controlled trial, 4 weeks
Participants 60 patients with moderate neurotic depression according toDSM-III and ICD-9 criteria
(endogenous depression excluded) with a RDS score of at least 8 and a HDRS score of
at least 18
Aged 18 to 70 years
Interventions Alprazolam versus amitriptyline (30/30 patients)
Placebo washout period for 4 to 7 days
Maximum dose: alprazolam 4.5 mg and amitriptyline 225 mg
Mean daily dose: alprazolam 2.3mg and amitriptyline 97.7 mg
Outcomes Primary outcome:
Mean HDRS after 4 weeks: alprazolam 8.25 (initial score 26), amitriptyline 8.06 (initial
score 26)
Secondary outcomes:
All-cause withdrawals: alprazolam 8 (27%), amitriptyline 8 (27%)
Withdrawals due to side effects: alprazolam 3 (10%), amitriptyline 0 (0%)
Notes HDRS-21
Risk of bias
27Alprazolam for depression (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
di Perri 1990 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “...randomized allocation”.No further informa-
tion is provided
Allocation concealment (selection bias) Unclear risk No information provided
Blinding (performance bias and detection
bias)
Patients
Low risk “...double blind study... active drug supplied in
capsules of identical aspect.” No further infor-
mation provided
Blinding (performance bias and detection
bias)
Physicians
Unclear risk “...double blind study”. No further information
is provided
Blinding (performance bias and detection
bias)
Investigators
Unclear risk No information provided
Incomplete outcome data (attrition bias)
HDRS
Unclear risk Lack of clarity concerning analysis, probably
endpoint analysis of remaining patients
Incomplete outcome data (attrition bias)
Withdrawals/side effects
High risk No information provided
Selective reporting (reporting bias) High risk SD not reported
Other bias Unclear risk No information provided
Placebo washout High risk 4 to 7 days
Draper 1983
Methods Randomised controlled trial, 6 weeks
Participants 36 o utpatients with neurotic/reactive depression and a minimum RDS of 8 which had
to equal or exceed the CAS score indicating that depression predominated. They had to
satisfy FDC criteria for primary affective disorder and achieve a minimum score of 17
on the HDRS
201 had a diagnosis of depression (151 of whom had neurotic depression). 60 did not
fulfil severity criteria, 30 refused, or had other treatment etc., 25 left because of physical
illness, 16 had wrong age, 11 responded to existing therapy, and 7 had the wrong clinical
presentation
Of 52 participants remaining, 51 had neurotic depression and of these 36 met the
inclusion criteria, 11 failed to reattend and 15 were ultimately available for the final
assessments
Aged 18 to 60 years
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Draper 1983 (Continued)
Interventions Alprazolam versus amitriptyline
Placebo wash-out period 4 to 7 days
Mean dosage: 2.15 mg alprazolam per day and 85 mg amitriptyline per day
Outcomes Primary outcome:
Mean HDRS after 4 weeks: alprazolam 8.25 (initial 26), amitriptyline 8.06 (initial 26)
Secondary outcome:
All-cause withdrawals: alprazolam 8 (27%), amitriptyline 8 (27%)
Withdrawals due to side effects:
Alprazolam 3 (10%), amitriptyline 0 (0%)
Notes At 6 weeks n = 10, alprazolam and n = 10 to n = 5 for amitriptyline
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “The design of the study was double blind with
random allocation.”
No further information provided
Allocation concealment (selection bias) Unclear risk No information provided
Blinding (performance bias and detection
bias)
Patients
Low risk “...in matched capsules.” “The design of the
study was double blind”
We assume patients were blinded
Blinding (performance bias and detection
bias)
Physicians
Unclear risk No information provided
Blinding (performance bias and detection
bias)
Investigators
Unclear risk No information provided
Incomplete outcome data (attrition bias)
HDRS
High risk 31% of the recruited patients were non-avail-
able
Incomplete outcome data (attrition bias)
Withdrawals/side effects
High risk “Two-thirds of the alprazolam treated group re-
mained in trial at week six compared with one
half of the amitriptyline treated group.”
Of the 15 patients in the alprazolam group,
10 were available at the end, while for the
amitriptyline group, of the 10 patients, 5 were
available
Selective reporting (reporting bias) Unclear risk No information provided
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Draper 1983 (Continued)
Other bias High risk Dosing of medication, at least for amitriptyline
Placebo washout High risk 4 to 7 days
Fabre 1980
Methods Randomised controlled trial, 6 weeks
Participants 154 outpatients with primary depression of moderate to severe degree, a RDS score of
at least 8, at least 5 associated items on Feighner depression checklist, CAS equal or
less than the Raskin and a HDRS score of at least 18. Patients were selected from the
outpatient population at the Fabre Clinic in Houston, Texas
104 participants were included in the statistical analysis
Aged 17 to 65 years
Interventions Alprazolam versus imipramine versus placebo
Placebo washout 4 to 7 days
Mean dosage of alprazolam 2.7 mg/day and for imipramine 126.5 mg/day
Outcomes Primary outcome:
Mean HDRS after 6 weeks: alprazolam 15.5 (initial 28), imipramine 15.7 (initial 28),
placebo 19 (initial 28)
Secondary outcomes:
All-cause dropouts: alprazolam 20 /51 (3 9 % ) , imipramine 1 8 /52 (3 5 % ) , placebo
36/51 (71 % )
Notes No numbers in the text; results were read from figure
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “The design of the study was double blind with
random allocation to test drug, standard drug
and placebo. The randomisation was forced so
that in each consecutive group of six patients
there were two on each drug treatment.”
No further information provided
Allocation concealment (selection bias) Unclear risk No further information on the ’blocked ran-
domisation’ provided
Blinding (performance bias and detection
bias)
Patients
Unclear risk “...double blind...” use of capsules
We assume that identical capsules were used,
but this is not stated in the paper
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Fabre 1980 (Continued)
Blinding (performance bias and detection
bias)
Physicians
Unclear risk No information is provided
Blinding (performance bias and detection
bias)
Investigators
Unclear risk No information is provided
Incomplete outcome data (attrition bias)
HDRS
High risk Unclear whether patients with ineffective med-
ication were included in the analysis
“31 of 35 alprazolam patients completed the
study and 34 of 38 receiving imipramine com-
pleted the study as compared to only 15 of the
31 receiving placebo.”
Incomplete outcome data (attrition bias)
Withdrawals/side effects
High risk 154 entered the study, but 104 were included
in the statistical analysis
“Sixteen of the unavailable patients were in the
alprazolam group, fourteen in the imipramine
group and twenty in the placebo group.” The
majority were lost to follow-up: 13, 13 and 19.
Others: one inter-current life event, 2 moved
away and 1 refused to co-operate with the in-
vestigator
Unclear whether the analysis at week 6 is with
all patients or only with those who completed
the study
Selective reporting (reporting bias) Unclear risk No information provided
Other bias Unclear risk No information provided
Placebo washout Unclear risk 4 to 7 days
Feighner 1983a
Methods Randomised controlled trial, 6 weeks
Participants 129outpatients suffering frommoderate to severe symptomsof unipolarmajor depressive
disorder, RDS score at least 8, CAS less or equal RDS, HDRS score at least 18
Age: 18 to 70 years
Interventions Alprazolam versus imipramine versus placebo (41/43/45)
Placebo ’washout’ period 4 to 7 days
Maximum dose alprazolam: 4.5 mg, imipramine 225 mg, placebo 12 capsules
Mean daily dose alprazolam: 2.7 mg, imipramine 117.3 mg, placebo 7.2 capsules
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Feighner 1983a (Continued)
Outcomes Primary outcome:
Mean HDRS after 6 weeks: alprazolam 16.1 (initial score of 30.5, SD 14.4), imipramine
17.4 (initial score of 30.4, SD 12.5), placebo 28.0 (initial score of 30.0, SD 14)
Secondary outcome:
All-cause withdrawals: alprazolam 4 (9.8%), imipramine 11 (25.6%), placebo 21 (46.
7%)
Notes Endpoint analysis
HDRS-21
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information is provided
Allocation concealment (selection bias) Unclear risk No information is provided
Blinding (performance bias and detection
bias)
Patients
Unclear risk “Patients...took identical appearing capsules
daily for 42 days.” Drugs compared to placebo;
patients taking placebo will not experience (as
many) side effects
Blinding (performance bias and detection
bias)
Physicians
Unclear risk No information is provided
Blinding (performance bias and detection
bias)
Investigators
Unclear risk No information is provided
Incomplete outcome data (attrition bias)
HDRS
Unclear risk “Patients could be terminated if they showed
clinical deterioration or minimal response.”
Minimal response is not specified and it is not
reported when patients dropped out
Incomplete outcome data (attrition bias)
Withdrawals/side effects
Unclear risk Dropouts due to ineffectivemedication and due
to side effects are grouped together
Selective reporting (reporting bias) Unclear risk No information is provided
Other bias Unclear risk No information is provided
Placebo washout Unclear risk 4 to 7 days
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Goldberg 1986
Methods Randomised controlled trial
Participants 60 symptomatic volunteers with major depressive disorder according to DSM-III. At
least 18 on HDRS, at least 3 (out of 5) Bielski and Friedel criteria
Interventions Alprazolam versus imipramine (30/30 patients)
Placebo ’washout’ period 1 week
Maximum dose alprazolam 4.5 mg, imipramine 225 mg
Mean daily dose: alprazolam 3.9 mg and imipramine 193.3 mg
Aged 18 to 55 years
Outcomes Primary outcome:
Mean HDRS after 6 weeks: alprazolam 14 (initial score of 26), imipramine 12 (initial
score of 26)
Secondary outcome:
All-cause withdrawals: alprazolam 4 (13.3%), imipramine 5 (16.7%)
Withdrawals due to side effects after 6 weeks: alprazolam 1 (3.3%), imipramine 1 (3.
3%)
Notes HDRS-21
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “....patients were randomly assigned...” No information
is provided
Allocation concealment (selection bias) Unclear risk No information is provided
Blinding (performance bias and detection
bias)
Patients
Low risk “The drugs were in identical appearing capsules...”
Blinding (performance bias and detection
bias)
Physicians
Unclear risk No information is provided
Blinding (performance bias and detection
bias)
Investigators
Unclear risk No information is provided
Incomplete outcome data (attrition bias)
HDRS
Low risk All dropouts are reported and endpoint analysis is used
Incomplete outcome data (attrition bias)
Withdrawals/side effects
Low risk All dropouts are reported
Selective reporting (reporting bias) High risk SD not reported
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Goldberg 1986 (Continued)
Other bias High risk Special group of patients: volunteers, recruited through
a newspaper advertisement
Support from alprazolam manufacturer
Placebo washout High risk 1 week
Imlah 1985
Methods Randomised controlled trial, 4 weeks
Participants 65 out- and inpatients with reactive or neurotic depression with or without anxiety, and
a score of at least 18 on Hamilton Anxiety Rating Scale (HARS) and 2 on the depressed
mood component of the HARS
Age 18 to 60 years
Interventions Alprazolam versus amitriptyline versus placebo (23/18/20 patients)
Placebo ’washout’ period 1 week
Maximum dose: alprazolam 3 mg, amitriptyline 150 mg, placebo 6 capsules
Outcomes Primary outcome:
Not described
Secondary outcome:
All-cause withdrawals: alprazolam 0 (60%), amitriptyline 0 (16.7%), placebo 5 (25%)
Physician’s assessment of severity after 4weeks; differences: alprazolam -2.4, amitriptyline
-1.6, placebo -1.2
Notes Not clear how many inpatients
Endpoint analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “...on a double-blind randomised group com-
parative basis...” No information is provided
Allocation concealment (selection bias) Unclear risk No information is provided
Blinding (performance bias and detection
bias)
Patients
Unclear risk Unclear if identical capsules were used
Blinding (performance bias and detection
bias)
Physicians
Unclear risk No information is provided
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Imlah 1985 (Continued)
Blinding (performance bias and detection
bias)
Investigators
Unclear risk No information is provided
Incomplete outcome data (attrition bias)
HDRS
Unclear risk Not measured. Patients who did not benefit af-
ter 2 weeks could be withdrawn!
Incomplete outcome data (attrition bias)
Withdrawals/side effects
Low risk All dropouts are described
Selective reporting (reporting bias) High risk SD not reported
Other bias High risk Mean or average dose for the treatment groups
is not given
Support from alprazolam manufacturer
Placebo washout High risk 1 week
Laakman 1995
Methods Randomised controlled trial
Participants 288 of 342 outpatients suffering from mild to moderate depression were available for
analysis
Aged 19 to 75 years
Interventions Alprazolam versus lorazepam versus amitriptyline versus placebo (70/66/72/74 patients)
Placebo ’washout’ period 3 to 7 days
The 6 weeks of drug treatment were followed by a drug taper period
Maximum dose: alprazolam 4 mg, lorazepam 10 mg, amitriptyline 200 mg, placebo 4
tablets
Mean daily dose: alprazolam2.08mg, lorazepam4.93mg, amitriptyline 102mg, placebo
2.79 tablets
Outcomes Primary outcomes:
Mean HDRS after 6 weeks: alprazolam 8.6 (initial score of 20.2, SD 5.5), lorazepam 8.5
(initial score of 19.6, SD 5.7), amitriptyline 7.9 (initial score of 19.7, SD 5.1), placebo
14.4 (initial score of 19.2, SD 5.1)
50% or greater reduction on HDRS after 6 weeks: alprazolam 38 (61%), lorazepam 39
(66%), amitriptyline 50 (73%), placebo 15 (22%)
Secondary outcome:
All-cause withdrawals: alprazolam 8 (11.4%), lorazepam 7 (10.6%), amitriptyline 3 (4.
2%), placebo 7 (9.5%)
Withdrawals due to side effects: alprazolam 3 (4.3%), lorazepam 1 (1.5%), amitriptyline
and placebo 0
Adverse effects after dose reduction, after 8 weeks: alprazolam 5 (8.1%), amitriptyline 2
(2.9%), lorazepam and placebo 0
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Laakman 1995 (Continued)
Notes Analysis of treatment for all patients who participated for at least 1 week; sample size
varies at each point (no endpoint analysis)
HDRS-17
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Patients were randomly assigned to the four treatment
groups...” No further information is provided
Allocation concealment (selection bias) Unclear risk No information is provided
Blinding (performance bias and detection
bias)
Patients
Unclear risk “...under double-blind conditions...” Unclear if identical
capsules were used
Blinding (performance bias and detection
bias)
Physicians
Unclear risk No information is provided
Blinding (performance bias and detection
bias)
Investigators
Unclear risk No information is provided
Incomplete outcome data (attrition bias)
HDRS
Low risk “Of the 342 depressive patients who were admitted to
the study, 282 were available, 257 finished 6 weeks”
All withdrawals are listed and there are no significant
differences between the treatment groups
Incomplete outcome data (attrition bias)
Withdrawals/side effects
Low risk All withdrawals are well documented
Selective reporting (reporting bias) Unclear risk No information is provided
Other bias Unclear risk No information is provided
Placebo washout High risk 3 to 7 days
Lapierre 1994
Methods Randomised controlled trial, 6 weeks
Participants 43 outpatients with depression of at least a moderate degree. Score at least 8 on RDS, at
least 18 on HDRS, and equal or less on CAS
Age 18 to 70 years
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Lapierre 1994 (Continued)
Interventions Alprazolam versus amitriptyline (23/20 patients)
Placebo ’washout’ period 4 to 7 days
Maximum dose: alprazolam 4.5 mg, amitriptyline 225 mg
Mean final dosage: alprazolam 3.2 mg, amitriptyline 115 mg
Outcomes Primary outcome:
MeanHDRS after 6weeks: alprazolam12.03 (initial score of 26.86, SD7.23), amitripty-
line 5.56 (initial score of 26.50, SD 8.29)
50%decrease of totalHDRS after 6weeks: alprazolam12 (60%), amitriptyline 13 (73%)
Secondary outcome:
All-cause withdrawals: alprazolam 3 (13%), amitriptyline 2 (10%)
Notes HDRS version not specified, HDRS-21 assumed
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “...assigned to two treatment groups by forced
randomization such that in each consecutive
group of six enrolled patients, three were as-
signed to each drug.” No further information is
provided
Allocation concealment (selection bias) Unclear risk No further information is provided. Since there
were fixed groups of 6 patients (3 per drug),
one could predict the treatment group for the
last patient in the group, but no information is
provided on how they assigned patients to the
groups
Blinding (performance bias and detection
bias)
Patients
Low risk “Both active study medications were supplied
in capsules of identical appearance.”
Blinding (performance bias and detection
bias)
Physicians
Unclear risk No information is provided
Blinding (performance bias and detection
bias)
Investigators
Unclear risk No information is provided
Incomplete outcome data (attrition bias)
HDRS
Low risk Patients who dropped out due to inefficacy were
equally distributed between the 2 treatment
groups
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Lapierre 1994 (Continued)
Incomplete outcome data (attrition bias)
Withdrawals/side effects
Low risk Dropped out patient well documented
Selective reporting (reporting bias) Unclear risk No information is provided
Other bias Low risk No information is provided
Placebo washout High risk 4 to 7 days
Mendels 1986
Methods Randomised controlled trial, 6 weeks
Participants 107 outpatients with major depressive disorder (12 agitated, 47 anxious, 39 retarded
depression). At least 8 on RDS and equal or less on CAS, at least 5 associated items on
FDC and at least 20 on HDRS
Age 18 to 60 years
Interventions Alprazolam versus imipramine versus placebo (34/36/37 patients)
Placebo washout period 7 days
Maximum dose: alprazolam 5 mg, imipramine 250 mg, placebo 5 tablets
Mean daily doses: alprazolam 3.67 mg, imipramine 167 mg, placebo 3.7 tablets
Outcomes Primary outcome:
Mean HDRS after 6 weeks: alprazolam 12.5 (initial score of 23.8), imipramine 14.5
(initial score of 23.7), placebo 18.6 (initial score of 23.9)
50% decrease of total HDRS after 6 weeks: alprazolam 15 (50%), imipramine 13 (38.
2%), placebo 6 (17.7%)
Secondary outcome:
All-cause withdrawals: alprazolam 13 (38.2%), imipramine 20 (55.6%), placebo 21 (56.
8%)
Withdrawals due to side effects: alprazolam 6 (17.6%), imipramine 8 (22.2%), placebo
1 (2.7%)
Notes Endpoint analysis
HDRS-17
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information is provided
Allocation concealment (selection bias) Unclear risk No information is provided
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Mendels 1986 (Continued)
Blinding (performance bias and detection
bias)
Patients
Unclear risk “...double-blind study.” Unclear if they used
identical tablets
Blinding (performance bias and detection
bias)
Physicians
Unclear risk No information is provided
Blinding (performance bias and detection
bias)
Investigators
Unclear risk No information is provided
Incomplete outcome data (attrition bias)
HDRS
Unclear risk The additional reasons for dropping out are not
specified for each treatment group. Other drop-
outs are equally distributed and endpoint anal-
ysis is used
Incomplete outcome data (attrition bias)
Withdrawals/side effects
Low risk Side effects are listed for all included patients
Selective reporting (reporting bias) High risk SD not reported
Other bias Low risk No information is provided
Placebo washout High risk 7 days
Murthy 1991
Methods Randomised controlled trial, 6 weeks
Participants 208 outpatients with moderate to severe depression meeting Feighner’s criteria for pri-
mary depression and DSM-III major depression criteria
Interventions Alprazolam versus imipramine (105/103 patients)
Placebo ’washout’ period: 3 to 7 days
Maximum dosages: alprazolam 4.5 mg per day, imipramine 225 mg per day
Mean dosages: alprazolam2.5mgper day, imipramine 125mgper day, and 80% required
less than 6 capsules of 0.5 mg per day
Outcomes Primary outcome:
Mean HDRS after 6 weeks: alprazolam 9.75 (initial score 23.81), SD 4.63; imipramine
9.20 (initial score of 23.44); SD 4.72
Secondary outcome:
All-cause withdrawals: alprazolam 29 (28%), imipramine 34 (33%)
“The frequency of side effects was higher for imipramine compared to alprazolam. Sig-
nificantly higher number of patients reported insomnia (P < 0.01) and tremor as side
effects (P < 0.01). None of the side effects reported was significantly more in the alpra-
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Murthy 1991 (Continued)
zolam group.”
Notes HDRS 21 items
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Assigned in double blind random fashion.”
In each consecutive group, there were 3 persons
who received alprazolam and 3 imipramine; but
there is no further information
Allocation concealment (selection bias) Unclear risk There is no information, except that “The drug
code of each patient was kept in a sealed enve-
lope which could be opened in case of emer-
gency.”
Blinding (performance bias and detection
bias)
Patients
Low risk Yes, identical capsules (there could have been a
specific and rapid tranquillising effect of alpra-
zolam)
Blinding (performance bias and detection
bias)
Physicians
Low risk Yes, identical capsules and the code was kept in
a sealed envelope:
“The drugswere dispensed in identical capsules,
each capsule containing alprazolam 0.5 mg or
imipramine 25 mg. Patients were started with
one capsule twice daily. The drug code for each
patient was kept in a sealed envelope which
could be opened in case of emergency.”
Blinding (performance bias and detection
bias)
Investigators
Unclear risk No further information is provided
Incomplete outcome data (attrition bias)
HDRS
Unclear risk No information is provided
Incomplete outcome data (attrition bias)
Withdrawals/side effects
Unclear risk Unclear, although dropouts are documented
Selective reporting (reporting bias) Unclear risk No information is provided
Other bias Unclear risk It seems that Upjohn sponsored the study
Placebo washout High risk 3 to 7 days
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Overall 1987
Methods Randomised controlled study, 6 weeks
Participants 104 outpatients with depressive disorder according to DSM-III and Zung Self Rating
DepressionScale score of 55or higher. 96% fulfilledDSM-III criteria formajor depressive
disorder and 4% for dysthymic disorder
104 entered the study, but only 90 returned for at least one follow-up, 60 (35/25)
completed the full 6 weeks
Aged 18 to 60 years
Interventions Alprazolam versus imipramine
Placebo washout period 4 to 7 days
Maximum dosages: alprazolam 6 mg, imipramine 300 mg
Median dosage at the end: alprazolam 3 mg and imipramine 200 mg (mean dosage at
week 5: alprazolam 3.6 mg and imipramine 201.0 mg)
Outcomes Primary outcome:
Mean HDRS, with the last observation carried forward strategy (LOCF). Imipramine
dropouts had a significantly poorer response at the last available point than imipramine
patients who completed the 6 weeks. In the imipramine there were more early dropouts
who were included as poor responders
HDRS (LOCF) after 6 weeks: alprazolam 9.5 (initial score of 23.4), imipramine 10.7
(initial score of 23.3)
HDRS (completers) after 6 weeks: alprazolam 7.3 (initial score of 23.4), imipramine 6.
2 (initial score of 23.3)
Secondary outcome:
All dropouts after inclusion. 14 participants (4 in alprazolam arm and 10 in imipramine
arm) did not return after baseline evaluation and were not included in efficacy analysis
Notes Two analytic strategies are presented: 1) the last available observation on each patient to
represent the best estimate of response to treatment (LOCF), and 2) completers: only
those who remained in treatment at each point were included. The LOCF data are used
The paper reports SDs that are much lower than in other studies (for instance, 1.4).
We assume they have calculated SEs instead of SDs. We recalculated SDs (table 4 SD
alprazolam at 6 weeks 1.800 and SD imipramine 1.605)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “...randomised, parallel-group design.” ”Pa-
tients were then randomised to treatment”
No further information is provided
Allocation concealment (selection bias) Unclear risk No information is provided
Blinding (performance bias and detection
bias)
Patients
Low risk “Drugs were supplied in identical appearing
capsules...”
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Overall 1987 (Continued)
Blinding (performance bias and detection
bias)
Physicians
High risk No information is provided
Blinding (performance bias and detection
bias)
Investigators
High risk It is not clear whether the investigator was the
same person who administered the medica-
tion. No information is provided on how they
managed to keep the capsules apart
Incomplete outcome data (attrition bias)
HDRS
High risk For both analysis there seems a great risk
of bias, since the dropout rate was much
greater for the imipramine group. LOCF may
underestimate the effect of imipramine and
analysing only the patients who stayed in treat-
ment overestimates the imipramine effect
Incomplete outcome data (attrition bias)
Withdrawals/side effects
Unclear risk 60/90 (67%) completed the 6-week study.
Two analyses have been done; LOCF and for
those who remained in treatment
Selective reporting (reporting bias) Unclear risk No information is provided
Other bias Unclear risk No information is provided
Placebo washout High risk 4 to 7 days
Remick 1988
Methods Randomised controlled trial, 6 weeks
Participants 52 outpatients suffering frommajor depressive disorder (12 dropped out before analysis)
, with a score of at least 21 on HDRS
Interventions Alprazolam versus desipramine (19/21 patients)
Placebo ’washout’ period 3 to 14 days
Maximum dose: alprazolam 4.5 mg, desipramine 225 mg
Mean daily dose at the end: alprazolam 3.34 mg, desipramine 192 mg
Outcomes Primary outcome:
Mean HDRS after 6 weeks: alprazolam 12.0 (initial 26.3), desipramine 17.5 (initial 26.
0)
Secondary outcome:
All-cause withdrawals: alprazolam 6 (31.6%), desipramine 7 (33.3%)
Withdrawals due to side effects: alprazolam 4 (21.1%), desipramine 5 (23.8%)
Notes There seems to be an overlap with the Remick 1985 paper. The 2 car accidents and the
side effects profile are the same, but this study has larger samples and allows for a higher
maximum dosage
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Remick 1988 (Continued)
21 patients completed an all-night polysomnographic recording and 37 completed a
modified dexamethasone suppression test
HDRS-17
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Patients were blindly assigned to either alpra-
zolam or desipramine.” No information is pro-
vided
Allocation concealment (selection bias) Unclear risk No information is provided
Blinding (performance bias and detection
bias)
Patients
Low risk “Medicine was dispensed in opaque gelatine
capsules containing...in a dose-dispensing sys-
tem administered by a pharmacist.”
Blinding (performance bias and detection
bias)
Physicians
Low risk “Weekly assessments were completed by the re-
search psychiatrist...” Drugs were distributed by
the pharmacist
Blinding (performance bias and detection
bias)
Investigators
Unclear risk No information is provided
Incomplete outcome data (attrition bias)
HDRS
Low risk 40 patients enrolled of whom 29 were analysed
for 6 weeks treatment. There was also an anal-
ysis for all 40 patients. Number and reasons for
dropping out are equally distributed between
the treatment groups
Incomplete outcome data (attrition bias)
Withdrawals/side effects
Unclear risk It is not specifiedwhen the patients dropped out
during the study
Selective reporting (reporting bias) High risk SD not reported
Other bias High risk “There was a trend for desipramine patients to
have more previous episodes than the alprazo-
lam group. In addition, more desipramine pa-
tients had their current episode characterized as
an exacerbation of a chronic condition while
more alprazolam patients were having their first
occurrences with no previous psychiatric illness.
” Group differences
Support from alprazolam manufacturer
Placebo washout High risk 3 to 14 days
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Rickels 1985
Methods Randomised controlled trial, 6 weeks
Participants 504 outpatients with major depressive disorder, conducted in 3 treatment centres. Pa-
tients with a RDS score of at least 8 and an equal or less score on the CAS and at least
18 on HDRS
Aged 18 to 70 years
Interventions Alprazolam versus amitriptyline versus doxepin versus placebo (126/119/120/126)
Placebo ’washout’ period 4 to 7 days
Maximum dose: alprazolam 4.5 mg, amitriptyline 225 mg, doxepin 225 mg, placebo 9
capsules
Mean daily dose during last 2 weeks: alprazolam 3 mg, amitriptyline 148 mg, doxepin
143 mg
Outcomes Primary outcome:
Mean HDRS after 6 weeks: alprazolam 13.59 (initial 25.19), amitriptyline 14.77 (initial
25.48), doxepin 13.23 (initial 25.85), placebo 18.90 (initial 26.38)
Secondary outcome:
All-cause withdrawals: alprazolam 24 (18.8%), amitriptyline 34 (27.4%), doxepin 23
(18.9%), placebo 59 (45.4%)
Withdrawals due to side effects: alprazolam 3 (2.3%), amitriptyline 17 (13.7%), doxepin
12 (9.8%), placebo 10 (7.7%)
Notes Endpoint analysis
HDRS-21
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “...randomly assigned...” No further informa-
tion is provided
Allocation concealment (selection bias) Unclear risk No information is provided
Blinding (performance bias and detection
bias)
Patients
Low risk “Medication,..., was administered in identical
capsules containing...”
Blinding (performance bias and detection
bias)
Physicians
Unclear risk No information is provided
Blinding (performance bias and detection
bias)
Investigators
Unclear risk Unclear if they used independent investigators
for the assessments
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Rickels 1985 (Continued)
Incomplete outcome data (attrition bias)
HDRS
Unclear risk “... persistent side effects and worsening of
symptoms or lack of improvement permitted
removal of the patient from the study.”
“... statistically significant differences among
treatment groups with respect to dropout rate,
with significantly more patients given placebo
dropping out, end-point analyses, including pa-
tients with at least one week of efficacy data,
were also performed for all efficacy variables.”
“... but the set of analyses based on actual pa-
tients numbers reached at each evaluation pe-
riod provided rather similar results.”
Incomplete outcome data (attrition bias)
Withdrawals/side effects
Unclear risk Not all causes for withdrawal are described.
Dropout rates are different between the groups
due to ineffectiveness (alprazolam 19 patients,
amitriptyline 11, doxepin 8 and placebo 48),
but these last scores are taken in the analysis
There were also differences for dropouts due to
side effects: alprazolam 3 patients, amitriptyline
17, doxepin 12 and placebo 10. It is not clear
for which side effects patients were withdrawn
from the study, so there can be a bias regarding
patients who dropped out too soon before there
was any effect of treatment
Selective reporting (reporting bias) Unclear risk No information is provided
Other bias High risk The mean doses are given, but it is unclear how
fast they increased the dosages
Support from alprazolam manufacturer
Placebo washout High risk 4 to 7 days
Rickels 1987
Methods Randomised controlled trial
Participants 241 outpatients (48% family practice, 52% psychiatric practice) suffering from major
depressive disorder (DSM-III), and a RDS score of at least 8, equal or less on CAS score,
and at least 18 on the HDRS
Aged 18 to 65 years
Interventions Alprazolam versus imipramine versus diazepam versus placebo (58/63/59/61 patients)
Placebo washout period 7 days
Maximum dose: alprazolam 4.5 mg, diazepam 45 mg, imipramine 225 mg, placebo 9
capsules. Mean daily dose: alprazolam 3.1 mg, diazepam 24 mg, imipramine 143 mg,
placebo 6.8 capsules
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Rickels 1987 (Continued)
Outcomes Primary outcome:
Mean HDRS after 6 weeks: alprazolam 13.3 (initial 23.2), imipramine 14.3 (initial 24.
4), diazepam 16.3 (initial 23.7), placebo 19.5 (initial 24.5)
50%decrease of totalHDRS after 6weeks: alprazolam70%, imipramine 70%, diazepam
45%, placebo 39%
Secondary outcome:
All-cause withdrawals: alprazolam 33%, imipramine 41%, diazepam 42.4%, placebo
39%
Notes Endpoint analysis and analysis for all patients available at a given moment
HDRS-21
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information is provided
Allocation concealment (selection bias) Unclear risk No information is provided
Blinding (performance bias and detection
bias)
Patients
Low risk “Medication was randomized and prepared in identical
looking capsules...”
Blinding (performance bias and detection
bias)
Physicians
Unclear risk No information is provided
Blinding (performance bias and detection
bias)
Investigators
Unclear risk Unclear if they used independent investigators for the
assessments
Incomplete outcome data (attrition bias)
HDRS
Unclear risk Side effects were the major reason for dropout for the
active treatment groups, whereas this was ineffectiveness
for placebo. 61% completed 6 weeks of therapy
Incomplete outcome data (attrition bias)
Withdrawals/side effects
Unclear risk Actual reasons for dropping out are not listed
Selective reporting (reporting bias) High risk SD not reported
Other bias High risk Maximum doses are in the same range for the different
drugs
Support from alprazolam manufacturer
Placebo washout High risk 7 days
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Rush 1985
Methods Randomised controlled trial, 6 weeks
Participants 52 out- and inpatients suffering from major depression, non-psychotic type. At least 18
on HDRS and at least a mean REM latency less or equal to 65
Aged 18 to 65 years
Interventions Alprazolam versus amitriptyline (26/26 patients)
Placebo washout 10 to 14 days
Maximum dose: alprazolam 6 mg, amitriptyline 300 mg
Mean final dose: alprazolam 4.4 mg, amitriptyline 190 mg
Outcomes Primary outcome:
Mean HDRS after 6 weeks: alprazolam 12.7 (initial score of 24.1, SD 8.5), amitriptyline
6.9 (initial score of 26.1, SD 6.0)
50% decrease of total HDRS after 6 weeks: alprazolam 11 (44%), amitriptyline 21 (87.
5%)
Secondary outcome:
All-cause withdrawals: alprazolam 12 (48%), amitriptyline 8 (33%)
Notes Endpoint and raw score data analyses were employed
HDRS-17
(After 3 weeks, 32 outpatients and 17 inpatients had assessments)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Treatments were assigned on a randomized,
double-blind basis and were independent of
all pretreatment clinical and laboratory evalua-
tions.” No information is provided
Allocation concealment (selection bias) Unclear risk No information is provided
Blinding (performance bias and detection
bias)
Patients
Unclear risk Unclear if they used identical tablets
Blinding (performance bias and detection
bias)
Physicians
Unclear risk No information is provided
Blinding (performance bias and detection
bias)
Investigators
Unclear risk No information is provided
Incomplete outcome data (attrition bias)
HDRS
Unclear risk Only endpoint analysis is given while dropout
rate is not equally distributed between the treat-
ment groups
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Rush 1985 (Continued)
Incomplete outcome data (attrition bias)
Withdrawals/side effects
Unclear risk The reasons for dropping out are not listed
Selective reporting (reporting bias) Unclear risk No information is provided
Other bias High risk A selective group of patients, due to the require-
ment of a shortened REM latency
Support from alprazolam manufacturer
Placebo washout High risk 10 to 14 days
Singh 1988
Methods Randomised controlled trial
Participants 130 outpatients suffering from moderate to severe nonpsychotic depression. Score of at
least 8 on RDS and equal or less on CAS, presence of at least 5 items on FDC and at
least a score of 18 on the HDRS
Aged 18 to 65 years
Interventions Alprazolam versus amitriptyline (67/63 patients)
Placebo ’washout’ period of 4 to 7 days, single-blind
Max dose: alprazolam 4.5 mg, amitriptyline 225 mg
Mean daily dose: alprazolam 2.4 mg, amitriptyline 135 mg
Outcomes Primary outcome:
Mean HDRS after 6 weeks: alprazolam 5.5 (initial 23.8), amitriptyline 6.7 (initial 23.9)
Secondary outcome:
All-cause withdrawals: alprazolam 1 (1.5%), amitriptyline 5 (7.9%)
Notes HDRS version not specified, HDRS-21 assumed
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “...patients were assigned sequentially by a computer-
generated randomisation list to receive treatment with
alprazolam or amitriptyline...”
Allocation concealment (selection bias) Low risk No information is provided
Blinding (performance bias and detection
bias)
Patients
Low risk “...were provided in identical appearing capsules that
were packaged and labelled for each patient.”
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Singh 1988 (Continued)
Blinding (performance bias and detection
bias)
Physicians
Unclear risk No information is provided
Blinding (performance bias and detection
bias)
Investigators
Unclear risk No information is provided
Incomplete outcome data (attrition bias)
HDRS
Unclear risk Unclear which method they used for analysing patients’
outcome, endpoint or the patients at any given moment
Incomplete outcome data (attrition bias)
Withdrawals/side effects
Unclear risk Dropouts are listed
Selective reporting (reporting bias) Unclear risk SD not reported
Other bias High risk Dosing ofmedication: both the daily doses for alprazolam
and amitriptyline are lower than the recommended doses
of 3.0 mg and 150 mg
Placebo washout High risk 4 to 7 days
CAS: Covi Anxiety Score
FDC: Feighner Depression Checklist
HADS: Hospital Anxiety and Depression Scale
HARS: Hamilton Anxiety Rating Scale
HDRS: Hamilton Depression Rating Scale
LOCF: last observation carried forward
RDS: Raskin Depression Scale
SD: standard deviation
SE: standard error
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Aden 1983 Clinically anxious patients with depressed mood
Beutler 1987 Psychotherapy arm and complex factorial design
Ceskova 1989 Insufficient information
Eriksson 1987 Patients with no clinical response to adequate dosages of tricyclic antidepressants during the present episode were
excluded
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(Continued)
Ettigi 1988 Outpatients; cortisol primary outcome
Fawcett 1987 Treatment was not double-blind: desipramine blood levels were monitored and dose adjustments were made
Feighner 1983b Contains combined data from (probably) previously published studies
Hubain 1990 Inpatients suffering from severe endogenous depression
Keller 1993 Primary diagnosis anxiety syndrome
Kravitz 1990 Secondary analysis of trial reported by Fawcett 1987, which we consider not to be double-blind
Lenox 1984 Inpatients only
Pitts 1983 Inpatients, open label study
Pollack 1994 Results reported by Keller et al, primary diagnosis was an anxiety disorder
Rickels 1982 Lack of usable outcomes, the authors report only change scores
Rimon 1991 Oxazepam control condition
Rothblum 1982 Treatment was combined with interpersonal psychotherapy
Weissman 1985 Treatment was combined with interpersonal psychotherapy
Weissman 1992 Treatment was combined with interpersonal psychotherapy
Zung 1983 Alprazolam versus natural history; different comparison
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D A T A A N D A N A L Y S E S
Comparison 1. Alprazolam versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Hamilton Depression Rating
Scale (HDRS) continuous
7 771 Mean Difference (IV, Random, 95% CI) -5.34 [-7.48, -3.20]
2 50% improvement versus less
than 50% improvement RR
3 312 Risk Ratio (M-H, Fixed, 95% CI) 2.47 [1.78, 3.43]
3 50% improvement versus less
than 50% improvement RD
3 312 Risk Difference (M-H, Fixed, 95% CI) 0.32 [0.22, 0.42]
4 All-cause withdrawals versus no
withdrawals RR
5 742 Risk Ratio (M-H, Random, 95% CI) 0.78 [0.48, 1.27]
5 All-cause withdrawals versus no
withdrawals RD
5 742 Risk Difference (M-H, Random, 95% CI) -0.09 [-0.26, 0.08]
6 Withdrawal due to adverse
effects versus no withdrawals
RR
2 402 Risk Ratio (M-H, Random, 95% CI) 1.14 [0.05, 26.35]
7 Withdrawal due to adverse
effects versus no withdrawals
RD
2 402 Risk Difference (M-H, Random, 95% CI) -0.01 [-0.10, 0.09]
8 Withdrawal due to
ineffectiveness versus no
withdrawals RR
2 402 Risk Ratio (M-H, Fixed, 95% CI) 0.40 [0.26, 0.64]
9 Withdrawal due to
ineffectiveness versus no
withdrawals RD
2 402 Risk Difference (M-H, Random, 95% CI) -0.13 [-0.35, 0.09]
10 Hamilton Depression Rating
Scale (HDRS) timeline week 1
7 798 Mean Difference (IV, Random, 95% CI) -2.88 [-4.95, -0.81]
11 Hamilton Depression Rating
Scale (HDRS) timeline week 2
5 426 Mean Difference (IV, Random, 95% CI) -3.34 [-6.07, -0.61]
12 Hamilton Depression Rating
Scale (HDRS) timeline week 3
2 146 Mean Difference (IV, Random, 95% CI) -0.42 [-3.69, 2.85]
13 Hamilton Depression Rating
Scale (HDRS) timeline week 4
6 719 Mean Difference (IV, Random, 95% CI) -4.78 [-8.17, -1.39]
14 Hamilton Depression Rating
Scale (HDRS) timeline week 6
6 733 Mean Difference (IV, Random, 95% CI) -5.19 [-7.72, -2.66]
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Comparison 2. Alprazolam versus TCAs
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 HDRS continuous 17 1636 Mean Difference (IV, Random, 95% CI) 0.25 [-0.93, 1.43]
2 HDRS continuous (subgrouped
by TCA comparator)
17 Std. Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.1 Alprazolam versus
amitriptyline
8 732 Std. Mean Difference (IV, Fixed, 95% CI) 0.12 [-0.03, 0.27]
2.2 Alprazolam versus
imipramine
7 629 Std. Mean Difference (IV, Fixed, 95% CI) -0.05 [-0.21, 0.11]
2.3 Alprazolam versus doxepin 2 372 Std. Mean Difference (IV, Fixed, 95% CI) 0.02 [-0.18, 0.22]
2.4 Alprazolam versus
desipramine
1 29 Std. Mean Difference (IV, Fixed, 95% CI) -1.14 [-1.93, -0.34]
3 50% improvement vs less than
50% improvement RR
7 543 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.75, 0.99]
4 50% improvement vs less
than 50% improvement
RR (subgrouped by TCA
comparator)
7 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 Alprazolam versus
amitriptyline
5 358 Risk Ratio (M-H, Fixed, 95% CI) 0.77 [0.66, 0.89]
4.2 Alprazolam versus
imipramine
2 185 Risk Ratio (M-H, Fixed, 95% CI) 1.19 [0.86, 1.65]
5 50% improvement vs less than
50% improvement RD
7 543 Risk Difference (M-H, Random, 95% CI) -0.11 [-0.24, 0.01]
6 50% improvement vs less
than 50% improvement
RD (subgrouped by TCA
comparator)
7 Risk Difference (M-H, Random, 95% CI) Subtotals only
6.1 Alprazolam versus
amitriptyline
5 358 Risk Difference (M-H, Random, 95% CI) -0.19 [-0.30, -0.07]
6.2 Alprazolam versus
imipramine
2 185 Risk Difference (M-H, Random, 95% CI) 0.08 [-0.07, 0.22]
7 All-cause withdrawals vs no
withdrawals RR
18 1873 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.72, 1.00]
8 All-cause withdrawals vs no
withdrawals RR (subgrouped
by TCA comparator)
18 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
8.1 Alprazolam versus
amitriptyline
9 830 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.63, 1.10]
8.2 Alprazolam versus
imipramine
6 636 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.56, 0.90]
8.3 Alprazolam versus doxepin 2 395 Risk Ratio (M-H, Fixed, 95% CI) 1.25 [0.82, 1.90]
8.4 Alprazolam versus
dothiepin
1 100 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.41, 2.46]
8.5 Alprazolam versus
desipramine
1 40 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.39, 2.32]
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9 All-cause withdrawals vs no
withdrawals RD
17 1848 Risk Difference (M-H, Fixed, 95% CI) -0.04 [-0.07, 8.06]
10 All-cause withdrawals vs no
withdrawals RD (subgrouped
by TCA comparator)
17 Risk Difference (M-H, Fixed, 95% CI) Subtotals only
10.1 Alprazolam versus
amitriptyline
8 805 Risk Difference (M-H, Fixed, 95% CI) -0.03 [-0.08, 0.02]
10.2 Alprazolam versus
imipramine
6 636 Risk Difference (M-H, Fixed, 95% CI) -0.10 [-0.17, -0.03]
10.3 Alprazolam versus
doxepin
2 395 Risk Difference (M-H, Fixed, 95% CI) 0.04 [-0.04, 0.12]
10.4 Alprazolam versus
dothiepin
1 100 Risk Difference (M-H, Fixed, 95% CI) 0.0 [-0.14, 0.14]
10.5 Alprazolam versus
desipramine
1 40 Risk Difference (M-H, Fixed, 95% CI) -0.02 [-0.31, 0.27]
11 Adverse effects withdrawals vs
no withdrawals RR
11 1139 Risk Ratio (M-H, Fixed, 95% CI) 0.62 [0.43, 0.88]
12 Adverse effects withdrawals
vs no withdrawals RR
(subgrouped by TCA
comparator)
11 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
12.1 Alprazolam versus
amitriptyline
7 751 Risk Ratio (M-H, Fixed, 95% CI) 0.58 [0.37, 0.90]
12.2 Alprazolam versus
imipramine
2 130 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.33, 2.01]
12.3 Alprazolam versus
doxepin
1 250 Risk Ratio (M-H, Fixed, 95% CI) 0.24 [0.07, 0.82]
12.4 Alprazolam versus
dothiepin
1 96 Risk Ratio (M-H, Fixed, 95% CI) 0.53 [0.19, 1.47]
12.5 Alprazolam versus
desipramine
1 40 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.28, 2.82]
13 Adverse effects withdrawals vs
no withdrawals RD
11 1240 Risk Difference (M-H, Random, 95% CI) -0.04 [-0.08, 0.01]
14 Adverse effects withdrawals
vs no withdrawals RD
(subgrouped by TCA
comparator)
11 Risk Difference (M-H, Random, 95% CI) Subtotals only
14.1 Alprazolam versus
amitriptyline
6 726 Risk Difference (M-H, Random, 95% CI) -0.03 [-0.10, 0.04]
14.2 Alprazolam versus
imipramine
2 130 Risk Difference (M-H, Random, 95% CI) -0.01 [-0.09, 0.07]
14.3 Alprazolam versus
doxepin
2 376 Risk Difference (M-H, Random, 95% CI) -0.08 [-0.14, -0.03]
14.4 Alprazolam versus
dothiepin
1 96 Risk Difference (M-H, Random, 95% CI) -0.09 [-0.23, 0.05]
14.5 Alprazolam versus
desipramine
1 40 Risk Difference (M-H, Random, 95% CI) -0.03 [-0.29, 0.23]
15 Ineffectiveness withdrawals vs
no withdrawals RR
4 686 Risk Ratio (M-H, Fixed, 95% CI) 1.66 [0.99, 2.79]
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16 Ineffectiveness withdrawals
vs no withdrawals RR
(subgrouped by TCA
comparator)
4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
16.1 Alprazolam versus
amitriptyline
3 524 Risk Ratio (M-H, Fixed, 95% CI) 1.58 [0.82, 3.04]
16.2 Alprazolam versus
doxepin
1 250 Risk Ratio (M-H, Fixed, 95% CI) 2.26 [1.03, 4.98]
16.3 Alprazolam versus
desipramine
1 40 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [0.32, 3.82]
17 Ineffectiveness withdrawals vs
no withdrawals RD
4 686 Risk Difference (M-H, Random, 95% CI) 0.02 [-0.04, 0.08]
18 Ineffectiveness withdrawals
vs no withdrawals RD
(subgrouped by TCA
comparator)
4 Risk Difference (M-H, Random, 95% CI) Subtotals only
18.1 Alprazolam versus
amitriptyline
3 524 Risk Difference (M-H, Random, 95% CI) 0.01 [-0.04, 0.06]
18.2 Alprazolam versus
desipramine
1 40 Risk Difference (M-H, Random, 95% CI) 0.02 [-0.23, 0.27]
18.3 Alprazolam versus
doxepin
1 250 Risk Difference (M-H, Random, 95% CI) 0.08 [0.01, 0.16]
19 HDRS timeline week 1 17 1692 Mean Difference (IV, Random, 95% CI) -1.48 [-2.77, -0.18]
20 HDRS timeline week
1 (subgrouped by TCA
comparator)
17 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
20.1 Alprazolam versus
amitriptyline
8 742 Std. Mean Difference (IV, Random, 95% CI) -0.05 [-0.41, 0.31]
20.2 Alprazolam versus
imipramine
7 675 Std. Mean Difference (IV, Random, 95% CI) -0.32 [-0.50, -0.13]
20.3 Alprazolam versus
doxepin
2 372 Std. Mean Difference (IV, Random, 95% CI) -0.12 [-0.32, 0.09]
20.4 Alprazolam versus
desipramine
1 29 Std. Mean Difference (IV, Random, 95% CI) -1.24 [-2.05, -0.44]
21 HDRS timeline week 2 15 1184 Mean Difference (IV, Random, 95% CI) -1.57 [-3.39, 0.25]
22 HDRS timeline week
2 (subgrouped by TCA
comparator)
15 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
22.1 Alprazolam versus
amitriptyline
7 494 Std. Mean Difference (IV, Random, 95% CI) 0.02 [-0.43, 0.48]
22.2 Alprazolam versus
imipramine
6 535 Std. Mean Difference (IV, Random, 95% CI) -0.25 [-0.44, -0.06]
22.3 Alprazolam versus
doxepin
1 126 Std. Mean Difference (IV, Random, 95% CI) -0.11 [-0.46, 0.24]
22.4 Alprazolam versus
desipramine
1 29 Std. Mean Difference (IV, Random, 95% CI) -1.55 [-2.40, -0.71]
23 HDRS timeline week 3 4 281 Mean Difference (IV, Random, 95% CI) 1.47 [-1.99, 4.94]
24 HDRS timeline week
3 (subgrouped by TCA
comparator)
4 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
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24.1 Alprazolam versus
amitriptyline
3 217 Std. Mean Difference (IV, Random, 95% CI) 0.29 [-0.40, 0.98]
24.2 Alprazolam versus
imipramine
1 64 Std. Mean Difference (IV, Random, 95% CI) 0.0 [-0.49, 0.49]
25 HDRS timeline week 4 14 1406 Mean Difference (IV, Random, 95% CI) 0.25 [-1.20, 1.70]
26 HDRS timeline week
4 (subgrouped by TCA
comparator)
14 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
26.1 Alprazolam versus
amitriptyline
6 561 Std. Mean Difference (IV, Random, 95% CI) 0.33 [0.00, 0.65]
26.2 Alprazolam versus
imipramine
6 570 Std. Mean Difference (IV, Random, 95% CI) -0.03 [-0.20, 0.14]
26.3 Alprazolam versus
doxepin
2 372 Std. Mean Difference (IV, Random, 95% CI) -0.06 [-0.26, 0.14]
26.4 Alprazolam versus
desipramine
1 29 Std. Mean Difference (IV, Random, 95% CI) -1.14 [-1.93, -0.34]
27 HDRS timeline week 5 2 113 Mean Difference (IV, Random, 95% CI) 0.83 [-5.13, 6.80]
28 HDRS timeline week
5 (subgrouped by TCA
comparator)
2 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
28.1 Alprazolam versus
amitriptyline
1 49 Std. Mean Difference (IV, Random, 95% CI) 0.57 [-0.00, 1.14]
28.2 Alprazolam versus
imipramine
1 64 Std. Mean Difference (IV, Random, 95% CI) -0.42 [-0.92, 0.08]
29 HDRS timeline week 6 14 1448 Mean Difference (IV, Random, 95% CI) 0.24 [-1.06, 1.54]
30 HDRS timeline week
6 (subgrouped by TCA
comparator)
14 Std. Mean Difference (IV, Fixed, 95% CI) Subtotals only
30.1 Alprazolam versus
amitriptyline
6 608 Std. Mean Difference (IV, Fixed, 95% CI) 0.08 [-0.08, 0.24]
30.2 Alprazolam versus
imipramine
6 565 Std. Mean Difference (IV, Fixed, 95% CI) -0.01 [-0.17, 0.16]
30.3 Alprazolam versus
doxepin
2 372 Std. Mean Difference (IV, Fixed, 95% CI) 0.02 [-0.18, 0.22]
30.4 Alprazolam versus
desipramine
1 29 Std. Mean Difference (IV, Fixed, 95% CI) -1.14 [-1.93, -0.34]
Comparison 3. Alprazolam versus heterocyclics
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Hamilton Depression Rating
Scale (HDRS) continuous
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 Alprazolam versus
mianserin
1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 All-cause withdrawals versus no
withdrawals RR
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
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2.1 Alprazolam versus
mianserin
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 All-cause withdrawals versus no
withdrawals RD
1 Risk Difference (M-H, Fixed, 95% CI) Totals not selected
3.1 Alprazolam versus
mianserin
1 Risk Difference (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Adverse effects withdrawals
versus no withdrawals RR
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
4.1 Alprazolam versus
mianserin
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Adverse effects withdrawals
versus no withdrawals RD
1 Risk Difference (M-H, Fixed, 95% CI) Totals not selected
5.1 Alprazolam versus
mianserin
1 Risk Difference (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Ineffectiveness withdrawals
versus no withdrawals RR
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
6.1 Alprazolam versus
mianserin
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Ineffectiveness withdrawals
versus no withdrawals RD
1 Risk Difference (M-H, Fixed, 95% CI) Totals not selected
7.1 Alprazolam versus
mianserin
1 Risk Difference (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Hamilton Depression Rating
Scale (HDRS) timeline week 2
1 Std. Mean Difference (IV, Random, 95% CI) Totals not selected
8.1 Alprazolam versus
mianserin
1 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9 Hamilton Depression Rating
Scale (HDRS) timeline week 4
1 Std. Mean Difference (IV, Random, 95% CI) Totals not selected
9.1 Alprazolam versus
mianserin
1 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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Analysis 1.1. Comparison 1 Alprazolam versus placebo, Outcome 1 Hamilton Depression Rating Scale
(HDRS) continuous.
Review: Alprazolam for depression
Comparison: 1 Alprazolam versus placebo
Outcome: 1 Hamilton Depression Rating Scale (HDRS) continuous
Study or subgroup Alprazolam Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Feighner 1983a 41 16.1 (10) 45 28 (14) 9.9 % -11.90 [ -17.01, -6.79 ]
Rickels 1987 58 13.3 (9) 61 19.5 (9) 15.0 % -6.20 [ -9.44, -2.96 ]
Mendels 1986 30 12.5 (4.7) 34 18.6 (4.7) 18.1 % -6.10 [ -8.41, -3.79 ]
Laakman 1995 62 8.6 (5.5) 67 14.4 (5.1) 19.6 % -5.80 [ -7.63, -3.97 ]
Rickels 1985 126 13.59 (13.2) 126 18.9 (15.8) 13.9 % -5.31 [ -8.90, -1.72 ]
Fabre 1980 31 15.5 (9) 15 19 (9) 9.0 % -3.50 [ -9.05, 2.05 ]
Borison 1989 50 12.21 (7.2) 25 11.74 (7.15) 14.4 % 0.47 [ -2.97, 3.91 ]
Total (95% CI) 398 373 100.0 % -5.34 [ -7.48, -3.20 ]
Heterogeneity: Tau2 = 5.21; Chi2 = 18.62, df = 6 (P = 0.005); I2 =68%
Test for overall effect: Z = 4.89 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.2. Comparison 1 Alprazolam versus placebo, Outcome 2 50% improvement versus less than 50%
improvement RR.
Review: Alprazolam for depression
Comparison: 1 Alprazolam versus placebo
Outcome: 2 50% improvement versus less than 50% improvement RR
Study or subgroup Alprazolam Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Laakman 1995 38/62 15/67 42.8 % 2.74 [ 1.68, 4.46 ]
Mendels 1986 15/30 6/34 16.7 % 2.83 [ 1.26, 6.37 ]
Rickels 1987 27/58 14/61 40.5 % 2.03 [ 1.19, 3.47 ]
Total (95% CI) 150 162 100.0 % 2.47 [ 1.78, 3.43 ]
Total events: 80 (Alprazolam), 35 (Placebo)
Heterogeneity: Chi2 = 0.80, df = 2 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 5.38 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.3. Comparison 1 Alprazolam versus placebo, Outcome 3 50% improvement versus less than 50%
improvement RD.
Review: Alprazolam for depression
Comparison: 1 Alprazolam versus placebo
Outcome: 3 50% improvement versus less than 50% improvement RD
Study or subgroup Alprazolam Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Laakman 1995 38/62 15/67 41.4 % 0.39 [ 0.23, 0.55 ]
Mendels 1986 15/30 6/34 20.5 % 0.32 [ 0.10, 0.54 ]
Rickels 1987 27/58 14/61 38.2 % 0.24 [ 0.07, 0.40 ]
Total (95% CI) 150 162 100.0 % 0.32 [ 0.22, 0.42 ]
Total events: 80 (Alprazolam), 35 (Placebo)
Heterogeneity: Chi2 = 1.72, df = 2 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 6.13 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.4. Comparison 1 Alprazolam versus placebo, Outcome 4 All-cause withdrawals versus no
withdrawals RR.
Review: Alprazolam for depression
Comparison: 1 Alprazolam versus placebo
Outcome: 4 All-cause withdrawals versus no withdrawals RR
Study or subgroup Alprazolam Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Borison 1989 29/79 8/40 17.9 % 1.84 [ 0.93, 3.64 ]
Fabre 1980 20/51 36/51 23.6 % 0.56 [ 0.38, 0.82 ]
Laakman 1995 8/70 7/74 13.4 % 1.21 [ 0.46, 3.16 ]
Rickels 1985 24/128 59/130 23.2 % 0.41 [ 0.28, 0.62 ]
Rickels 1987 19/58 24/61 21.8 % 0.83 [ 0.51, 1.35 ]
Total (95% CI) 386 356 100.0 % 0.78 [ 0.48, 1.27 ]
Total events: 100 (Alprazolam), 134 (Placebo)
Heterogeneity: Tau2 = 0.22; Chi2 = 16.93, df = 4 (P = 0.002); I2 =76%
Test for overall effect: Z = 1.01 (P = 0.31)
Test for subgroup differences: Not applicable
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Analysis 1.5. Comparison 1 Alprazolam versus placebo, Outcome 5 All-cause withdrawals versus no
withdrawals RD.
Review: Alprazolam for depression
Comparison: 1 Alprazolam versus placebo
Outcome: 5 All-cause withdrawals versus no withdrawals RD
Study or subgroup Alprazolam Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Borison 1989 29/79 8/40 19.4 % 0.17 [ 0.00, 0.33 ]
Fabre 1980 20/51 36/51 18.5 % -0.31 [ -0.50, -0.13 ]
Laakman 1995 8/70 7/74 21.7 % 0.02 [ -0.08, 0.12 ]
Rickels 1985 24/128 59/130 21.4 % -0.27 [ -0.38, -0.16 ]
Rickels 1987 19/58 24/61 19.0 % -0.07 [ -0.24, 0.11 ]
Total (95% CI) 386 356 100.0 % -0.09 [ -0.26, 0.08 ]
Total events: 100 (Alprazolam), 134 (Placebo)
Heterogeneity: Tau2 = 0.03; Chi2 = 31.00, df = 4 (P<0.00001); I2 =87%
Test for overall effect: Z = 1.04 (P = 0.30)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 Alprazolam versus placebo, Outcome 6 Withdrawal due to adverse effects
versus no withdrawals RR.
Review: Alprazolam for depression
Comparison: 1 Alprazolam versus placebo
Outcome: 6 Withdrawal due to adverse effects versus no withdrawals RR
Study or subgroup Alprazolam Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Laakman 1995 3/70 0/74 41.3 % 7.39 [ 0.39, 140.62 ]
Rickels 1985 3/128 10/130 58.7 % 0.30 [ 0.09, 1.08 ]
Total (95% CI) 198 204 100.0 % 1.14 [ 0.05, 26.35 ]
Total events: 6 (Alprazolam), 10 (Placebo)
Heterogeneity: Tau2 = 3.96; Chi2 = 3.96, df = 1 (P = 0.05); I2 =75%
Test for overall effect: Z = 0.08 (P = 0.94)
Test for subgroup differences: Not applicable
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Analysis 1.7. Comparison 1 Alprazolam versus placebo, Outcome 7 Withdrawal due to adverse effects
versus no withdrawals RD.
Review: Alprazolam for depression
Comparison: 1 Alprazolam versus placebo
Outcome: 7 Withdrawal due to adverse effects versus no withdrawals RD
Study or subgroup Alprazolam Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Laakman 1995 3/70 0/74 49.9 % 0.04 [ -0.01, 0.10 ]
Rickels 1985 3/128 10/130 50.1 % -0.05 [ -0.11, 0.00 ]
Total (95% CI) 198 204 100.0 % -0.01 [ -0.10, 0.09 ]
Total events: 6 (Alprazolam), 10 (Placebo)
Heterogeneity: Tau2 = 0.00; Chi2 = 6.75, df = 1 (P = 0.01); I2 =85%
Test for overall effect: Z = 0.11 (P = 0.91)
Test for subgroup differences: Not applicable
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Analysis 1.8. Comparison 1 Alprazolam versus placebo, Outcome 8 Withdrawal due to ineffectiveness
versus no withdrawals RR.
Review: Alprazolam for depression
Comparison: 1 Alprazolam versus placebo
Outcome: 8 Withdrawal due to ineffectiveness versus no withdrawals RR
Study or subgroup Alprazolam Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Laakman 1995 2/70 5/74 9.3 % 0.42 [ 0.08, 2.11 ]
Rickels 1985 19/128 48/130 90.7 % 0.40 [ 0.25, 0.64 ]
Total (95% CI) 198 204 100.0 % 0.40 [ 0.26, 0.64 ]
Total events: 21 (Alprazolam), 53 (Placebo)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 3.92 (P = 0.000089)
Test for subgroup differences: Not applicable
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Analysis 1.9. Comparison 1 Alprazolam versus placebo, Outcome 9 Withdrawal due to ineffectiveness
versus no withdrawals RD.
Review: Alprazolam for depression
Comparison: 1 Alprazolam versus placebo
Outcome: 9 Withdrawal due to ineffectiveness versus no withdrawals RD
Study or subgroup Alprazolam Placebo
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Laakman 1995 2/70 5/74 51.5 % -0.04 [ -0.11, 0.03 ]
Rickels 1985 19/128 48/130 48.5 % -0.22 [ -0.32, -0.12 ]
Total (95% CI) 198 204 100.0 % -0.13 [ -0.35, 0.09 ]
Total events: 21 (Alprazolam), 53 (Placebo)
Heterogeneity: Tau2 = 0.02; Chi2 = 12.44, df = 1 (P = 0.00042); I2 =92%
Test for overall effect: Z = 1.14 (P = 0.26)
Test for subgroup differences: Not applicable
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Analysis 1.10. Comparison 1 Alprazolam versus placebo, Outcome 10 Hamilton Depression Rating Scale
(HDRS) timeline week 1.
Review: Alprazolam for depression
Comparison: 1 Alprazolam versus placebo
Outcome: 10 Hamilton Depression Rating Scale (HDRS) timeline week 1
Study or subgroup Alprazolam Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Borison 1989 50 16.22 (5.24) 32 16.22 (4.55) 15.7 % 0.0 [ -2.14, 2.14 ]
Fabre 1980 35 21 (9) 31 26 (9) 10.3 % -5.00 [ -9.35, -0.65 ]
Feighner 1983a 41 21.3 (8) 45 27.8 (9) 12.0 % -6.50 [ -10.09, -2.91 ]
Laakman 1995 62 16.5 (5.5) 67 18 (5.1) 16.4 % -1.50 [ -3.33, 0.33 ]
Mendels 1986 30 23.5 (4.7) 34 23 (4.7) 15.3 % 0.50 [ -1.81, 2.81 ]
Rickels 1985 126 19.13 (11.6) 126 22.82 (10.6) 14.1 % -3.69 [ -6.43, -0.95 ]
Rickels 1987 58 17.2 (5.3) 61 22.7 (5.3) 16.2 % -5.50 [ -7.41, -3.59 ]
Total (95% CI) 402 396 100.0 % -2.88 [ -4.95, -0.81 ]
Heterogeneity: Tau2 = 5.90; Chi2 = 29.14, df = 6 (P = 0.00006); I2 =79%
Test for overall effect: Z = 2.73 (P = 0.0063)
Test for subgroup differences: Not applicable
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Analysis 1.11. Comparison 1 Alprazolam versus placebo, Outcome 11 Hamilton Depression Rating Scale
(HDRS) timeline week 2.
Review: Alprazolam for depression
Comparison: 1 Alprazolam versus placebo
Outcome: 11 Hamilton Depression Rating Scale (HDRS) timeline week 2
Study or subgroup Alprazolam Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Borison 1989 50 16.22 (5.24) 32 16.22 (4.55) 23.7 % 0.0 [ -2.14, 2.14 ]
Fabre 1980 34 20 (9) 31 24 (9) 16.2 % -4.00 [ -8.38, 0.38 ]
Feighner 1983a 41 17.8 (8) 45 26.9 (12) 16.5 % -9.10 [ -13.38, -4.82 ]
Laakman 1995 62 13 (9) 67 17 (9) 20.4 % -4.00 [ -7.11, -0.89 ]
Mendels 1986 30 19 (4.7) 34 20.6 (4.7) 23.2 % -1.60 [ -3.91, 0.71 ]
Total (95% CI) 217 209 100.0 % -3.34 [ -6.07, -0.61 ]
Heterogeneity: Tau2 = 6.99; Chi2 = 16.22, df = 4 (P = 0.003); I2 =75%
Test for overall effect: Z = 2.40 (P = 0.017)
Test for subgroup differences: Not applicable
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Analysis 1.12. Comparison 1 Alprazolam versus placebo, Outcome 12 Hamilton Depression Rating Scale
(HDRS) timeline week 3.
Review: Alprazolam for depression
Comparison: 1 Alprazolam versus placebo
Outcome: 12 Hamilton Depression Rating Scale (HDRS) timeline week 3
Study or subgroup Alprazolam Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Borison 1989 50 14.74 (7.05) 32 13.4 (5.63) 47.3 % 1.34 [ -1.42, 4.10 ]
Mendels 1986 30 18 (4.7) 34 20 (4.7) 52.7 % -2.00 [ -4.31, 0.31 ]
Total (95% CI) 80 66 100.0 % -0.42 [ -3.69, 2.85 ]
Heterogeneity: Tau2 = 3.89; Chi2 = 3.31, df = 1 (P = 0.07); I2 =70%
Test for overall effect: Z = 0.25 (P = 0.80)
Test for subgroup differences: Not applicable
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Analysis 1.13. Comparison 1 Alprazolam versus placebo, Outcome 13 Hamilton Depression Rating Scale
(HDRS) timeline week 4.
Review: Alprazolam for depression
Comparison: 1 Alprazolam versus placebo
Outcome: 13 Hamilton Depression Rating Scale (HDRS) timeline week 4
Study or subgroup Alprazolam Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Borison 1989 50 14.68 (6.71) 32 12.61 (6.99) 17.4 % 2.07 [ -0.98, 5.12 ]
Fabre 1980 31 17 (9) 20 21 (9) 14.0 % -4.00 [ -9.06, 1.06 ]
Feighner 1983a 41 16.5 (8) 45 28.7 (11.5) 15.5 % -12.20 [ -16.36, -8.04 ]
Laakman 1995 62 11.8 (5.5) 67 15.4 (5.1) 19.1 % -3.60 [ -5.43, -1.77 ]
Rickels 1985 126 14.59 (13.2) 126 19.34 (13.9) 16.9 % -4.75 [ -8.10, -1.40 ]
Rickels 1987 58 12.3 (9) 61 19.3 (9) 17.1 % -7.00 [ -10.24, -3.76 ]
Total (95% CI) 368 351 100.0 % -4.78 [ -8.17, -1.39 ]
Heterogeneity: Tau2 = 14.73; Chi2 = 33.78, df = 5 (P<0.00001); I2 =85%
Test for overall effect: Z = 2.77 (P = 0.0057)
Test for subgroup differences: Not applicable
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Analysis 1.14. Comparison 1 Alprazolam versus placebo, Outcome 14 Hamilton Depression Rating Scale
(HDRS) timeline week 6.
Review: Alprazolam for depression
Comparison: 1 Alprazolam versus placebo
Outcome: 14 Hamilton Depression Rating Scale (HDRS) timeline week 6
Study or subgroup Alprazolam Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Borison 1989 50 12.21 (7.24) 32 11.74 (6.71) 17.6 % 0.47 [ -2.60, 3.54 ]
Fabre 1980 50 15 (9) 15 19 (9) 11.9 % -4.00 [ -9.19, 1.19 ]
Feighner 1983a 41 16.1 (10) 45 28 (14) 12.1 % -11.90 [ -17.01, -6.79 ]
Laakman 1995 62 8.6 (5.5) 67 14.4 (5.1) 21.1 % -5.80 [ -7.63, -3.97 ]
Rickels 1985 126 13.59 (9) 126 18.9 (9) 20.1 % -5.31 [ -7.53, -3.09 ]
Rickels 1987 58 13.3 (9) 61 19.5 (9) 17.1 % -6.20 [ -9.44, -2.96 ]
Total (95% CI) 387 346 100.0 % -5.19 [ -7.72, -2.66 ]
Heterogeneity: Tau2 = 7.02; Chi2 = 20.65, df = 5 (P = 0.00094); I2 =76%
Test for overall effect: Z = 4.01 (P = 0.000060)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 Alprazolam versus TCAs, Outcome 1 HDRS continuous.
Review: Alprazolam for depression
Comparison: 2 Alprazolam versus TCAs
Outcome: 1 HDRS continuous
Study or subgroup Alprazolam TCAs
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Ansseau 1984 59 11 (9) 67 11 (9) 6.5 % 0.0 [ -3.15, 3.15 ]
Banerji 1989 40 9.2 (7.56) 40 5.9 (6.53) 6.6 % 3.30 [ 0.20, 6.40 ]
di Perri 1990 22 8.25 (9) 22 8.06 (9) 3.5 % 0.19 [ -5.13, 5.51 ]
Draper 1983 10 14.9 (4.9) 5 11.4 (7.3) 2.3 % 3.50 [ -3.58, 10.58 ]
Fabre 1980 31 15.5 (9) 34 15.7 (9) 4.5 % -0.20 [ -4.58, 4.18 ]
Feighner 1983a 41 16.1 (10) 43 17.4 (12.5) 4.0 % -1.30 [ -6.13, 3.53 ]
Goldberg 1986 30 14 (9) 30 12 (9) 4.3 % 2.00 [ -2.55, 6.55 ]
Laakman 1995 62 8.6 (5.5) 69 7.9 (5.1) 9.4 % 0.70 [ -1.12, 2.52 ]
Lapierre 1994 20 12.03 (7.23) 18 5.56 (8.29) 3.9 % 6.47 [ 1.50, 11.44 ]
Mendels 1986 30 12.5 (4.7) 34 14.5 (4.7) 8.3 % -2.00 [ -4.31, 0.31 ]
Murthy 1991 76 9.75 (4.63) 69 9.2 (4.72) 10.1 % 0.55 [ -0.97, 2.07 ]
Overall 1987 48 9.5 (9) 42 10.7 (9) 5.5 % -1.20 [ -4.93, 2.53 ]
Remick 1988 14 12 (4.7) 15 17.5 (4.7) 6.0 % -5.50 [ -8.92, -2.08 ]
Rickels 1985 126 13.59 (13.2) 239 14 (12.5) 7.2 % -0.41 [ -3.21, 2.39 ]
Rickels 1987 58 13.3 (9) 63 14.3 (9) 6.4 % -1.00 [ -4.21, 2.21 ]
Rush 1985 25 12.7 (8.5) 24 6.9 (6) 4.9 % 5.80 [ 1.69, 9.91 ]
Singh 1988 67 5.5 (9) 63 6.7 (9) 6.6 % -1.20 [ -4.30, 1.90 ]
Total (95% CI) 759 877 100.0 % 0.25 [ -0.93, 1.43 ]
Heterogeneity: Tau2 = 3.00; Chi2 = 35.63, df = 16 (P = 0.003); I2 =55%
Test for overall effect: Z = 0.42 (P = 0.68)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 Alprazolam versus TCAs, Outcome 2 HDRS continuous (subgrouped by TCA
comparator).
Review: Alprazolam for depression
Comparison: 2 Alprazolam versus TCAs
Outcome: 2 HDRS continuous (subgrouped by TCA comparator)
Study or subgroup Alprazolam TCAs
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Alprazolam versus amitriptyline
Banerji 1989 40 9.2 (7.56) 40 5.9 (6.53) 10.8 % 0.46 [ 0.02, 0.91 ]
di Perri 1990 22 8.25 (9) 22 8.06 (9) 6.1 % 0.02 [ -0.57, 0.61 ]
Draper 1983 10 14.9 (4.9) 5 11.4 (7.3) 1.8 % 0.57 [ -0.53, 1.67 ]
Laakman 1995 62 8.6 (5.5) 69 7.9 (5.1) 18.1 % 0.13 [ -0.21, 0.47 ]
Lapierre 1994 20 12.03 (7.23) 18 5.56 (8.29) 4.8 % 0.82 [ 0.15, 1.48 ]
Rickels 1985 126 13.59 (13.2) 119 14.77 (14.4) 34.0 % -0.09 [ -0.34, 0.17 ]
Rush 1985 25 12.7 (8.5) 24 6.9 (6) 6.3 % 0.77 [ 0.19, 1.36 ]
Singh 1988 67 5.5 (9) 63 6.7 (9) 18.0 % -0.13 [ -0.48, 0.21 ]
Subtotal (95% CI) 372 360 100.0 % 0.12 [ -0.03, 0.27 ]
Heterogeneity: Chi2 = 16.74, df = 7 (P = 0.02); I2 =58%
Test for overall effect: Z = 1.62 (P = 0.11)
2 Alprazolam versus imipramine
Fabre 1980 31 15.5 (9) 34 15.7 (9) 10.4 % -0.02 [ -0.51, 0.46 ]
Feighner 1983a 41 16.1 (10) 43 17.4 (12.5) 13.4 % -0.11 [ -0.54, 0.31 ]
Goldberg 1986 30 14 (9) 30 12 (9) 9.5 % 0.22 [ -0.29, 0.73 ]
Mendels 1986 30 12.5 (4.7) 34 14.5 (4.7) 10.0 % -0.42 [ -0.92, 0.08 ]
Murthy 1991 76 9.75 (4.63) 69 9.2 (4.72) 23.1 % 0.12 [ -0.21, 0.44 ]
Overall 1987 48 9.5 (9) 42 10.7 (9) 14.3 % -0.13 [ -0.55, 0.28 ]
Rickels 1987 58 13.3 (9) 63 14.3 (9) 19.3 % -0.11 [ -0.47, 0.25 ]
Subtotal (95% CI) 314 315 100.0 % -0.05 [ -0.21, 0.11 ]
Heterogeneity: Chi2 = 4.58, df = 6 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.65 (P = 0.52)
3 Alprazolam versus doxepin
Ansseau 1984 59 11 (9) 67 11 (9) 33.8 % 0.0 [ -0.35, 0.35 ]
Rickels 1985 126 13.59 (13.2) 120 13.23 (10.3) 66.2 % 0.03 [ -0.22, 0.28 ]
Subtotal (95% CI) 185 187 100.0 % 0.02 [ -0.18, 0.22 ]
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(. . . Continued)
Study or subgroup Alprazolam TCAs
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 0.19 (P = 0.85)
4 Alprazolam versus desipramine
Remick 1988 14 12 (4.7) 15 17.5 (4.7) 100.0 % -1.14 [ -1.93, -0.34 ]
Subtotal (95% CI) 14 15 100.0 % -1.14 [ -1.93, -0.34 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.81 (P = 0.0050)
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Analysis 2.3. Comparison 2 Alprazolam versus TCAs, Outcome 3 50% improvement vs less than 50%
improvement RR.
Review: Alprazolam for depression
Comparison: 2 Alprazolam versus TCAs
Outcome: 3 50% improvement vs less than 50% improvement RR
Study or subgroup Alprazolam TCAs Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Banerji 1989 26/40 32/40 18.7 % 0.81 [ 0.62, 1.07 ]
di Perri 1990 15/30 20/30 11.7 % 0.75 [ 0.48, 1.16 ]
Laakman 1995 38/62 50/69 27.6 % 0.85 [ 0.66, 1.08 ]
Lapierre 1994 12/20 13/18 8.0 % 0.83 [ 0.53, 1.31 ]
Mendels 1986 15/30 13/34 7.1 % 1.31 [ 0.75, 2.28 ]
Rickels 1987 27/58 26/63 14.5 % 1.13 [ 0.75, 1.69 ]
Rush 1985 11/25 21/24 12.5 % 0.50 [ 0.32, 0.80 ]
Total (95% CI) 265 278 100.0 % 0.86 [ 0.75, 0.99 ]
Total events: 144 (Alprazolam), 175 (TCAs)
Heterogeneity: Chi2 = 9.53, df = 6 (P = 0.15); I2 =37%
Test for overall effect: Z = 2.15 (P = 0.032)
Test for subgroup differences: Not applicable
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Analysis 2.4. Comparison 2 Alprazolam versus TCAs, Outcome 4 50% improvement vs less than 50%
improvement RR (subgrouped by TCA comparator).
Review: Alprazolam for depression
Comparison: 2 Alprazolam versus TCAs
Outcome: 4 50% improvement vs less than 50% improvement RR (subgrouped by TCA comparator)
Study or subgroup Alprazolam TCAs Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Alprazolam versus amitriptyline
Banerji 1989 26/40 32/40 23.8 % 0.81 [ 0.62, 1.07 ]
di Perri 1990 15/30 20/30 14.9 % 0.75 [ 0.48, 1.16 ]
Laakman 1995 38/62 50/69 35.2 % 0.85 [ 0.66, 1.08 ]
Lapierre 1994 12/20 13/18 10.2 % 0.83 [ 0.53, 1.31 ]
Rush 1985 11/25 21/24 15.9 % 0.50 [ 0.32, 0.80 ]
Subtotal (95% CI) 177 181 100.0 % 0.77 [ 0.66, 0.89 ]
Total events: 102 (Alprazolam), 136 (TCAs)
Heterogeneity: Chi2 = 4.04, df = 4 (P = 0.40); I2 =1%
Test for overall effect: Z = 3.43 (P = 0.00061)
2 Alprazolam versus imipramine
Mendels 1986 15/30 13/34 32.8 % 1.31 [ 0.75, 2.28 ]
Rickels 1987 27/58 26/63 67.2 % 1.13 [ 0.75, 1.69 ]
Subtotal (95% CI) 88 97 100.0 % 1.19 [ 0.86, 1.65 ]
Total events: 42 (Alprazolam), 39 (TCAs)
Heterogeneity: Chi2 = 0.18, df = 1 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 1.03 (P = 0.30)
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Analysis 2.5. Comparison 2 Alprazolam versus TCAs, Outcome 5 50% improvement vs less than 50%
improvement RD.
Review: Alprazolam for depression
Comparison: 2 Alprazolam versus TCAs
Outcome: 5 50% improvement vs less than 50% improvement RD
Study or subgroup Alprazolam TCAs
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Banerji 1989 26/40 32/40 15.8 % -0.15 [ -0.34, 0.04 ]
di Perri 1990 15/30 20/30 12.8 % -0.17 [ -0.41, 0.08 ]
Laakman 1995 38/62 50/69 17.8 % -0.11 [ -0.27, 0.05 ]
Lapierre 1994 12/20 13/18 10.4 % -0.12 [ -0.42, 0.18 ]
Mendels 1986 15/30 13/34 13.0 % 0.12 [ -0.12, 0.36 ]
Rickels 1987 27/58 26/63 16.8 % 0.05 [ -0.12, 0.23 ]
Rush 1985 11/25 21/24 13.4 % -0.44 [ -0.67, -0.20 ]
Total (95% CI) 265 278 100.0 % -0.11 [ -0.24, 0.01 ]
Total events: 144 (Alprazolam), 175 (TCAs)
Heterogeneity: Tau2 = 0.02; Chi2 = 14.45, df = 6 (P = 0.02); I2 =58%
Test for overall effect: Z = 1.74 (P = 0.082)
Test for subgroup differences: Not applicable
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Analysis 2.6. Comparison 2 Alprazolam versus TCAs, Outcome 6 50% improvement vs less than 50%
improvement RD (subgrouped by TCA comparator).
Review: Alprazolam for depression
Comparison: 2 Alprazolam versus TCAs
Outcome: 6 50% improvement vs less than 50% improvement RD (subgrouped by TCA comparator)
Study or subgroup Alprazolam TCAs
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Alprazolam versus amitriptyline
Banerji 1989 26/40 32/40 23.6 % -0.15 [ -0.34, 0.04 ]
di Perri 1990 15/30 20/30 16.6 % -0.17 [ -0.41, 0.08 ]
Laakman 1995 38/62 50/69 29.9 % -0.11 [ -0.27, 0.05 ]
Lapierre 1994 12/20 13/18 12.1 % -0.12 [ -0.42, 0.18 ]
Rush 1985 11/25 21/24 17.7 % -0.44 [ -0.67, -0.20 ]
Subtotal (95% CI) 177 181 100.0 % -0.19 [ -0.30, -0.07 ]
Total events: 102 (Alprazolam), 136 (TCAs)
Heterogeneity: Tau2 = 0.00; Chi2 = 5.48, df = 4 (P = 0.24); I2 =27%
Test for overall effect: Z = 3.25 (P = 0.0011)
2 Alprazolam versus imipramine
Mendels 1986 15/30 13/34 34.7 % 0.12 [ -0.12, 0.36 ]
Rickels 1987 27/58 26/63 65.3 % 0.05 [ -0.12, 0.23 ]
Subtotal (95% CI) 88 97 100.0 % 0.08 [ -0.07, 0.22 ]
Total events: 42 (Alprazolam), 39 (TCAs)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.18, df = 1 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 1.03 (P = 0.30)
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Analysis 2.7. Comparison 2 Alprazolam versus TCAs, Outcome 7 All-cause withdrawals vs no withdrawals
RR.
Review: Alprazolam for depression
Comparison: 2 Alprazolam versus TCAs
Outcome: 7 All-cause withdrawals vs no withdrawals RR
Study or subgroup Alprazolam TCAs Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ansseau 1984 17/72 9/73 4.0 % 1.92 [ 0.91, 4.01 ]
Banerji 1989 10/51 13/53 5.7 % 0.80 [ 0.39, 1.66 ]
Cropper 1987 8/50 8/50 3.6 % 1.00 [ 0.41, 2.46 ]
di Perri 1990 8/22 8/22 3.6 % 1.00 [ 0.46, 2.19 ]
Draper 1983 5/15 5/10 2.7 % 0.67 [ 0.26, 1.72 ]
Feighner 1983a 4/41 11/32 5.5 % 0.28 [ 0.10, 0.81 ]
Goldberg 1986 4/30 5/30 2.2 % 0.80 [ 0.24, 2.69 ]
Imlah 1985 0/23 3/18 1.8 % 0.11 [ 0.01, 2.06 ]
Laakman 1995 8/70 3/72 1.3 % 2.74 [ 0.76, 9.92 ]
Lapierre 1994 3/23 2/20 1.0 % 1.30 [ 0.24, 7.04 ]
Mendels 1986 6/34 8/36 3.5 % 0.79 [ 0.31, 2.05 ]
Murthy 1991 29/105 34/103 15.4 % 0.84 [ 0.55, 1.27 ]
Overall 1987 17/52 27/52 12.1 % 0.63 [ 0.39, 1.01 ]
Remick 1988 6/19 7/21 3.0 % 0.95 [ 0.39, 2.32 ]
Rickels 1985 24/128 57/246 17.5 % 0.81 [ 0.53, 1.24 ]
Rickels 1987 19/58 26/63 11.2 % 0.79 [ 0.50, 1.27 ]
Rush 1985 12/25 8/24 3.7 % 1.44 [ 0.72, 2.89 ]
Singh 1988 1/67 5/63 2.3 % 0.19 [ 0.02, 1.57 ]
Total (95% CI) 885 988 100.0 % 0.84 [ 0.72, 1.00 ]
Total events: 181 (Alprazolam), 239 (TCAs)
Heterogeneity: Chi2 = 20.65, df = 17 (P = 0.24); I2 =18%
Test for overall effect: Z = 1.99 (P = 0.047)
Test for subgroup differences: Not applicable
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Analysis 2.8. Comparison 2 Alprazolam versus TCAs, Outcome 8 All-cause withdrawals vs no withdrawals
RR (subgrouped by TCA comparator).
Review: Alprazolam for depression
Comparison: 2 Alprazolam versus TCAs
Outcome: 8 All-cause withdrawals vs no withdrawals RR (subgrouped by TCA comparator)
Study or subgroup Alprazolam TCAs Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Alprazolam versus amitriptyline
Banerji 1989 10/51 13/53 15.2 % 0.80 [ 0.39, 1.66 ]
di Perri 1990 8/22 8/22 9.6 % 1.00 [ 0.46, 2.19 ]
Draper 1983 5/15 5/10 7.2 % 0.67 [ 0.26, 1.72 ]
Imlah 1985 0/23 3/18 4.7 % 0.11 [ 0.01, 2.06 ]
Laakman 1995 8/70 3/72 3.5 % 2.74 [ 0.76, 9.92 ]
Lapierre 1994 3/23 2/20 2.6 % 1.30 [ 0.24, 7.04 ]
Rickels 1985 24/128 34/124 41.3 % 0.68 [ 0.43, 1.08 ]
Rush 1985 12/25 8/24 9.8 % 1.44 [ 0.72, 2.89 ]
Singh 1988 1/67 5/63 6.2 % 0.19 [ 0.02, 1.57 ]
Subtotal (95% CI) 424 406 100.0 % 0.84 [ 0.63, 1.10 ]
Total events: 71 (Alprazolam), 81 (TCAs)
Heterogeneity: Chi2 = 10.78, df = 8 (P = 0.21); I2 =26%
Test for overall effect: Z = 1.28 (P = 0.20)
2 Alprazolam versus imipramine
Feighner 1983a 4/41 11/32 11.1 % 0.28 [ 0.10, 0.81 ]
Goldberg 1986 4/30 5/30 4.5 % 0.80 [ 0.24, 2.69 ]
Mendels 1986 6/34 8/36 7.0 % 0.79 [ 0.31, 2.05 ]
Murthy 1991 29/105 34/103 30.8 % 0.84 [ 0.55, 1.27 ]
Overall 1987 17/52 27/52 24.2 % 0.63 [ 0.39, 1.01 ]
Rickels 1987 19/58 26/63 22.4 % 0.79 [ 0.50, 1.27 ]
Subtotal (95% CI) 320 316 100.0 % 0.71 [ 0.56, 0.90 ]
Total events: 79 (Alprazolam), 111 (TCAs)
Heterogeneity: Chi2 = 4.10, df = 5 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 2.81 (P = 0.0050)
3 Alprazolam versus doxepin
Ansseau 1984 17/72 9/73 27.5 % 1.92 [ 0.91, 4.01 ]
Rickels 1985 24/128 23/122 72.5 % 0.99 [ 0.59, 1.67 ]
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(. . . Continued)
Study or subgroup Alprazolam TCAs Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Subtotal (95% CI) 200 195 100.0 % 1.25 [ 0.82, 1.90 ]
Total events: 41 (Alprazolam), 32 (TCAs)
Heterogeneity: Chi2 = 2.03, df = 1 (P = 0.15); I2 =51%
Test for overall effect: Z = 1.04 (P = 0.30)
4 Alprazolam versus dothiepin
Cropper 1987 8/50 8/50 100.0 % 1.00 [ 0.41, 2.46 ]
Subtotal (95% CI) 50 50 100.0 % 1.00 [ 0.41, 2.46 ]
Total events: 8 (Alprazolam), 8 (TCAs)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
5 Alprazolam versus desipramine
Remick 1988 6/19 7/21 100.0 % 0.95 [ 0.39, 2.32 ]
Subtotal (95% CI) 19 21 100.0 % 0.95 [ 0.39, 2.32 ]
Total events: 6 (Alprazolam), 7 (TCAs)
Heterogeneity: not applicable
Test for overall effect: Z = 0.12 (P = 0.91)
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Analysis 2.9. Comparison 2 Alprazolam versus TCAs, Outcome 9 All-cause withdrawals vs no withdrawals
RD.
Review: Alprazolam for depression
Comparison: 2 Alprazolam versus TCAs
Outcome: 9 All-cause withdrawals vs no withdrawals RD
Study or subgroup Alprazolam TCAs
Risk
Difference Weight
Risk
Difference
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ansseau 1984 17/72 9/73 8.0 % 0.11 [ -0.01, 0.24 ]
Banerji 1989 10/51 13/53 5.7 % -0.05 [ -0.21, 0.11 ]
Cropper 1987 8/50 8/50 5.5 % 0.0 [ -0.14, 0.14 ]
di Perri 1990 8/22 8/22 2.4 % 0.0 [ -0.28, 0.28 ]
Feighner 1983a 4/41 11/32 4.0 % -0.25 [ -0.43, -0.06 ]
Goldberg 1986 4/30 5/30 3.3 % -0.03 [ -0.21, 0.15 ]
Imlah 1985 0/23 3/18 2.2 % -0.17 [ -0.35, 0.02 ]
Laakman 1995 8/70 3/72 7.9 % 0.07 [ -0.02, 0.16 ]
Lapierre 1994 3/23 2/20 2.4 % 0.03 [ -0.16, 0.22 ]
Mendels 1986 6/34 8/36 3.9 % -0.05 [ -0.23, 0.14 ]
Murthy 1991 29/105 34/103 11.5 % -0.05 [ -0.18, 0.07 ]
Overall 1987 17/52 27/52 5.8 % -0.19 [ -0.38, -0.01 ]
Remick 1988 6/19 7/21 2.2 % -0.02 [ -0.31, 0.27 ]
Rickels 1985 24/128 57/246 18.6 % -0.04 [ -0.13, 0.04 ]
Rickels 1987 19/58 26/63 6.7 % -0.09 [ -0.26, 0.09 ]
Rush 1985 12/25 8/24 2.7 % 0.15 [ -0.13, 0.42 ]
Singh 1988 1/67 5/63 7.2 % -0.06 [ -0.14, 0.01 ]
Total (95% CI) 870 978 100.0 % -0.04 [ -0.07, 0.00 ]
Total events: 176 (Alprazolam), 234 (TCAs)
Heterogeneity: Chi2 = 24.48, df = 16 (P = 0.08); I2 =35%
Test for overall effect: Z = 1.92 (P = 0.055)
Test for subgroup differences: Not applicable
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Analysis 2.10. Comparison 2 Alprazolam versus TCAs, Outcome 10 All-cause withdrawals vs no
withdrawals RD (subgrouped by TCA comparator).
Review: Alprazolam for depression
Comparison: 2 Alprazolam versus TCAs
Outcome: 10 All-cause withdrawals vs no withdrawals RD (subgrouped by TCA comparator)
Study or subgroup Alprazolam TCAs
Risk
Difference Weight
Risk
Difference
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Alprazolam versus amitriptyline
Banerji 1989 10/51 13/53 12.9 % -0.05 [ -0.21, 0.11 ]
di Perri 1990 8/22 8/22 5.5 % 0.0 [ -0.28, 0.28 ]
Imlah 1985 0/23 3/18 5.0 % -0.17 [ -0.35, 0.02 ]
Laakman 1995 8/70 3/72 17.7 % 0.07 [ -0.02, 0.16 ]
Lapierre 1994 3/23 2/20 5.3 % 0.03 [ -0.16, 0.22 ]
Rickels 1985 24/128 34/124 31.3 % -0.09 [ -0.19, 0.02 ]
Rush 1985 12/25 8/24 6.1 % 0.15 [ -0.13, 0.42 ]
Singh 1988 1/67 5/63 16.2 % -0.06 [ -0.14, 0.01 ]
Subtotal (95% CI) 409 396 100.0 % -0.03 [ -0.08, 0.02 ]
Total events: 66 (Alprazolam), 76 (TCAs)
Heterogeneity: Chi2 = 11.51, df = 7 (P = 0.12); I2 =39%
Test for overall effect: Z = 1.12 (P = 0.26)
2 Alprazolam versus imipramine
Feighner 1983a 4/41 11/32 11.3 % -0.25 [ -0.43, -0.06 ]
Goldberg 1986 4/30 5/30 9.5 % -0.03 [ -0.21, 0.15 ]
Mendels 1986 6/34 8/36 11.0 % -0.05 [ -0.23, 0.14 ]
Murthy 1991 29/105 34/103 32.8 % -0.05 [ -0.18, 0.07 ]
Overall 1987 17/52 27/52 16.4 % -0.19 [ -0.38, -0.01 ]
Rickels 1987 19/58 26/63 19.0 % -0.09 [ -0.26, 0.09 ]
Subtotal (95% CI) 320 316 100.0 % -0.10 [ -0.17, -0.03 ]
Total events: 79 (Alprazolam), 111 (TCAs)
Heterogeneity: Chi2 = 4.67, df = 5 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 2.86 (P = 0.0042)
3 Alprazolam versus doxepin
Ansseau 1984 17/72 9/73 36.7 % 0.11 [ -0.01, 0.24 ]
Rickels 1985 24/128 23/122 63.3 % 0.00 [ -0.10, 0.10 ]
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(. . . Continued)
Study or subgroup Alprazolam TCAs
Risk
Difference Weight
Risk
Difference
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Subtotal (95% CI) 200 195 100.0 % 0.04 [ -0.04, 0.12 ]
Total events: 41 (Alprazolam), 32 (TCAs)
Heterogeneity: Chi2 = 2.02, df = 1 (P = 0.16); I2 =50%
Test for overall effect: Z = 1.05 (P = 0.29)
4 Alprazolam versus dothiepin
Cropper 1987 8/50 8/50 100.0 % 0.0 [ -0.14, 0.14 ]
Subtotal (95% CI) 50 50 100.0 % 0.0 [ -0.14, 0.14 ]
Total events: 8 (Alprazolam), 8 (TCAs)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
5 Alprazolam versus desipramine
Remick 1988 6/19 7/21 100.0 % -0.02 [ -0.31, 0.27 ]
Subtotal (95% CI) 19 21 100.0 % -0.02 [ -0.31, 0.27 ]
Total events: 6 (Alprazolam), 7 (TCAs)
Heterogeneity: not applicable
Test for overall effect: Z = 0.12 (P = 0.91)
-0.5 -0.25 0 0.25 0.5
Favours alprazolam Favours TCAs
81Alprazolam for depression (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.11. Comparison 2 Alprazolam versus TCAs, Outcome 11 Adverse effects withdrawals vs no
withdrawals RR.
Review: Alprazolam for depression
Comparison: 2 Alprazolam versus TCAs
Outcome: 11 Adverse effects withdrawals vs no withdrawals RR
Study or subgroup Alprazolam TCAs Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Banerji 1989 6/51 11/53 15.9 % 0.57 [ 0.23, 1.42 ]
Cropper 1987 5/49 9/47 13.5 % 0.53 [ 0.19, 1.47 ]
di Perri 1990 3/30 0/30 0.7 % 7.00 [ 0.38, 129.93 ]
Draper 1983 9/15 6/10 10.6 % 1.00 [ 0.52, 1.92 ]
Goldberg 1986 1/30 1/30 1.5 % 1.00 [ 0.07, 15.26 ]
Imlah 1985 0/23 1/18 2.5 % 0.26 [ 0.01, 6.12 ]
Laakman 1995 3/70 0/72 0.7 % 7.20 [ 0.38, 136.84 ]
Mendels 1986 6/34 8/36 11.4 % 0.79 [ 0.31, 2.05 ]
Remick 1988 4/19 5/21 7.0 % 0.88 [ 0.28, 2.82 ]
Rickels 1985 3/125 29/246 28.7 % 0.20 [ 0.06, 0.66 ]
Singh 1988 1/67 5/63 7.6 % 0.19 [ 0.02, 1.57 ]
Total (95% CI) 513 626 100.0 % 0.62 [ 0.43, 0.88 ]
Total events: 41 (Alprazolam), 75 (TCAs)
Heterogeneity: Chi2 = 13.24, df = 10 (P = 0.21); I2 =24%
Test for overall effect: Z = 2.64 (P = 0.0084)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours alprazolam Favours TCAs
82Alprazolam for depression (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.12. Comparison 2 Alprazolam versus TCAs, Outcome 12 Adverse effects withdrawals vs no
withdrawals RR (subgrouped by TCA comparator).
Review: Alprazolam for depression
Comparison: 2 Alprazolam versus TCAs
Outcome: 12 Adverse effects withdrawals vs no withdrawals RR (subgrouped by TCA comparator)
Study or subgroup Alprazolam TCAs Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Alprazolam versus amitriptyline
Banerji 1989 6/51 11/53 25.2 % 0.57 [ 0.23, 1.42 ]
di Perri 1990 3/30 0/30 1.2 % 7.00 [ 0.38, 129.93 ]
Draper 1983 9/15 6/10 16.8 % 1.00 [ 0.52, 1.92 ]
Imlah 1985 0/23 1/18 3.9 % 0.26 [ 0.01, 6.12 ]
Laakman 1995 3/70 0/72 1.1 % 7.20 [ 0.38, 136.84 ]
Rickels 1985 3/125 17/124 39.8 % 0.18 [ 0.05, 0.58 ]
Singh 1988 1/67 5/63 12.0 % 0.19 [ 0.02, 1.57 ]
Subtotal (95% CI) 381 370 100.0 % 0.58 [ 0.37, 0.90 ]
Total events: 25 (Alprazolam), 40 (TCAs)
Heterogeneity: Chi2 = 13.44, df = 6 (P = 0.04); I2 =55%
Test for overall effect: Z = 2.41 (P = 0.016)
2 Alprazolam versus imipramine
Goldberg 1986 1/30 1/30 11.4 % 1.00 [ 0.07, 15.26 ]
Mendels 1986 6/34 8/36 88.6 % 0.79 [ 0.31, 2.05 ]
Subtotal (95% CI) 64 66 100.0 % 0.82 [ 0.33, 2.01 ]
Total events: 7 (Alprazolam), 9 (TCAs)
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 0.44 (P = 0.66)
3 Alprazolam versus doxepin
Rickels 1985 3/128 12/122 100.0 % 0.24 [ 0.07, 0.82 ]
Subtotal (95% CI) 128 122 100.0 % 0.24 [ 0.07, 0.82 ]
Total events: 3 (Alprazolam), 12 (TCAs)
Heterogeneity: not applicable
Test for overall effect: Z = 2.27 (P = 0.023)
4 Alprazolam versus dothiepin
Cropper 1987 5/49 9/47 100.0 % 0.53 [ 0.19, 1.47 ]
Subtotal (95% CI) 49 47 100.0 % 0.53 [ 0.19, 1.47 ]
Total events: 5 (Alprazolam), 9 (TCAs)
Heterogeneity: not applicable
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Study or subgroup Alprazolam TCAs Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Test for overall effect: Z = 1.21 (P = 0.23)
5 Alprazolam versus desipramine
Remick 1988 4/19 5/21 100.0 % 0.88 [ 0.28, 2.82 ]
Subtotal (95% CI) 19 21 100.0 % 0.88 [ 0.28, 2.82 ]
Total events: 4 (Alprazolam), 5 (TCAs)
Heterogeneity: not applicable
Test for overall effect: Z = 0.21 (P = 0.84)
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Analysis 2.13. Comparison 2 Alprazolam versus TCAs, Outcome 13 Adverse effects withdrawals vs no
withdrawals RD.
Review: Alprazolam for depression
Comparison: 2 Alprazolam versus TCAs
Outcome: 13 Adverse effects withdrawals vs no withdrawals RD
Study or subgroup Alprazolam TCAs
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Ansseau 1984 32/59 45/67 5.8 % -0.13 [ -0.30, 0.04 ]
Banerji 1989 6/51 11/53 7.3 % -0.09 [ -0.23, 0.05 ]
Cropper 1987 5/49 9/47 7.3 % -0.09 [ -0.23, 0.05 ]
di Perri 1990 3/30 0/30 8.8 % 0.10 [ -0.02, 0.22 ]
Goldberg 1986 1/30 1/30 11.3 % 0.0 [ -0.09, 0.09 ]
Imlah 1985 0/23 1/18 7.8 % -0.06 [ -0.19, 0.08 ]
Laakman 1995 3/70 0/72 15.1 % 0.04 [ -0.01, 0.10 ]
Mendels 1986 6/34 8/36 5.0 % -0.05 [ -0.23, 0.14 ]
Remick 1988 4/19 5/21 3.0 % -0.03 [ -0.29, 0.23 ]
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Study or subgroup Alprazolam TCAs
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Rickels 1985 3/125 29/246 15.6 % -0.09 [ -0.14, -0.05 ]
Singh 1988 1/67 5/63 13.1 % -0.06 [ -0.14, 0.01 ]
Total (95% CI) 557 683 100.0 % -0.04 [ -0.08, 0.01 ]
Total events: 64 (Alprazolam), 114 (TCAs)
Heterogeneity: Tau2 = 0.00; Chi2 = 24.74, df = 10 (P = 0.01); I2 =60%
Test for overall effect: Z = 1.43 (P = 0.15)
Test for subgroup differences: Not applicable
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Analysis 2.14. Comparison 2 Alprazolam versus TCAs, Outcome 14 Adverse effects withdrawals vs no
withdrawals RD (subgrouped by TCA comparator).
Review: Alprazolam for depression
Comparison: 2 Alprazolam versus TCAs
Outcome: 14 Adverse effects withdrawals vs no withdrawals RD (subgrouped by TCA comparator)
Study or subgroup Alprazolam TCAs
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Alprazolam versus amitriptyline
Banerji 1989 6/51 11/53 12.7 % -0.09 [ -0.23, 0.05 ]
di Perri 1990 3/30 0/30 14.5 % 0.10 [ -0.02, 0.22 ]
Imlah 1985 0/23 1/18 13.2 % -0.06 [ -0.19, 0.08 ]
Laakman 1995 3/70 0/72 20.8 % 0.04 [ -0.01, 0.10 ]
Rickels 1985 3/125 17/124 19.7 % -0.11 [ -0.18, -0.05 ]
Singh 1988 1/67 5/63 19.1 % -0.06 [ -0.14, 0.01 ]
Subtotal (95% CI) 366 360 100.0 % -0.03 [ -0.10, 0.04 ]
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Study or subgroup Alprazolam TCAs
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 16 (Alprazolam), 34 (TCAs)
Heterogeneity: Tau2 = 0.01; Chi2 = 21.36, df = 5 (P = 0.00069); I2 =77%
Test for overall effect: Z = 0.80 (P = 0.43)
2 Alprazolam versus imipramine
Goldberg 1986 1/30 1/30 80.9 % 0.0 [ -0.09, 0.09 ]
Mendels 1986 6/34 8/36 19.1 % -0.05 [ -0.23, 0.14 ]
Subtotal (95% CI) 64 66 100.0 % -0.01 [ -0.09, 0.07 ]
Total events: 7 (Alprazolam), 9 (TCAs)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.33, df = 1 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 0.21 (P = 0.83)
3 Alprazolam versus doxepin
Ansseau 1984 32/59 45/67 10.8 % -0.13 [ -0.30, 0.04 ]
Rickels 1985 3/128 12/122 89.2 % -0.07 [ -0.13, -0.02 ]
Subtotal (95% CI) 187 189 100.0 % -0.08 [ -0.14, -0.03 ]
Total events: 35 (Alprazolam), 57 (TCAs)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.54, df = 1 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 2.84 (P = 0.0045)
4 Alprazolam versus dothiepin
Cropper 1987 5/49 9/47 100.0 % -0.09 [ -0.23, 0.05 ]
Subtotal (95% CI) 49 47 100.0 % -0.09 [ -0.23, 0.05 ]
Total events: 5 (Alprazolam), 9 (TCAs)
Heterogeneity: not applicable
Test for overall effect: Z = 1.24 (P = 0.21)
5 Alprazolam versus desipramine
Remick 1988 4/19 5/21 100.0 % -0.03 [ -0.29, 0.23 ]
Subtotal (95% CI) 19 21 100.0 % -0.03 [ -0.29, 0.23 ]
Total events: 4 (Alprazolam), 5 (TCAs)
Heterogeneity: not applicable
Test for overall effect: Z = 0.21 (P = 0.83)
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Analysis 2.15. Comparison 2 Alprazolam versus TCAs, Outcome 15 Ineffectiveness withdrawals vs no
withdrawals RR.
Review: Alprazolam for depression
Comparison: 2 Alprazolam versus TCAs
Outcome: 15 Ineffectiveness withdrawals vs no withdrawals RR
Study or subgroup Alprazolam TCAs Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Laakman 1995 2/70 2/72 1.03 [ 0.15, 7.10 ]
Remick 1988 4/19 4/21 1.11 [ 0.32, 3.82 ]
Rickels 1985 19/128 19/246 1.92 [ 1.06, 3.50 ]
Singh 1988 0/67 0/63 0.0 [ 0.0, 0.0 ]
Total (95% CI) 284 402 1.66 [ 0.99, 2.79 ]
Total events: 25 (Alprazolam), 25 (TCAs)
Heterogeneity: Chi2 = 0.88, df = 2 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 1.93 (P = 0.053)
Test for subgroup differences: Not applicable
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Analysis 2.16. Comparison 2 Alprazolam versus TCAs, Outcome 16 Ineffectiveness withdrawals vs no
withdrawals RR (subgrouped by TCA comparator).
Review: Alprazolam for depression
Comparison: 2 Alprazolam versus TCAs
Outcome: 16 Ineffectiveness withdrawals vs no withdrawals RR (subgrouped by TCA comparator)
Study or subgroup Alprazolam TCAs Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Alprazolam versus amitriptyline
Laakman 1995 2/70 2/72 1.03 [ 0.15, 7.10 ]
Rickels 1985 19/128 11/124 1.67 [ 0.83, 3.37 ]
Singh 1988 0/67 0/63 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 265 259 1.58 [ 0.82, 3.04 ]
Total events: 21 (Alprazolam), 13 (TCAs)
Heterogeneity: Chi2 = 0.22, df = 1 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 1.36 (P = 0.17)
2 Alprazolam versus doxepin
Rickels 1985 19/128 8/122 2.26 [ 1.03, 4.98 ]
Subtotal (95% CI) 128 122 2.26 [ 1.03, 4.98 ]
Total events: 19 (Alprazolam), 8 (TCAs)
Heterogeneity: not applicable
Test for overall effect: Z = 2.03 (P = 0.042)
3 Alprazolam versus desipramine
Remick 1988 4/19 4/21 1.11 [ 0.32, 3.82 ]
Subtotal (95% CI) 19 21 1.11 [ 0.32, 3.82 ]
Total events: 4 (Alprazolam), 4 (TCAs)
Heterogeneity: not applicable
Test for overall effect: Z = 0.16 (P = 0.87)
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Analysis 2.17. Comparison 2 Alprazolam versus TCAs, Outcome 17 Ineffectiveness withdrawals vs no
withdrawals RD.
Review: Alprazolam for depression
Comparison: 2 Alprazolam versus TCAs
Outcome: 17 Ineffectiveness withdrawals vs no withdrawals RD
Study or subgroup Alprazolam TCAs
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Laakman 1995 2/70 2/72 30.8 % 0.00 [ -0.05, 0.06 ]
Remick 1988 4/19 4/21 4.6 % 0.02 [ -0.23, 0.27 ]
Rickels 1985 19/128 19/246 25.9 % 0.07 [ 0.00, 0.14 ]
Singh 1988 0/67 0/63 38.7 % 0.0 [ -0.03, 0.03 ]
Total (95% CI) 284 402 100.0 % 0.02 [ -0.04, 0.08 ]
Total events: 25 (Alprazolam), 25 (TCAs)
Heterogeneity: Tau2 = 0.00; Chi2 = 9.14, df = 3 (P = 0.03); I2 =67%
Test for overall effect: Z = 0.68 (P = 0.49)
Test for subgroup differences: Not applicable
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Analysis 2.18. Comparison 2 Alprazolam versus TCAs, Outcome 18 Ineffectiveness withdrawals vs no
withdrawals RD (subgrouped by TCA comparator).
Review: Alprazolam for depression
Comparison: 2 Alprazolam versus TCAs
Outcome: 18 Ineffectiveness withdrawals vs no withdrawals RD (subgrouped by TCA comparator)
Study or subgroup Alprazolam TCAs
Risk
Difference Weight
Risk
Difference
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Alprazolam versus amitriptyline
Laakman 1995 2/70 2/72 32.4 % 0.00 [ -0.05, 0.06 ]
Rickels 1985 19/128 11/124 22.2 % 0.06 [ -0.02, 0.14 ]
Singh 1988 0/67 0/63 45.4 % 0.0 [ -0.03, 0.03 ]
Subtotal (95% CI) 265 259 100.0 % 0.01 [ -0.04, 0.06 ]
Total events: 21 (Alprazolam), 13 (TCAs)
Heterogeneity: Tau2 = 0.00; Chi2 = 5.27, df = 2 (P = 0.07); I2 =62%
Test for overall effect: Z = 0.55 (P = 0.59)
2 Alprazolam versus desipramine
Remick 1988 4/19 4/21 100.0 % 0.02 [ -0.23, 0.27 ]
Subtotal (95% CI) 19 21 100.0 % 0.02 [ -0.23, 0.27 ]
Total events: 4 (Alprazolam), 4 (TCAs)
Heterogeneity: not applicable
Test for overall effect: Z = 0.16 (P = 0.87)
3 Alprazolam versus doxepin
Rickels 1985 19/128 8/122 100.0 % 0.08 [ 0.01, 0.16 ]
Subtotal (95% CI) 128 122 100.0 % 0.08 [ 0.01, 0.16 ]
Total events: 19 (Alprazolam), 8 (TCAs)
Heterogeneity: not applicable
Test for overall effect: Z = 2.15 (P = 0.032)
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Analysis 2.19. Comparison 2 Alprazolam versus TCAs, Outcome 19 HDRS timeline week 1.
Review: Alprazolam for depression
Comparison: 2 Alprazolam versus TCAs
Outcome: 19 HDRS timeline week 1
Study or subgroup Alprazolam TCAs
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Ansseau 1984 59 21 (9) 67 22 (9) 5.7 % -1.00 [ -4.15, 2.15 ]
Banerji 1989 40 15.5 (4.7) 40 12 (4.7) 7.1 % 3.50 [ 1.44, 5.56 ]
di Perri 1990 22 21 (9.5) 22 20 (8) 3.6 % 1.00 [ -4.19, 6.19 ]
Draper 1983 15 18.7 (6.1) 10 15.7 (7.2) 3.4 % 3.00 [ -2.43, 8.43 ]
Fabre 1980 35 21 (9) 37 23 (9) 4.6 % -2.00 [ -6.16, 2.16 ]
Feighner 1983a 41 21.3 (8) 43 24.5 (8) 5.4 % -3.20 [ -6.62, 0.22 ]
Goldberg 1986 30 16 (5.3) 30 18.5 (5.3) 6.3 % -2.50 [ -5.18, 0.18 ]
Laakman 1995 62 16.5 (5.5) 69 16.5 (5.1) 7.4 % 0.0 [ -1.82, 1.82 ]
Lapierre 1994 20 18 (5.3) 18 18 (5.3) 5.4 % 0.0 [ -3.37, 3.37 ]
Mendels 1986 30 23.5 (4.7) 34 23 (4.7) 6.8 % 0.50 [ -1.81, 2.81 ]
Murthy 1991 98 16.65 (10.62) 86 17.88 (11.18) 5.7 % -1.23 [ -4.39, 1.93 ]
Overall 1987 48 12.9 (6.1) 42 16.1 (6) 6.5 % -3.20 [ -5.70, -0.70 ]
Remick 1988 14 15 (4.7) 15 21 (4.7) 5.4 % -6.00 [ -9.42, -2.58 ]
Rickels 1985 126 19.13 (11.6) 239 20.4 (8.9) 6.7 % -1.27 [ -3.59, 1.05 ]
Rickels 1987 58 17.2 (5.3) 63 20.4 (5.3) 7.3 % -3.20 [ -5.09, -1.31 ]
Rush 1985 25 14 (7.1) 24 16.4 (4.5) 5.5 % -2.40 [ -5.71, 0.91 ]
Singh 1988 67 16 (5.3) 63 21 (5.3) 7.4 % -5.00 [ -6.82, -3.18 ]
Total (95% CI) 790 902 100.0 % -1.48 [ -2.77, -0.18 ]
Heterogeneity: Tau2 = 5.05; Chi2 = 60.06, df = 16 (P<0.00001); I2 =73%
Test for overall effect: Z = 2.24 (P = 0.025)
Test for subgroup differences: Not applicable
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Analysis 2.20. Comparison 2 Alprazolam versus TCAs, Outcome 20 HDRS timeline week 1 (subgrouped by
TCA comparator).
Review: Alprazolam for depression
Comparison: 2 Alprazolam versus TCAs
Outcome: 20 HDRS timeline week 1 (subgrouped by TCA comparator)
Study or subgroup Alprazolam TCAs
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Alprazolam versus amitriptyline
Banerji 1989 40 15.5 (4.7) 40 12 (4.7) 13.1 % 0.74 [ 0.28, 1.19 ]
di Perri 1990 22 21 (9.5) 22 20 (8) 11.5 % 0.11 [ -0.48, 0.70 ]
Draper 1983 15 18.7 (6.1) 10 15.7 (7.2) 9.0 % 0.44 [ -0.37, 1.25 ]
Laakman 1995 62 16.5 (5.5) 69 16.5 (5.1) 14.3 % 0.0 [ -0.34, 0.34 ]
Lapierre 1994 20 18 (5.3) 18 18 (5.3) 10.9 % 0.0 [ -0.64, 0.64 ]
Rickels 1985 126 19.13 (11.6) 119 20.5 (9.6) 15.3 % -0.13 [ -0.38, 0.12 ]
Rush 1985 25 14 (7.1) 24 16.4 (4.5) 11.8 % -0.40 [ -0.96, 0.17 ]
Singh 1988 67 16 (5.3) 63 21 (5.3) 14.1 % -0.94 [ -1.30, -0.57 ]
Subtotal (95% CI) 377 365 100.0 % -0.05 [ -0.41, 0.31 ]
Heterogeneity: Tau2 = 0.21; Chi2 = 37.19, df = 7 (P<0.00001); I2 =81%
Test for overall effect: Z = 0.26 (P = 0.79)
2 Alprazolam versus imipramine
Fabre 1980 35 21 (9) 37 23 (9) 12.1 % -0.22 [ -0.68, 0.24 ]
Feighner 1983a 41 21.3 (8) 43 24.5 (8) 13.4 % -0.40 [ -0.83, 0.04 ]
Goldberg 1986 30 16 (5.3) 30 18.5 (5.3) 10.4 % -0.47 [ -0.98, 0.05 ]
Mendels 1986 30 23.5 (4.7) 34 23 (4.7) 11.1 % 0.11 [ -0.39, 0.60 ]
Murthy 1991 98 16.65 (10.62) 86 17.88 (11.18) 22.2 % -0.11 [ -0.40, 0.18 ]
Overall 1987 48 12.9 (6) 42 16.1 (6.1) 13.9 % -0.52 [ -0.95, -0.10 ]
Rickels 1987 58 17.2 (5.3) 63 20.4 (5.3) 16.9 % -0.60 [ -0.96, -0.24 ]
Subtotal (95% CI) 340 335 100.0 % -0.32 [ -0.50, -0.13 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 8.60, df = 6 (P = 0.20); I2 =30%
Test for overall effect: Z = 3.32 (P = 0.00091)
3 Alprazolam versus doxepin
Ansseau 1984 59 21 (9) 67 22 (9) 33.8 % -0.11 [ -0.46, 0.24 ]
Rickels 1985 126 19.13 (11.6) 120 20.34 (8.1) 66.2 % -0.12 [ -0.37, 0.13 ]
Subtotal (95% CI) 185 187 100.0 % -0.12 [ -0.32, 0.09 ]
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(. . . Continued)
Study or subgroup Alprazolam TCAs
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 1.12 (P = 0.26)
4 Alprazolam versus desipramine
Remick 1988 14 15 (4.7) 15 21 (4.7) 100.0 % -1.24 [ -2.05, -0.44 ]
Subtotal (95% CI) 14 15 100.0 % -1.24 [ -2.05, -0.44 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.02 (P = 0.0025)
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Analysis 2.21. Comparison 2 Alprazolam versus TCAs, Outcome 21 HDRS timeline week 2.
Review: Alprazolam for depression
Comparison: 2 Alprazolam versus TCAs
Outcome: 21 HDRS timeline week 2
Study or subgroup Alprazolam TCAs
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Ansseau 1984 59 17 (9) 67 18 (9) 7.2 % -1.00 [ -4.15, 2.15 ]
Banerji 1989 40 12.7 (4.7) 40 8.3 (4.7) 8.2 % 4.40 [ 2.34, 6.46 ]
di Perri 1990 22 16 (8) 22 17.5 (10.5) 5.0 % -1.50 [ -7.02, 4.02 ]
Draper 1983 14 16.9 (7) 8 14 (8.1) 4.1 % 2.90 [ -3.80, 9.60 ]
Fabre 1980 34 20 (9) 36 21 (9) 6.2 % -1.00 [ -5.22, 3.22 ]
Feighner 1983a 41 17.8 (8) 43 21.7 (10) 6.5 % -3.90 [ -7.76, -0.04 ]
Goldberg 1986 30 15 (9) 30 17.5 (9) 5.8 % -2.50 [ -7.05, 2.05 ]
Laakman 1995 62 13 (5.5) 69 13 (5.1) 8.4 % 0.0 [ -1.82, 1.82 ]
Lapierre 1994 20 15 (9) 18 22.5 (9) 4.8 % -7.50 [ -13.23, -1.77 ]
Mendels 1986 30 19 (4.7) 34 20.9 (4.7) 8.0 % -1.90 [ -4.21, 0.41 ]
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(. . . Continued)
Study or subgroup Alprazolam TCAs
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Murthy 1991 91 14.4 (8.77) 76 14.11 (8.49) 7.7 % 0.29 [ -2.33, 2.91 ]
Overall 1987 48 11 (6.8) 42 14.6 (6.8) 7.5 % -3.60 [ -6.42, -0.78 ]
Remick 1988 14 12 (4.7) 15 19.5 (4.7) 6.9 % -7.50 [ -10.92, -4.08 ]
Rush 1985 25 14.7 (7.6) 24 11.5 (6.9) 6.3 % 3.20 [ -0.86, 7.26 ]
Singh 1988 67 11 (9) 63 16 (9) 7.3 % -5.00 [ -8.10, -1.90 ]
Total (95% CI) 597 587 100.0 % -1.57 [ -3.39, 0.25 ]
Heterogeneity: Tau2 = 9.31; Chi2 = 65.51, df = 14 (P<0.00001); I2 =79%
Test for overall effect: Z = 1.70 (P = 0.090)
Test for subgroup differences: Not applicable
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Analysis 2.22. Comparison 2 Alprazolam versus TCAs, Outcome 22 HDRS timeline week 2 (subgrouped by
TCA comparator).
Review: Alprazolam for depression
Comparison: 2 Alprazolam versus TCAs
Outcome: 22 HDRS timeline week 2 (subgrouped by TCA comparator)
Study or subgroup Alprazolam TCAs
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Alprazolam versus amitriptyline
Banerji 1989 40 12.7 (4.7) 40 8.3 (4.7) 15.3 % 0.93 [ 0.46, 1.39 ]
di Perri 1990 22 16 (8) 22 17.5 (10.5) 13.9 % -0.16 [ -0.75, 0.43 ]
Draper 1983 14 16.9 (7) 8 14 (8.1) 10.8 % 0.38 [ -0.50, 1.25 ]
Laakman 1995 62 13 (5.5) 69 13 (5.1) 16.5 % 0.0 [ -0.34, 0.34 ]
Lapierre 1994 20 15 (9) 18 22.5 (9) 13.0 % -0.82 [ -1.48, -0.15 ]
Rush 1985 25 14.7 (7.6) 24 11.5 (6.9) 14.1 % 0.43 [ -0.13, 1.00 ]
Singh 1988 67 11 (9) 63 16 (9) 16.4 % -0.55 [ -0.90, -0.20 ]
Subtotal (95% CI) 250 244 100.0 % 0.02 [ -0.43, 0.48 ]
Heterogeneity: Tau2 = 0.29; Chi2 = 33.92, df = 6 (P<0.00001); I2 =82%
Test for overall effect: Z = 0.11 (P = 0.91)
2 Alprazolam versus imipramine
Fabre 1980 34 20 (9) 36 21 (9) 14.2 % -0.11 [ -0.58, 0.36 ]
Feighner 1983a 41 17.8 (8) 43 21.7 (10) 16.2 % -0.43 [ -0.86, 0.01 ]
Goldberg 1986 30 15 (9) 30 17.5 (9) 12.4 % -0.27 [ -0.78, 0.23 ]
Mendels 1986 30 19 (4.7) 34 20.9 (4.7) 13.0 % -0.40 [ -0.90, 0.10 ]
Murthy 1991 91 14.4 (8.77) 76 14.11 (8.49) 27.3 % 0.03 [ -0.27, 0.34 ]
Overall 1987 48 11 (6.8) 42 14.6 (6.8) 16.9 % -0.52 [ -0.95, -0.10 ]
Subtotal (95% CI) 274 261 100.0 % -0.25 [ -0.44, -0.06 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 6.26, df = 5 (P = 0.28); I2 =20%
Test for overall effect: Z = 2.52 (P = 0.012)
3 Alprazolam versus doxepin
Ansseau 1984 59 22 (9) 67 23 (9) 100.0 % -0.11 [ -0.46, 0.24 ]
Subtotal (95% CI) 59 67 100.0 % -0.11 [ -0.46, 0.24 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.54)
4 Alprazolam versus desipramine
Remick 1988 14 12 (4.7) 15 19.5 (4.7) 100.0 % -1.55 [ -2.40, -0.71 ]
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Study or subgroup Alprazolam TCAs
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 14 15 100.0 % -1.55 [ -2.40, -0.71 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.60 (P = 0.00032)
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Analysis 2.23. Comparison 2 Alprazolam versus TCAs, Outcome 23 HDRS timeline week 3.
Review: Alprazolam for depression
Comparison: 2 Alprazolam versus TCAs
Outcome: 23 HDRS timeline week 3
Study or subgroup Alprazolam TCAs
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Lapierre 1994 20 15 (9) 18 10 (9) 18.0 % 5.00 [ -0.73, 10.73 ]
Mendels 1986 30 18 (4.7) 34 18 (4.7) 30.6 % 0.0 [ -2.31, 2.31 ]
Rush 1985 25 15.5 (8.2) 24 10.2 (6.2) 23.8 % 5.30 [ 1.24, 9.36 ]
Singh 1988 67 9 (9) 63 11.5 (9) 27.6 % -2.50 [ -5.60, 0.60 ]
Total (95% CI) 142 139 100.0 % 1.47 [ -1.99, 4.94 ]
Heterogeneity: Tau2 = 8.84; Chi2 = 11.52, df = 3 (P = 0.01); I2 =74%
Test for overall effect: Z = 0.83 (P = 0.41)
Test for subgroup differences: Not applicable
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Analysis 2.24. Comparison 2 Alprazolam versus TCAs, Outcome 24 HDRS timeline week 3 (subgrouped by
TCA comparator).
Review: Alprazolam for depression
Comparison: 2 Alprazolam versus TCAs
Outcome: 24 HDRS timeline week 3 (subgrouped by TCA comparator)
Study or subgroup Alprazolam TCAs
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Alprazolam versus amitriptyline
Lapierre 1994 20 15 (9) 18 10 (9) 30.3 % 0.54 [ -0.11, 1.19 ]
Rush 1985 25 15.5 (8.2) 24 10.2 (6.2) 32.1 % 0.72 [ 0.14, 1.29 ]
Singh 1988 67 9 (9) 63 11.5 (9) 37.6 % -0.28 [ -0.62, 0.07 ]
Subtotal (95% CI) 112 105 100.0 % 0.29 [ -0.40, 0.98 ]
Heterogeneity: Tau2 = 0.30; Chi2 = 10.66, df = 2 (P = 0.005); I2 =81%
Test for overall effect: Z = 0.83 (P = 0.41)
2 Alprazolam versus imipramine
Mendels 1986 30 18 (4.7) 34 18 (4.7) 100.0 % 0.0 [ -0.49, 0.49 ]
Subtotal (95% CI) 30 34 100.0 % 0.0 [ -0.49, 0.49 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
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Analysis 2.25. Comparison 2 Alprazolam versus TCAs, Outcome 25 HDRS timeline week 4.
Review: Alprazolam for depression
Comparison: 2 Alprazolam versus TCAs
Outcome: 25 HDRS timeline week 4
Study or subgroup Alprazolam TCAs
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Ansseau 1984 59 14 (9) 67 15 (9) 7.8 % -1.00 [ -4.15, 2.15 ]
Banerji 1989 36 9.2 (4.7) 38 5.9 (4.7) 9.7 % 3.30 [ 1.16, 5.44 ]
di Perri 1990 22 8.25 (9) 22 8.06 (9) 4.6 % 0.19 [ -5.13, 5.51 ]
Draper 1983 12 14.3 (6.8) 6 12.7 (7.3) 3.2 % 1.60 [ -5.39, 8.59 ]
Fabre 1980 31 17 (9) 34 17 (9) 5.8 % 0.0 [ -4.38, 4.38 ]
Feighner 1983a 41 16.5 (8) 43 18.9 (11) 6.2 % -2.40 [ -6.50, 1.70 ]
Goldberg 1986 30 14.5 (9) 30 13.5 (9) 5.6 % 1.00 [ -3.55, 5.55 ]
Laakman 1995 62 11.8 (5.5) 69 9 (5.1) 10.3 % 2.80 [ 0.98, 4.62 ]
Murthy 1991 81 12.93 (7.17) 69 11.26 (6.46) 9.6 % 1.67 [ -0.51, 3.85 ]
Overall 1987 48 10.3 (7.9) 42 12.2 (7.9) 7.6 % -1.90 [ -5.17, 1.37 ]
Remick 1988 14 10.5 (4.7) 15 16 (4.7) 7.3 % -5.50 [ -8.92, -2.08 ]
Rickels 1985 126 14.59 (13.2) 239 15.28 (11.3) 8.6 % -0.69 [ -3.40, 2.02 ]
Rickels 1987 58 12.3 (9) 63 13.5 (9) 7.7 % -1.20 [ -4.41, 2.01 ]
Rush 1985 25 13.5 (8.9) 24 8.6 (6.3) 5.9 % 4.90 [ 0.60, 9.20 ]
Total (95% CI) 645 761 100.0 % 0.25 [ -1.20, 1.70 ]
Heterogeneity: Tau2 = 4.46; Chi2 = 36.06, df = 13 (P = 0.00058); I2 =64%
Test for overall effect: Z = 0.34 (P = 0.74)
Test for subgroup differences: Not applicable
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Analysis 2.26. Comparison 2 Alprazolam versus TCAs, Outcome 26 HDRS timeline week 4 (subgrouped by
TCA comparator).
Review: Alprazolam for depression
Comparison: 2 Alprazolam versus TCAs
Outcome: 26 HDRS timeline week 4 (subgrouped by TCA comparator)
Study or subgroup Alprazolam TCAs
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Alprazolam versus amitriptyline
Banerji 1989 36 9.2 (4.7) 38 5.9 (4.7) 17.6 % 0.69 [ 0.22, 1.16 ]
di Perri 1990 22 8.25 (9) 22 8.06 (9) 14.5 % 0.02 [ -0.57, 0.61 ]
Draper 1983 12 14.3 (6.8) 6 12.7 (7.3) 7.8 % 0.22 [ -0.76, 1.20 ]
Laakman 1995 62 11.8 (5.5) 69 9 (5.1) 21.2 % 0.53 [ 0.18, 0.87 ]
Rickels 1985 126 14.59 (13.2) 119 15.58 (12.8) 24.0 % -0.08 [ -0.33, 0.17 ]
Rush 1985 25 13.5 (8.9) 24 8.6 (6.3) 14.9 % 0.62 [ 0.05, 1.20 ]
Subtotal (95% CI) 283 278 100.0 % 0.33 [ 0.00, 0.65 ]
Heterogeneity: Tau2 = 0.10; Chi2 = 14.51, df = 5 (P = 0.01); I2 =66%
Test for overall effect: Z = 1.99 (P = 0.047)
2 Alprazolam versus imipramine
Fabre 1980 31 17 (9) 34 17 (9) 11.8 % 0.0 [ -0.49, 0.49 ]
Feighner 1983a 41 16.5 (8) 43 18.9 (11) 14.9 % -0.25 [ -0.68, 0.18 ]
Goldberg 1986 30 14.5 (9) 30 13.5 (9) 10.9 % 0.11 [ -0.40, 0.62 ]
Murthy 1991 81 12.93 (7.17) 69 11.26 (6.46) 25.5 % 0.24 [ -0.08, 0.56 ]
Overall 1987 48 10.3 (7.9) 42 12.2 (7.9) 15.9 % -0.24 [ -0.65, 0.18 ]
Rickels 1987 58 12.3 (9) 63 13.5 (9) 21.1 % -0.13 [ -0.49, 0.22 ]
Subtotal (95% CI) 289 281 100.0 % -0.03 [ -0.20, 0.14 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 5.31, df = 5 (P = 0.38); I2 =6%
Test for overall effect: Z = 0.33 (P = 0.74)
3 Alprazolam versus doxepin
Ansseau 1984 59 14 (9) 67 15 (9) 33.8 % -0.11 [ -0.46, 0.24 ]
Rickels 1985 126 14.59 (13.2) 120 14.98 (9.7) 66.2 % -0.03 [ -0.28, 0.22 ]
Subtotal (95% CI) 185 187 100.0 % -0.06 [ -0.26, 0.14 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.12, df = 1 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 0.57 (P = 0.57)
4 Alprazolam versus desipramine
Remick 1988 14 10.5 (4.7) 15 16 (4.7) 100.0 % -1.14 [ -1.93, -0.34 ]
-2 -1 0 1 2
Favours alprazolam Favours TCAs
(Continued . . . )
99Alprazolam for depression (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Alprazolam TCAs
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 14 15 100.0 % -1.14 [ -1.93, -0.34 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.81 (P = 0.0050)
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Analysis 2.27. Comparison 2 Alprazolam versus TCAs, Outcome 27 HDRS timeline week 5.
Review: Alprazolam for depression
Comparison: 2 Alprazolam versus TCAs
Outcome: 27 HDRS timeline week 5
Study or subgroup Alprazolam TCAs
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Mendels 1986 30 12.5 (4.7) 34 14.5 (4.7) 53.5 % -2.00 [ -4.31, 0.31 ]
Rush 1985 25 12.6 (8.5) 24 8.5 (5.2) 46.5 % 4.10 [ 0.17, 8.03 ]
Total (95% CI) 55 58 100.0 % 0.83 [ -5.13, 6.80 ]
Heterogeneity: Tau2 = 15.90; Chi2 = 6.89, df = 1 (P = 0.01); I2 =85%
Test for overall effect: Z = 0.27 (P = 0.78)
Test for subgroup differences: Not applicable
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Analysis 2.28. Comparison 2 Alprazolam versus TCAs, Outcome 28 HDRS timeline week 5 (subgrouped by
TCA comparator).
Review: Alprazolam for depression
Comparison: 2 Alprazolam versus TCAs
Outcome: 28 HDRS timeline week 5 (subgrouped by TCA comparator)
Study or subgroup Alprazolam TCAs
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Alprazolam versus amitriptyline
Rush 1985 25 12.6 (8.5) 24 8.5 (5.2) 100.0 % 0.57 [ 0.00, 1.14 ]
Subtotal (95% CI) 25 24 100.0 % 0.57 [ 0.00, 1.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.95 (P = 0.051)
2 Alprazolam versus imipramine
Mendels 1986 30 12.5 (4.7) 34 14.5 (4.7) 100.0 % -0.42 [ -0.92, 0.08 ]
Subtotal (95% CI) 30 34 100.0 % -0.42 [ -0.92, 0.08 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.66 (P = 0.097)
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Analysis 2.29. Comparison 2 Alprazolam versus TCAs, Outcome 29 HDRS timeline week 6.
Review: Alprazolam for depression
Comparison: 2 Alprazolam versus TCAs
Outcome: 29 HDRS timeline week 6
Study or subgroup Alprazolam TCAs
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Ansseau 1984 59 13 (9) 67 13 (9) 8.0 % 0.0 [ -3.15, 3.15 ]
Draper 1983 10 14.9 (4.9) 5 11.4 (7.3) 2.7 % 3.50 [ -3.58, 10.58 ]
Fabre 1980 31 15 (9) 34 15 (9) 5.5 % 0.0 [ -4.38, 4.38 ]
Feighner 1983a 41 16.1 (10) 43 17.4 (12.5) 4.9 % -1.30 [ -6.13, 3.53 ]
Goldberg 1986 30 14 (9) 30 12 (9) 5.3 % 2.00 [ -2.55, 6.55 ]
Laakman 1995 62 8.6 (5.5) 69 7.9 (5.1) 11.6 % 0.70 [ -1.12, 2.52 ]
Lapierre 1994 20 12.03 (7.23) 18 5.56 (8.29) 4.7 % 6.47 [ 1.50, 11.44 ]
Murthy 1991 76 9.75 (4.63) 69 9.2 (4.72) 12.4 % 0.55 [ -0.97, 2.07 ]
Overall 1987 48 9.5 (9) 42 10.7 (9) 6.7 % -1.20 [ -4.93, 2.53 ]
Remick 1988 14 12 (4.7) 15 17.5 (4.7) 7.3 % -5.50 [ -8.92, -2.08 ]
Rickels 1985 126 13.59 (13.2) 239 14 (12.5) 8.9 % -0.41 [ -3.21, 2.39 ]
Rickels 1987 58 13.3 (9) 63 14.3 (9) 7.8 % -1.00 [ -4.21, 2.21 ]
Rush 1985 25 12.7 (8.5) 24 6.9 (6) 6.0 % 5.80 [ 1.69, 9.91 ]
Singh 1988 67 5.5 (9) 63 6.7 (9) 8.1 % -1.20 [ -4.30, 1.90 ]
Total (95% CI) 667 781 100.0 % 0.24 [ -1.06, 1.54 ]
Heterogeneity: Tau2 = 2.92; Chi2 = 28.27, df = 13 (P = 0.01); I2 =54%
Test for overall effect: Z = 0.37 (P = 0.71)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours alprazolam Favours TCAs
102Alprazolam for depression (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.30. Comparison 2 Alprazolam versus TCAs, Outcome 30 HDRS timeline week 6 (subgrouped by
TCA comparator).
Review: Alprazolam for depression
Comparison: 2 Alprazolam versus TCAs
Outcome: 30 HDRS timeline week 6 (subgrouped by TCA comparator)
Study or subgroup Alprazolam TCAs
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Alprazolam versus amitriptyline
Draper 1983 10 14.9 (4.9) 5 11.4 (7.3) 2.1 % 0.57 [ -0.53, 1.67 ]
Laakman 1995 62 8.6 (5.5) 69 7.9 (5.1) 21.8 % 0.13 [ -0.21, 0.47 ]
Lapierre 1994 20 12.03 (7.23) 18 5.56 (8.29) 5.8 % 0.82 [ 0.15, 1.48 ]
Rickels 1985 126 13.59 (13.2) 119 14.77 (14.4) 41.0 % -0.09 [ -0.34, 0.17 ]
Rush 1985 25 12.7 (8.5) 24 6.9 (6) 7.6 % 0.77 [ 0.19, 1.36 ]
Singh 1988 67 5.5 (9) 63 6.7 (9) 21.7 % -0.13 [ -0.48, 0.21 ]
Subtotal (95% CI) 310 298 100.0 % 0.08 [ -0.08, 0.24 ]
Heterogeneity: Chi2 = 14.14, df = 5 (P = 0.01); I2 =65%
Test for overall effect: Z = 1.02 (P = 0.31)
2 Alprazolam versus imipramine
Fabre 1980 31 15 (9) 34 15 (9) 11.5 % 0.0 [ -0.49, 0.49 ]
Feighner 1983a 41 16.1 (10) 43 17.4 (12.5) 14.9 % -0.11 [ -0.54, 0.31 ]
Goldberg 1986 30 14 (9) 30 12 (9) 10.6 % 0.22 [ -0.29, 0.73 ]
Murthy 1991 76 9.75 (4.63) 69 9.2 (4.72) 25.7 % 0.12 [ -0.21, 0.44 ]
Overall 1987 48 9.5 (9) 42 10.7 (9) 15.9 % -0.13 [ -0.55, 0.28 ]
Rickels 1987 58 13.3 (9) 63 14.3 (9) 21.4 % -0.11 [ -0.47, 0.25 ]
Subtotal (95% CI) 284 281 100.0 % -0.01 [ -0.17, 0.16 ]
Heterogeneity: Chi2 = 2.23, df = 5 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 0.10 (P = 0.92)
3 Alprazolam versus doxepin
Ansseau 1984 59 13 (9) 67 13 (9) 33.8 % 0.0 [ -0.35, 0.35 ]
Rickels 1985 126 13.59 (13.2) 120 13.23 (10.3) 66.2 % 0.03 [ -0.22, 0.28 ]
Subtotal (95% CI) 185 187 100.0 % 0.02 [ -0.18, 0.22 ]
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 0.19 (P = 0.85)
4 Alprazolam versus desipramine
Remick 1988 14 12 (4.7) 15 17.5 (4.7) 100.0 % -1.14 [ -1.93, -0.34 ]
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(. . . Continued)
Study or subgroup Alprazolam TCAs
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Subtotal (95% CI) 14 15 100.0 % -1.14 [ -1.93, -0.34 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.81 (P = 0.0050)
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Analysis 3.1. Comparison 3 Alprazolam versus heterocyclics, Outcome 1 Hamilton Depression Rating Scale
(HDRS) continuous.
Review: Alprazolam for depression
Comparison: 3 Alprazolam versus heterocyclics
Outcome: 1 Hamilton Depression Rating Scale (HDRS) continuous
Study or subgroup Alprazolam Heterocyclics
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Alprazolam versus mianserin
Bassi 1990 31 10 (9) 30 12.5 (9) -2.50 [ -7.02, 2.02 ]
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Analysis 3.2. Comparison 3 Alprazolam versus heterocyclics, Outcome 2 All-cause withdrawals versus no
withdrawals RR.
Review: Alprazolam for depression
Comparison: 3 Alprazolam versus heterocyclics
Outcome: 2 All-cause withdrawals versus no withdrawals RR
Study or subgroup Alprazolam Heterocyclics Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Alprazolam versus mianserin
Bassi 1990 1/31 4/30 0.24 [ 0.03, 2.04 ]
0.005 0.1 1 10 200
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Analysis 3.3. Comparison 3 Alprazolam versus heterocyclics, Outcome 3 All-cause withdrawals versus no
withdrawals RD.
Review: Alprazolam for depression
Comparison: 3 Alprazolam versus heterocyclics
Outcome: 3 All-cause withdrawals versus no withdrawals RD
Study or subgroup Alprazolam Heterocyclics
Risk
Difference
Risk
Difference
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Alprazolam versus mianserin
Bassi 1990 1/31 4/30 -0.10 [ -0.24, 0.04 ]
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Analysis 3.4. Comparison 3 Alprazolam versus heterocyclics, Outcome 4 Adverse effects withdrawals
versus no withdrawals RR.
Review: Alprazolam for depression
Comparison: 3 Alprazolam versus heterocyclics
Outcome: 4 Adverse effects withdrawals versus no withdrawals RR
Study or subgroup Alprazolam Heterocyclics Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Alprazolam versus mianserin
Bassi 1990 1/31 2/30 0.48 [ 0.05, 5.06 ]
0.05 0.2 1 5 20
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Analysis 3.5. Comparison 3 Alprazolam versus heterocyclics, Outcome 5 Adverse effects withdrawals
versus no withdrawals RD.
Review: Alprazolam for depression
Comparison: 3 Alprazolam versus heterocyclics
Outcome: 5 Adverse effects withdrawals versus no withdrawals RD
Study or subgroup Alprazolam Heterocyclics
Risk
Difference
Risk
Difference
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Alprazolam versus mianserin
Bassi 1990 1/31 2/30 -0.03 [ -0.14, 0.07 ]
-0.2 -0.1 0 0.1 0.2
Favours alprazolam Favours heterocyclics
106Alprazolam for depression (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.6. Comparison 3 Alprazolam versus heterocyclics, Outcome 6 Ineffectiveness withdrawals versus
no withdrawals RR.
Review: Alprazolam for depression
Comparison: 3 Alprazolam versus heterocyclics
Outcome: 6 Ineffectiveness withdrawals versus no withdrawals RR
Study or subgroup Alprazolam Heterocyclics Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Alprazolam versus mianserin
Bassi 1990 0/31 2/30 0.19 [ 0.01, 3.88 ]
0.01 0.1 1 10 100
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Analysis 3.7. Comparison 3 Alprazolam versus heterocyclics, Outcome 7 Ineffectiveness withdrawals versus
no withdrawals RD.
Review: Alprazolam for depression
Comparison: 3 Alprazolam versus heterocyclics
Outcome: 7 Ineffectiveness withdrawals versus no withdrawals RD
Study or subgroup Alprazolam Heterocyclics
Risk
Difference
Risk
Difference
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Alprazolam versus mianserin
Bassi 1990 0/31 2/30 -0.07 [ -0.17, 0.04 ]
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Analysis 3.8. Comparison 3 Alprazolam versus heterocyclics, Outcome 8 Hamilton Depression Rating Scale
(HDRS) timeline week 2.
Review: Alprazolam for depression
Comparison: 3 Alprazolam versus heterocyclics
Outcome: 8 Hamilton Depression Rating Scale (HDRS) timeline week 2
Study or subgroup Alprazolam Heterocyclics
Std.
Mean
Difference
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Alprazolam versus mianserin
Bassi 1990 31 14 (9) 30 16.5 (9) -0.27 [ -0.78, 0.23 ]
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Analysis 3.9. Comparison 3 Alprazolam versus heterocyclics, Outcome 9 Hamilton Depression Rating Scale
(HDRS) timeline week 4.
Review: Alprazolam for depression
Comparison: 3 Alprazolam versus heterocyclics
Outcome: 9 Hamilton Depression Rating Scale (HDRS) timeline week 4
Study or subgroup Alprazolam Heterocyclics
Std.
Mean
Difference
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Alprazolam versus mianserin
Bassi 1990 31 10 (9) 30 12.5 (9) -0.27 [ -0.78, 0.23 ]
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A P P E N D I C E S
Appendix 1. CCDANCTR
The Cochrane Depression, Anxiety and Neurosis Group (CCDAN)maintain two clinical trials registers at their editorial base in Bristol,
UK: a references register and a studies-based register. The CCDANCTR-References Register contains over 25,300 reports of trials in
depression, anxiety and neurosis. Approximately 65% of these references have been tagged to individual, coded trials. The coded trials
are held in the CCDANCTR-Studies Register and records are linked between the two registers through the use of unique Study ID
tags. Coding of trials is based on the EU-Psi coding manual. Please contact the CCDAN Trials Search Co-ordinator for further details.
Reports of trials for inclusion in the Group’s registers are collated from routine (weekly), generic searches of MEDLINE, EMBASE
and PsycINFO; quarterly searches of the Cochrane Central Register of Controlled Trials (CENTRAL) and review-specific searches
of additional databases. Reports of trials are also sourced from international trials registers c/o the World Health Organization’s trials
portal (ICTRP) (http://apps.who.int/trialsearch/), drug companies, the handsearching of key journals, conference proceedings and
other (non-Cochrane) systematic reviews and meta-analyses.
Details of CCDAN’s generic search strategies can be found in the ‘Specialised Register’ section of the Cochrane Depression, Anxiety
and Neurosis Group’s module text.
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External sources
• No sources of support supplied
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Clinical Global Impression (CGI) scale analysis was not performed: in several studies, the CGI was not studied or reported (Borison
1989; Goldberg 1986; Overall 1987; Rush 1985). In the remaining studies the CGI version was not specified (Ansseau 1984; Banerji
1989; Bassi 1990; Cropper 1987; di Perri 1990; Fabre 1980; Feighner 1983a; Imlah 1985; Lapierre 1994; Mendels 1986; Rickels 1985;
Rickels 1987; Singh 1988). Insufficient data were reported in the other studies (di Perri 1990; Lapierre 1994; Mendels 1986; Remick
1988; Singh 1988). The effects of alprazolam dosage and the loss of efficacy due to concomitant dose increase could not be analysed
due to insufficient data on alprazolam dosages in all the studies.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Alprazolam [∗therapeutic use]; Antidepressive Agents [∗therapeutic use]; Depression [∗drug therapy]; Randomized Controlled Trials
as Topic
MeSH check words
Adult; Aged; Humans; Middle Aged
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